<SEC-DOCUMENT>0001140361-26-017656.txt : 20260429
<SEC-HEADER>0001140361-26-017656.hdr.sgml : 20260429
<ACCEPTANCE-DATETIME>20260429083047
ACCESSION NUMBER:		0001140361-26-017656
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20260429
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260429
DATE AS OF CHANGE:		20260429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KalVista Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001348911
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				200915291
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36830
		FILM NUMBER:		26910714

	BUSINESS ADDRESS:	
		STREET 1:		200 CROSSING BOULEVARD
		CITY:			FRAMINGHAM
		STATE:			MA
		ZIP:			01702
		BUSINESS PHONE:		(857) 999-0075

	MAIL ADDRESS:	
		STREET 1:		200 CROSSING BOULEVARD
		CITY:			FRAMINGHAM
		STATE:			MA
		ZIP:			01702

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Carbylan Therapeutics, Inc.
		DATE OF NAME CHANGE:	20140916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Carbylan Biosurgery, Inc
		DATE OF NAME CHANGE:	20130102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Carbylan Biosurgery Inc
		DATE OF NAME CHANGE:	20060105
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20071670_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:kalv="http://kalvista.com/20260429" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_0927029055a944998c5f3eae8c1c5d33" contextRef="c20260429to20260429" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_4793f00a128144399bb86ba25b41f058" contextRef="c20260429to20260429">0001348911</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="kalv-20260429.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20260429to20260429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001348911</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-29</xbrli:startDate><xbrli:endDate>2026-04-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div> <div><span style="font-size: 10pt;"> </span></div>

    <div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
      <div>
<div><span style="font-size: 14pt;"> </span></div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

        <div style="font-size: 10pt;">
<div>&#160;
          </div>
<hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 100%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
        </div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_da52f360646941389fd94cc53270d2e9" contextRef="c20260429to20260429">8-K</ix:nonNumeric></div>

        <div><span style="font-size: 10pt;"><br/>
        </span></div>

        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
        </div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d)</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of the Securities Exchange Act of 1934</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_b96a77f90bb04995b4b3a547dfc4d84b" contextRef="c20260429to20260429" format="ixt:date-monthname-day-year-en">April 29, 2026</ix:nonNumeric></div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
        </div>

        <div style="text-align: left;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/></div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
        </div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_701e05c4a2314279a83db281cdeb27ef" contextRef="c20260429to20260429">KalVista Pharmaceuticals, Inc.</ix:nonNumeric><br/>
        </div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt;">(Exact name of registr</span>ant as specified in its charter)</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
        </div>

        <div style="text-align: left;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

        <div> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 32.85%; vertical-align: top; font-size: 10pt; text-align: center;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_5c7163ba233f4019a53e024e318b5b24" contextRef="c20260429to20260429" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span><br/>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_d392c14cf0044b479995ed571fa7354c" contextRef="c20260429to20260429">001-36830</ix:nonNumeric><br/>
                </div>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 32.85%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_3a49560e5ea14d97a69a488745f06b45" contextRef="c20260429to20260429">20-0915291</ix:nonNumeric><br/>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 32.85%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(State or other jurisdiction of incorporation)</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Commission File Number)</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 32.85%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(IRS Employer Identification No.)</div>
              </td>

  </tr>


</table>
        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
          </span></div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 78%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_896176a8bf494ebd9438871a1d2df236" contextRef="c20260429to20260429">200 Crossing Boulevard</ix:nonNumeric><br/>
                </div>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 21.3%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 78%; vertical-align: bottom; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_7bcf6a4dc21c4e5e9aa4dc1f309a90d6" contextRef="c20260429to20260429">Framingham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_a624f77f237b4eb882178c12e5908c14" contextRef="c20260429to20260429" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 21.3%; vertical-align: bottom; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_1805e2793a7f4b55b64c897451791dc7" contextRef="c20260429to20260429">01702</ix:nonNumeric><br/>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 78%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(Address of Principal Executive Offices)</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 21.3%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(Zip Code)</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_206263bd59314fb29d6d244ee8f0520b" contextRef="c20260429to20260429">857</ix:nonNumeric>)
          <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_ce37eea9e5e0408098692cc0625b3934" contextRef="c20260429to20260429">999-0075</ix:nonNumeric></div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Former name or former address, if changed since last report)</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
        </div>

        <div style="text-align: left;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
          provisions:</div>

        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
          </span></div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 18pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_92c066d0d4a9471ca33c608006e664ed" contextRef="c20260429to20260429" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
              </td>

  </tr>


</table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
          </span></div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_e4386cbce3d4444fa5dfdaafe740cb43" contextRef="c20260429to20260429" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
              </td>

  </tr>


</table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
          </span></div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_052994716c1c49188783957ec2953e75" contextRef="c20260429to20260429" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
              </td>

  </tr>


</table>
        <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
          </span></div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_87edba76fa904f7e8a0392ab9af38cc3" contextRef="c20260429to20260429" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Securities registered pursuant to Section 12(b) of the Act:</div>

        <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
          </span></div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 51%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Title of each class</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;"><br/>
              </td>

    <td style="width: 10.79%; vertical-align: bottom; border-bottom: #000000 2px solid;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Trading</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Symbol(s)</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;"><br/>
              </td>

    <td style="width: 36%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Name of each exchange</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">on which registered</div>
              </td>

  </tr>

  <tr>

    <td style="width: 51%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_05d780b24fb6405ea9e3937087185904" contextRef="c20260429to20260429">Common Stock, $0.001 par value per share</ix:nonNumeric><br/>
                </div>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 10.79%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_6578be1ba7514a7290f288bfe8d84895" contextRef="c20260429to20260429">KALV</ix:nonNumeric><br/>
                </div>
              </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 36%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_e7ad41f626404d39b6d9e350fd1b7e4d" contextRef="c20260429to20260429">NASDAQ</ix:nonNumeric><br/>
                </div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule
          12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_e21229dc42b74cc4b472d99a1b8de28c" contextRef="c20260429to20260429" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
          financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: 'Times New Roman';">&#9744;</span></div>

        <div style="text-align: left;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
          </span></div>

          <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item&#8201;1.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Entry into a Material Definitive Agreement.</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On April 29, 2026, KalVista Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Company</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Merger Agreement</span>&#8221;), by and among the Company, Chiesi
          Farmaceutici S.p.A., an Italian <span style="font-family: 'Times New Roman'; font-style: italic;">societ&#224; per azioni</span> (&#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Parent</span>&#8221;), Skyline Merger
          Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Purchaser</span>&#8221;), and KalVista Pharmaceuticals Limited, a private limited company
          organized under the laws of England and Wales. Capitalized terms used herein and not otherwise defined have the meaning set forth in the Merger Agreement.</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, among other things, Parent has agreed to cause
          Purchaser to commence a tender offer (the &#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Offer</span>&#8221;) to acquire all of the outstanding shares of common stock of the Company, par value $0.001 per share
          (the &#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Shares</span>&#8221;), other than the Excluded Shares and Dissenting Shares, for $27.00 per Share, net to the seller in cash, without interest and subject to any
          withholding of Taxes (&#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Offer Price</span>&#8221;).</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Merger Agreement provides that Purchaser will commence the Offer no later than 10 business days after the date of the Merger Agreement. The
          Offer will expire at one minute after 11:59 p.m., Eastern Time, on the date that is 20 business days from the commencement date of the Offer, unless extended in accordance with the terms of the Merger Agreement.</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The consummation of the Offer is subject to the satisfaction or waiver of various conditions set forth in the Merger Agreement, including (i) there
          being validly tendered (and not validly withdrawn) Shares that, considered together with all other Shares (if any) beneficially owned by Parent and its Affiliates, represent one more Share than 50% of the total number of Shares outstanding at the
          time of the expiration of the Offer (the &#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Minimum Condition</span>&#8221;); provided, however, that for purposes of determining whether the Minimum Condition has been
          satisfied, the Parties shall exclude Shares tendered in the Offer pursuant to guaranteed delivery procedures that have not yet been &#8220;received&#8221; (as such term is defined in Section 251(h)(6)(f) of the DGCL); (ii) any waiting period (or any
          extension thereof) applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, having expired or terminated and the obtainment of clearance, affirmative approval or confirmation of non-notifiability by the
          <a id="z_9kR3WTr26649JRK3nfv2ltD1u2suE"></a>Bundeskartellamt under applicable Antitrust Laws in Germany and the<a id="z_9kR3WTr2664ACXVrtykhsE2"></a> Presidenza del <a id="z_9kR3WTr2664ADLFx2ynruy"></a>Consiglio dei <a id="z_9kR3WTr2664AEWJrsyAA0"></a>Ministri under applicable Foreign Investment Laws in Italy; (iii) the accuracy of the representations and warranties of the Company contained in the Merger Agreement, subject to customary materiality
          standards, thresholds and exceptions; (iv) the Company&#8217;s compliance with, or performance of, in all material respects its covenants and agreements contained in the Merger Agreement; (v) there having not occurred any Material Adverse Effect; and
          (vi) other customary conditions set forth in Annex I to the Merger Agreement. The consummation of the Offer and Merger is not subject to a financing condition.</div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        </div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">As soon as practicable following the consummation of the Offer, Purchaser will be merged with and into the Company (the &#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Merger</span>&#8221;), with the Company continuing as the surviving corporation and a wholly owned Subsidiary of Parent, on the terms and subject to the conditions set forth in the Merger
          Agreement. In the Merger, each issued and outstanding Share as of the Effective Time (other than Shares held immediately prior to the Effective Time by the Company (or held in the Company&#8217;s treasury), Shares held immediately prior to the
          Effective Time by Parent, Purchaser or any other direct or indirect wholly owned Subsidiary of Parent or Purchaser (including any shares acquired in the Offer) and Shares as to which appraisal rights have been properly exercised and perfected
          under the DGCL) shall be converted into the right to receive the Offer Price (the &#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Merger Consideration</span>&#8221;).</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Board of Directors has (i) determined that the Merger Agreement and the Transactions, including the Offer and the Merger, are fair to, and in
          the best interest of, the Company and its stockholders, (ii) declared it advisable to enter into the Merger Agreement, (iii) approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the
          Transactions, including the Offer and the Merger, (iv) resolved that the Merger shall be effected under Section 251(h) of the DGCL, and (v) resolved to recommend that the stockholders of the Company tender their Shares to Purchaser pursuant to
          the Offer.</div>

        <div style="font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">At the Effective Time:</div>

        <div style="font-size: 10pt;"><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Each Company Option, that is then outstanding and unexercised and which has a per Share exercise price that is less than the Merger Consideration <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">will be, to the extent not then vested, deemed fully vested and cancelled and converted into the right to receive a cash payment (without interest) equal to the product of the excess of the Merger Consideration
                    over the per Share exercise price of such Company Option, multiplied by the total number of Shares subject to such Company Option immediately prior to the Effective Time</span>, which will be payable in accordance with the Merger
                  Agreement.</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;"><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Each Company Option that has a per Share exercise price equal to or greater than the Merger Consideration will be cancelled without payment.</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;"><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Each then outstanding Company RSU will be deemed fully vested and cancelled and converted into the right to receive a cash payment (without interest) equal to the product of the Merger
                  Consideration multiplied by the number of Shares subject to the Company RSU immediately prior to the Effective Time, which will be payable in accordance with the Merger Agreement.</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Merger Agreement includes representations, warranties and covenants of the Parties customary for a transaction of this nature, including
          customary covenants with respect to the operations of the business of the Company between signing and closing, governmental filings and approvals and other matters.</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Merger Agreement also contains customary non-solicitation restrictions which prohibit the Company&#8217;s solicitation of proposals relating to
          alternative transactions and restrict the Company&#8217;s ability to furnish information to, or participate in any discussions or negotiations with, any third party with respect to any such transaction, subject to customary exceptions in the event of
          an acquisition proposal that the Board of Directors determines, in good faith, after consultation with its financial advisors and outside legal counsel, constitutes or could reasonably be expected to lead to a Superior Offer. Moreover, the Board
          of Directors may make a Company Adverse Change Recommendation in response to an Intervening Event only if, among other conditions, the Board of Directors determines in good faith, after consultation with the Company&#8217;s outside legal counsel, that
          the failure to do so would be inconsistent with the fiduciary duties of the Board of Directors under applicable Legal Requirements.</div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        </div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Merger Agreement includes customary termination provisions for both the Company and Parent and provides that, in connection with the
          termination of the Merger Agreement under specified circumstances, including termination by the Company in order to enter into an acquisition agreement which the Board of Directors has determined constitutes a Superior Offer, the Company will be
          required to pay Parent a termination fee of $66,400,000.</div>

        <div style="font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its
          entirety by reference to the Merger Agreement, which is filed as Exhibit 2.1 hereto and which is incorporated herein by reference. The Merger Agreement has been filed to provide information to investors regarding its terms. The Merger Agreement
          is not intended to provide any other factual information about the Company, Parent or Purchaser, their respective businesses, or the actual conduct of their respective businesses during the period prior to the consummation of the Offer, the
          Merger or the other transactions contemplated therein. The Merger Agreement and this summary should not be relied upon as disclosure about the Company or Parent. None of the Company&#8217;s stockholders or any other third parties should rely on the
          representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or conditions of the Company, Parent, Purchaser or any of their respective subsidiaries or affiliates. The Merger Agreement
          contains representations and warranties that are the product of negotiations among the parties thereto and that the parties made to, and solely for the benefit of, each other as of specified dates. The assertions embodied in those representations
          and warranties are qualified in important part by confidential disclosure schedules delivered by the Company to Parent and Purchaser in connection with the Merger Agreement. Moreover, certain representations and warranties in the Merger Agreement
          may be subject to a contractual standard of materiality different from what might be viewed as material to stockholders or investors or may have been used for the purpose of allocating risk between the parties to the Merger Agreement instead of
          establishing these matters as facts. Accordingly, investors should consider the information in the Merger Agreement in conjunction with the entirety of the factual disclosure about the Company in the Company&#8217;s public reports filed with the
          Securities and Exchange Commission (the &#8220;<span style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">SEC</span>&#8221;). Information concerning the subject matter of the representations and warranties may change after the date
          of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company&#8217;s public disclosures.</div>

        <div style="font-size: 10pt;"><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item&#8201;7.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Regulation FD Disclosure.</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">On April 29, 2026, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement as described above. A copy
          of the joint press release is attached as Exhibit 99.1 and incorporated herein by reference.</div>

        <div style="font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The information contained in this Item 7.01 of this report, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 of Form 8-K
          and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with
          the SEC made by the Company regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.</div>

        <div style="font-size: 10pt;"><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item&#8201;9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits.</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;">&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(d)</div>
                </td>

    <td style="text-align: left; vertical-align: top;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Exhibits.</div>
                </td>

  </tr>


</table>
        </div>

        <div style="font-size: 10pt;"><br/>
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td colspan="1" style="width: 1%; vertical-align: top; font-size: 10pt; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; font-family: 'Times New Roman';">Exhibit No.</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; font-size: 10pt; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 88%; vertical-align: top; font-size: 10pt; border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; font-family: 'Times New Roman';">Description</div>
              </td>

  </tr>

  <tr>

    <td colspan="1" style="width: 1%; vertical-align: top; font-size: 10pt; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20071670_ex2-1.htm">2.1*</a></div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 88%; vertical-align: top; font-size: 10pt; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; font-family: 'Times New Roman';">Agreement and Plan of Merger, dated as of April 29, 2026, by and among KalVista Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Skyline Merger Sub, Inc. and KalVista
                  Pharmaceuticals Limited</div>
              </td>

  </tr>

  <tr>

    <td colspan="1" style="width: 1%; vertical-align: top; font-size: 10pt; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20071670_ex99-1.htm">99.1</a></div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 88%; vertical-align: top; font-size: 10pt; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; font-family: 'Times New Roman';">Joint Press Release, dated April 29, 2026, issued by KalVista Pharmaceuticals, Inc. and Chiesi Farmaceutici S.p.A.</div>
              </td>

  </tr>

  <tr>

    <td colspan="1" style="width: 1%; vertical-align: top; font-size: 10pt; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; font-family: 'Times New Roman';">104</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 88%; vertical-align: top; font-size: 10pt; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; font-family: 'Times New Roman';">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;"><br/>
        </div>

        <div style="font-size: 10pt;">
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 9pt;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">*</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of
                      any omitted exhibit or schedule to the SEC upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished.</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div style="font-size: 10pt;"> <br/>
        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additional Information and Where to Find It</div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The tender offer (the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Offer</span></span>&#8221;) for the outstanding shares of common stock (the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Shares</span></span>&#8221;) of KalVista Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Company</span></span>&#8221;), described in this communication has not yet commenced. This
          communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities of the Company, nor is it a substitute for the Offer materials that the Company, Chiesi Farmaceutici
          S.p.A., an Italian societ&#224; per azioni (&#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Parent</span></span>&#8221;) and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Purchaser</span></span>&#8221;), will file with the U.S. Securities and Exchange Commission (the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">SEC</span></span>&#8221;). A solicitation and offer to buy outstanding Shares of the Company will only
          be made pursuant to the Offer materials that Parent and Purchaser intend to file with the SEC. At the time the Offer is commenced, Parent and Purchaser will file Offer materials on Schedule TO with the SEC, and the Company will file a
          Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the Offer. THE OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER OFFER DOCUMENTS) AND THE
          SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY
          BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR
          SHARES IN THE OFFER. Free copies of these materials and certain other offering documents will be made available by the Company under the &#8220;Investors &amp; News&#8221; section of the Company&#8217;s website at https://www.kalvista.com/ or by directing requests
          for such materials to the information agent for the Offer, which will be named in the tender offer materials. The information contained in, or that can be accessed through, the Company&#8217;s website is not a part of, or incorporated by reference
          into, this communication. The Offer materials (including the Offer to Purchase, the related Letter of Transmittal and certain other Offer documents), as well as the Solicitation/Recommendation Statement on Schedule 14D-9, will also be made
          available for free on the SEC&#8217;s website at www.sec.gov.</div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">In addition to the Offer to Purchase, the related Letter of Transmittal and certain other Offer documents, as well as the Solicitation/Recommendation Statement on
          Schedule 14D-9, the Company files annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements, or other information filed by Parent and the Company with the SEC for free on the
          SEC&#8217;s website at www.sec.gov.</div>

        <div style="font-size: 10pt;"><br/>
        </div>

        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a id="z_Hlk147058051"></a>Forward Looking Statements</div>

        <div style="text-align: left; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-size: 10pt;"><br/>
          </span></div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a id="z_Hlk200480518"></a>This communication contains forward-looking statements related to the Company, Parent, the Offer, the merger of Purchaser with and into the
          Company, with the Company surviving as a wholly owned subsidiary of Parent (the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Merger</span></span>&#8221;), the Agreement and Plan of Merger, dated April 29, 2026, by and among Parent, Purchaser, the
          Company and KalVista Pharmaceuticals Limited, a private limited company organized under the laws of England and Wales (the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Merger Agreement</span></span>&#8221;), and the other transactions contemplated by
          the Merger Agreement (collectively, the &#8220;<span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Transactions</span></span>&#8221;) that involve substantial risks and uncertainties.&#160; Forward-looking statements can be identified by words such as: &#8220;anticipate,&#8221;
          &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;position,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will&#8221; or the negative of these terms or similar references to future periods, although not all
          forward-looking statements contain these words. In this communication, forward-looking statements include statements about the parties&#8217; ability to satisfy the conditions to the consummation of the Offer and the other conditions to the
          consummation of the Transactions; filings and approvals relating to the Transactions, statements regarding the expected timetable for completing the Transactions; statements regarding plans, objectives, expectations and intentions; the financial
          condition, results of operations and business of the Company and Parent; and post-closing operations and the outlook for the parties&#8217; businesses, including, without limitation, the ability to commercialize current and future product candidates
          (including further commercialization of EKTERLY<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>). Forward-looking statements are subject to certain risks, uncertainties or other factors that are difficult to
          predict, and could cause actual events or results to differ materially from those currently indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ
          from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the Offer and the Merger; uncertainties as to how many of the Company&#8217;s stockholders will tender their Shares in the Offer
          and the possibility that the acquisition does not close; the possibility that competing offers will be made; the possibility that various closing conditions for the Transactions may not be satisfied or waived, including that a governmental entity
          may prohibit, delay or refuse to grant approval for the consummation of the Transactions; the effects of the Transactions on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing
          or outcome of U.S. Food and Drug Administration approvals or actions, if any; the impact of competitive products and pricing; the risk that, if the Transactions are consummated, the businesses will not be integrated successfully and that Parent
          may not realize the potential benefits of the Transactions; other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217; control; transaction costs; actual or contingent liabilities; the
          success of the Company&#8217;s efforts to commercialize EKTERLY, including revenues from sales of EKTERLY; the Company&#8217;s ability to successfully obtain additional foreign regulatory approvals for sebetralstat; the Company&#8217;s expectations about the
          safety and efficacy of sebetralstat and the Company&#8217;s other product candidates; the timing of clinical trials and their results, the Company&#8217;s ability to commence clinical studies or complete ongoing clinical studies, including the Company&#8217;s
          KONFIDENT-S and KONFIDENT-KID trials, and the ability of EKTERLY to treat HAE; the timing of regulatory filings and product launches; the Company&#8217;s plans for international expansion; expectations regarding market adoption and utilization trends;
          and the Company&#8217;s ability to establish and maintain strategic partnerships.</div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        </div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Further information on potential risk factors that could affect the Company&#8217;s business and financial results are detailed in the Company&#8217;s filings with the SEC,
          including in the Company&#8217;s transition report on Form 10-KT for the transition period from May 1, 2025 to December 31, 2025, the Company&#8217;s quarterly reports on Form 10-Q, current reports on Form 8-K, as well as the Schedule 14D-9 to be filed by
          the Company and the Schedule TO and related tender offer documents to be filed by Parent and Purchaser. You should not place undue reliance on these statements. All forward-looking statements are based on information currently available to the
          Company and Parent, and the Company and Parent disclaim any obligation to update the information contained in this communication as new information becomes available.</div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        </div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
          duly authorized.</div>

        <div style="font-size: 10pt;"><br/>
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 30.08%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 3%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 67%; vertical-align: bottom; font-size: 10pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">KALVISTA PHARMACEUTICALS, INC.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 30.08%; vertical-align: middle; font-size: 10pt;">&#160;</td>

    <td style="width: 3%; vertical-align: middle; font-size: 10pt;">&#160;</td>

    <td style="width: 67%; vertical-align: middle; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 30.08%; vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Date: April 29, 2026</div>
              </td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">By:</div>
              </td>

    <td style="width: 67%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">/s/ Benjamin L. Palleiko</div>
                </div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 30.08%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 67%; vertical-align: bottom;">
                <div style="text-align: left; font-family: 'Times New Roman';">Benjamin L. Palleiko</div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 30.08%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 67%; vertical-align: bottom;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Chief Executive Officer</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;"><br/>
        </div>

        <div style="font-size: 10pt;">&#160;</div>

        <div style="font-size: 10pt;">
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      </div>

    </div>

    <div><span style="font-size: 10pt;"> </span></div>
 </div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ef20071670_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right;"><font style="font-weight: bold; font-size: 10pt;">Exhibit 2.1</font><font style="font-size: 10pt;"><br>
        </font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">AGREEMENT AND PLAN OF MERGER</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">among:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">KalVista Pharmaceuticals, Inc.</font><font style="font-size: 10pt;">,</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">a Delaware corporation;</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Chiesi Farmaceutici S.p.A.</font><font style="font-size: 10pt;">,</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">an Italian societ&#224; per azioni;</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Skyline Merger Sub, Inc</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: small-caps;">.</font><font style="font-size: 10pt;">,</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">a Delaware corporation; and</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">KalVista Pharmaceuticals Limited</font><font style="font-size: 10pt;">,</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">a private limited company organized under the laws of England and Wales</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Dated as of April 29, 2026</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%LCR%1%%%-->
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Table of Contents</div>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z2933df422cc7475793a9d0dc4eaec6ac" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">Section 1</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">THE OFFER</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">1.1</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">The Offer</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">2</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">1.2</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Company Actions</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">5</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">Section 2</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">MERGER TRANSACTION</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">2.1</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Merger of Purchaser into the Company</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">6</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">2.2</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Effect of the Merger</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">7</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">2.3</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Closing; Effective Time</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255); text-align: right;">7</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">2.4</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Certificate of Incorporation and Bylaws; Directors and Officers</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">7</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">2.5</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Conversion of Shares</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">8</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">2.6</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Surrender of Certificates; Stock Transfer Books</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; text-align: right;">9</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">2.7</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Dissenters&#8217; Rights</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">11</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">2.8</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Treatment of Company Equity Awards and Company ESPP</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">11</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">2.9</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Further Action</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">13</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">Section 3</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.1</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Due Organization; Subsidiaries, Etc</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">13</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.2</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Certificate of Incorporation and Bylaws</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.3</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Capitalization, Etc</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.4</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">SEC Filings; Financial Statements</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">16</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.5</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Absence of Changes; No Material Adverse Effect</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">18</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.6</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Title to Assets</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">18</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.7</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Real Property</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">18</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.8</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Intellectual Property</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.9</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Contracts</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.10</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Liabilities</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">25</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.11</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Compliance with Legal Requirements</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">25</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.12</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Regulatory Matters</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">25</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.13</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Certain Business Practices</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">29</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.14</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Governmental Authorizations</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">29</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.15</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Tax Matters</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">29</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.16</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Employee Matters</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">32</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.17</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Benefit Plans</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">33</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.18</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Environmental Matters</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">35</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.19</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Insurance</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">36</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">i</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="zb6141542d7df4214aa62b38810e033ed" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.20</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Legal Proceedings; Orders</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">36</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.21</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Authority; Binding Nature of Agreement</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">37</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.22</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Takeover Laws</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">37</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.23</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Non-Contravention; Consents</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">37</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.24</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Opinion of Financial Advisor</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">38</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">3.25</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Brokers and Other Advisors</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">38</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">3.26</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">No TID U.S. Business</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">38</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">Section 4</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">4.1</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Due Organization</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">4.2</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Purchaser</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">4.3</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Authority; Binding Nature of Agreement</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">4.4</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Non-Contravention; Consents</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">4.5</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Disclosure</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">4.6</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Absence of Litigation</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">4.7</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Funds</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">4.8</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Ownership of Shares</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">41</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">4.9</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Acknowledgement by Parent and Purchaser</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">41</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">4.10</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Brokers and Other Advisors</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">41</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">4.11</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Stockholder and Management Arrangements</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">42</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: middle; font-size: 10pt; text-align: center;" colspan="3">
              <div style="font-family: 'Times New Roman';">Section 5</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">CERTAIN COVENANTS OF THE COMPANY</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">5.1</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Access and Investigation</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">42</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">5.2</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Operation of the Acquired Corporations&#8217; Business</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">43</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">5.3</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">No Solicitation</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">48</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;" rowspan="1" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">Section 6</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">ADDITIONAL COVENANTS OF THE PARTIES</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">6.1</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Company Board Recommendation</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">50</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">6.2</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Filings, Consents and Approvals</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">52</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">6.3</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Employee Benefits</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">53</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">6.4</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Indemnification of Officers and Directors</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">55</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">6.5</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Stockholder Litigation</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">57</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">6.6</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Additional Agreements</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">57</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">6.7</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Disclosure</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">58</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">6.8</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Takeover Laws</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">58</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">6.9</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Section 16 Matters</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">58</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">6.10</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Rule 14d-10 Matters</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">59</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">6.11</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Stock Exchange Delisting; Deregistration</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">59</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">ii</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z4f0e3946e60542e896707bd1d1f8621c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">6.12</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Notices to Holders of Company Warrants</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">59</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">6.13</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Treatment of Convertible Senior Notes</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">59</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">6.14</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Financing Assistance</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">60</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;" rowspan="1" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">Section 7</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">CONDITIONS PRECEDENT TO THE MERGER</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">7.1</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">No Restraints</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">61</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">7.2</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Consummation of Offer</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">62</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;" rowspan="1" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">Section 8</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">TERMINATION</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">8.1</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Termination</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">62</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">8.2</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Effect of Termination</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">63</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">8.3</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Expenses; Termination Fees</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">64</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">Section 9</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3">
              <div style="text-align: center; font-family: 'Times New Roman';">MISCELLANEOUS PROVISIONS</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="3" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">9.1</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Amendment</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">65</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">9.2</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Waiver</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">65</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">9.3</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">No Survival of Representations and Warranties</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">66</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">9.4</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Entire Agreement; Counterparts</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">66</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">9.5</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">66</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">9.6</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Assignability</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">67</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">9.7</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">No Third Party Beneficiaries</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">68</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">9.8</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Transfer Taxes</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">68</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">9.9</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Notices</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">68</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">9.10</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Severability</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">69</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">9.11</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: left; font-family: 'Times New Roman';">Obligation of Parent</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: right; font-family: 'Times New Roman';">70</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">9.12</div>
            </td>
            <td style="width: 86%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Construction</div>
            </td>
            <td style="width: 6%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: right; font-family: 'Times New Roman';">70</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>Exhibits</u></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u> <br>
        </u></div>
      <div style="font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z2a7616f404c1469ba8f1e71cadc7d32c">

            <tr>
              <td style="width: 10%; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt; font-family: 'Times New Roman';">Exhibit A</font><font style="font-size: 10pt;"><br>
                </font></td>
              <td style="width: 90%; background-color: rgb(204, 238, 255);"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">Certain Definitions</font></font></td>
            </tr>

        </table>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>Annexes</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z1db44baa782a4d28884126931ddcb74a">

            <tr>
              <td style="width: 10%; background-color: rgb(204, 238, 255);">
                <div><font style="font-size: 10pt; font-family: 'Times New Roman';">Annex I</font><font style="font-size: 10pt;"> <br>
                  </font></div>
              </td>
              <td style="width: 90%; background-color: rgb(204, 238, 255);">
                <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">Conditions to the Offer</font></font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 10%;" rowspan="1">
                <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Annex II</font><font style="font-size: 10pt;"><br>
                  </font></div>
              </td>
              <td style="width: 90%;" rowspan="1"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';">Form of Certificate of Incorporation of the Surviving Corporation</font></font></td>
            </tr>

        </table>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><br>
          </font></font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">iii</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">AGREEMENT AND PLAN OF MERGER</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">THIS AGREEMENT AND PLAN OF MERGER</font><font style="font-size: 10pt;"> (this &#8220;<font style="font-family: 'Times New Roman';"><u>Agreement</u></font>&#8221;) is made and entered into as of April 29, 2026, by and among: Chiesi Farmaceutici S.p.A., an Italian societ&#224; per azioni (&#8220;<font style="font-family: 'Times New Roman';"><u>Parent</u></font>&#8221;); Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned <a name="z_9kMHG5YVt46678Cfdts0mnlvK"></a>subsidiary of Parent (&#8220;<font style="font-family: 'Times New Roman';"><u>Purchaser</u></font>&#8221;);
          KalVista Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="font-family: 'Times New Roman';"><u>Company</u></font>&#8221;); and KalVista Pharmaceuticals Limited, a private limited company organized under the laws of England and Wales (&#8220;<font style="font-family: 'Times New Roman';"><u>KalVista UK</u></font>&#8221;). Certain capitalized terms used in this Agreement are defined in <font style="font-family: 'Times New Roman';"><u>Exhibit A</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">INTRODUCTION</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref460608318"></a>Parent has agreed to cause Purchaser to commence a tender offer (as it may be amended from time to time as permitted under
        this Agreement, the &#8220;<font style="font-family: 'Times New Roman';"><u>Offer</u></font>&#8221;) to acquire all of the outstanding shares of Company Common Stock (the &#8220;<font style="font-family: 'Times New Roman';"><u>Shares</u></font>&#8221;), other than the
        Excluded Shares, for $27.00 per share, net to the seller in cash, without interest (such amount, or any higher amount per Share paid pursuant to the Offer, and as may be adjusted in accordance with <font style="font-family: 'Times New Roman';"><u>Section





            1.1(g)</u></font>, being the &#8220;<font style="font-family: 'Times New Roman';"><u>Offer Price</u></font>&#8221;), and subject to any withholding of Taxes, upon the terms and subject to the conditions of this Agreement.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref460608317"></a>As soon as practicable following the consummation of the Offer, Purchaser will be merged with and into the Company (the &#8220;<font style="font-family: 'Times New Roman';"><u>Merger</u></font>&#8221;), with the Company continuing as the surviving corporation in the Merger (the &#8220;<font style="font-family: 'Times New Roman';"><u>Surviving Corporation</u></font>&#8221;), on the terms and
        subject to the conditions set forth in this Agreement, whereby (i) each issued and outstanding Share as of the Effective Time (other than Excluded Shares and Dissenting Shares) shall be converted into the right to receive the Offer Price, in cash,
        without interest, and subject to any withholding of Taxes, and (ii) the Company shall become a wholly owned Subsidiary of Parent as a result of the Merger.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The board of directors of the Company (the &#8220;<font style="font-family: 'Times New Roman';"><u>Board of Directors</u></font>&#8221;) has (i) determined that
        this Agreement and the Transactions, including the Offer and the Merger, are fair to, and in the best interest of, the Company and its stockholders, (ii) declared it advisable to enter into this Agreement, (iii) approved the execution, delivery and
        performance by the Company of this Agreement and the consummation of the Transactions, including the Offer and the Merger, (iv) resolved that the Merger shall be effected under Section 251(h) of the DGCL, and (v) resolved to recommend that the
        stockholders of the Company tender their Shares to Purchaser pursuant to the Offer (the &#8220;<font style="font-family: 'Times New Roman';"><u>Company Board Recommendation</u></font>&#8221;), in each case, on the terms and subject to the conditions of this
        Agreement.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The board of directors of each of Parent and Purchaser have approved this Agreement and declared it advisable for Parent and Purchaser, respectively,
        to enter into this Agreement.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref460608316"></a>Parent, Purchaser and the Company acknowledge and agree that the Merger shall be effected pursuant to Section 251(h) of
        the DGCL and shall, subject to the satisfaction of the conditions set forth in this Agreement, be consummated as soon as practicable following the consummation of the Offer.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">1</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">AGREEMENT</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Parties to this Agreement, intending to be legally bound, agree as follows:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Toc227238374"></a><a name="z_Toc227238493"></a><a name="z_Toc228288312"></a>SECTION 1</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref473292749"></a><font style="font-family: 'Times New Roman';"><u>THE OFFER</u></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><a name="z_Toc228288313"></a><a name="z_Ref473195957"></a><a name="z_Toc227238375"></a><a name="z_Toc227238494"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">1.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">The Offer</font>.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608383"></a><a name="z_Ref196941412"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Commencement of the Offer</font>. Provided that this Agreement shall not have been terminated in accordance with <font style="font-family: 'Times New Roman';"><u>Section 8</u></font>, as promptly as practicable after the date of this Agreement but in no event more than ten (10) business days after the date of this Agreement (subject to the Company having timely provided any information
          required to be provided by it pursuant to <font style="font-family: 'Times New Roman';"><u>Sections 1.1(e)</u></font> and <font style="font-family: 'Times New Roman';"><u>1.2(b)</u></font>), Purchaser shall commence (within the meaning of Rule
          14d-2 under the Exchange Act) the Offer to purchase all of the outstanding Shares (other than Shares to be cancelled pursuant to <font style="font-family: 'Times New Roman';"><u>Sections 2.5(a)(i)</u></font> and <font style="font-family: 'Times New Roman';"><u>2.5(a)(ii)</u></font> (collectively, the &#8220;<font style="font-family: 'Times New Roman';"><u>Excluded Shares</u></font>&#8221;)), at a price per Share equal to the Offer Price, net to the seller in cash, without interest, and subject to
          any withholding of Taxes in accordance with <font style="font-family: 'Times New Roman';"><u>Section 2.6(e)</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473204354"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Terms and Conditions of the Offer</font>. The obligations of Purchaser to accept for payment, and pay for, any Shares validly tendered (and not validly withdrawn) pursuant to the Offer
          are subject only to the terms and conditions set forth in this Agreement, including the satisfaction or, to the extent waivable by Purchaser or Parent, waiver by Purchaser or Parent, of the Minimum Condition, the Termination Condition and the
          other conditions set forth in <font style="font-family: 'Times New Roman';"><u>Annex I</u></font> (collectively, the &#8220;<font style="font-family: 'Times New Roman';"><u>Offer Conditions</u></font>&#8221;). The Offer shall be made by means of an offer to
          purchase (the &#8220;<font style="font-family: 'Times New Roman';"><u>Offer to Purchase</u></font>&#8221;) that contains the Offer Conditions and the other terms set forth in this Agreement. Purchaser expressly reserves the right, to the extent permitted by
          applicable Legal Requirements, to (i) increase the Offer Price, (ii) waive any Offer Condition (except to the extent set forth in <font style="font-family: 'Times New Roman';"><u>clause (E)</u></font> of this <font style="font-family: 'Times New Roman';"><u>Section 1.1(b)</u></font>) and (iii) make any other changes in the terms and conditions of the Offer not inconsistent with the terms of this Agreement; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>,<font style="font-family: 'Times New Roman'; font-style: italic;"> however</font>, notwithstanding anything to the contrary contained in this Agreement, without the prior written consent of the Company, Parent and Purchaser shall not (A) decrease the
          Offer Price, (B) change the form of consideration payable in the Offer, (C) decrease the maximum number of Shares sought to be purchased in the Offer, (D) impose conditions or requirements to the Offer in addition to the Offer Conditions, (E)
          amend, modify or waive the Minimum Condition, Termination Condition or the conditions set forth in <font style="font-family: 'Times New Roman';"><u>clause (e)</u></font> or (g) of <font style="font-family: 'Times New Roman';"><u>Annex I</u></font>,
          (F) amend or modify any of the other terms of the Offer in a manner that adversely affects, individually or in the aggregate, any holder of Shares in its capacity as such or the ability of Parent or Purchaser to consummate the Offer, the Merger
          or any of the other Transactions, (G) except as provided in <font style="font-family: 'Times New Roman';"><u>Sections 1.1(c)</u></font> or <font style="font-family: 'Times New Roman';"><u>1.1(d)</u></font>, terminate the Offer or accelerate,
          extend or otherwise change the Expiration Date or (H) provide any &#8220;subsequent offering period&#8221; (or any extension thereof) within the meaning of Rule 14d-11 promulgated under the Exchange Act. The Offer may not be withdrawn prior to the time at
          which the Offer is then scheduled to expire on the Expiration Date (or any rescheduled Expiration Date) of the Offer, unless this Agreement is terminated in accordance with <font style="font-family: 'Times New Roman';"><u>Section 8</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608382"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Expiration and Extension of the Offer</font>. The Offer shall initially be scheduled to expire at one minute after 11:59 p.m. Eastern Time on the date that is twenty (20) business days
          (determined as set forth in Rule 14d-1(g)(3) and Rule 14e-1(a) under the Exchange Act) following the Offer Commencement Date (unless otherwise agreed to in writing by Parent and the Company) (the &#8220;<font style="font-family: 'Times New Roman';"><u>Initial





              Expiration Date</u></font>&#8221;, and such date or such subsequent date to which the Initial Expiration Date of the Offer is extended in accordance with the terms of this Agreement, the &#8220;<font style="font-family: 'Times New Roman';"><u>Expiration
              Date</u></font>&#8221;). Notwithstanding anything to the contrary contained in this Agreement, but subject to the Parties&#8217; respective termination rights under <font style="font-family: 'Times New Roman';"><u>Section 8</u></font>: (i) if, as of the
          then-scheduled time at which the Offer expires on the then-scheduled Expiration Date, any Offer Condition is not satisfied and has not been waived by Purchaser or Parent (to the extent waivable by Purchaser or Parent), Purchaser may, in its
          discretion (and without the consent of the Company or any other Person), extend the Offer on one or more occasions, for additional periods of up to ten (10) business days per extension, to permit such Offer Condition to be satisfied; <a name="z_Hlk224566033"></a>(ii) Purchaser shall extend the Offer from time to time for: (A) any period required by any Legal Requirement, any interpretation or position of the SEC, the staff thereof or Nasdaq applicable to the Offer, and <a name="z_Hlk224565634"></a>(B) one or more consecutive increments of up to ten (10) business days per extension, until any waiting period (and any extension thereof) applicable to the consummation of the Offer under the HSR Act, any foreign
          Antitrust Law and any Foreign Investment Law shall have expired or been terminated; and (iii) if, as of the then-scheduled Expiration Date, any Offer Condition is not satisfied and has not been waived (to the extent waivable by Purchaser or
          Parent), at the written request of the Company, Purchaser shall extend the Offer on one or more occasions for consecutive increments of such duration as requested by the Company, but not more than ten (10) business days per extension, to permit
          such Offer Condition to be satisfied; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>,<font style="font-family: 'Times New Roman'; font-style: italic;"> however</font>, that in no event shall Purchaser: (1) be
          required to extend the Offer beyond the earlier to occur of (x) the valid termination of this Agreement in accordance with <font style="font-family: 'Times New Roman';"><u>Section 8</u></font> and (y) the End Date (such earlier occurrence, the &#8220;<font style="font-family: 'Times New Roman';"><u>Extension Deadline</u></font>&#8221;); or (2) be permitted to extend the Offer beyond the Extension Deadline without the prior written consent of the Company; <font style="font-family: 'Times New Roman'; font-style: italic;">provided, further, however,</font> that if at any then-scheduled Expiration Date all of the Offer Conditions other than the Minimum Condition and any other conditions that by their nature are to be satisfied at the Offer
          Acceptance Time have been satisfied or waived and the Minimum Condition has not been satisfied, Purchaser shall not be required to, and Parent shall not be required to cause Purchaser to, extend the Offer pursuant to this <font style="font-family: 'Times New Roman';"><u>clause (iii)</u></font> on more than three (3) occasions in consecutive periods of up to ten (10) business days each. Purchaser shall not terminate the Offer, or permit the Offer to expire, prior to
          the Extension Deadline without the prior written consent of the Company.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473194673"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Termination of Offer</font>. Nothing in this <font style="font-family: 'Times New Roman';"><u>Section 1.1</u></font> shall be deemed to impair, limit or otherwise restrict in any
          manner the right of the Company, Parent or Purchaser to terminate this Agreement pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8</u></font>. In the event that this Agreement is validly terminated pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8</u></font>, Purchaser shall promptly, irrevocably and unconditionally terminate the Offer and shall not acquire any Shares pursuant to the Offer. If the Offer is terminated or withdrawn by
          Purchaser in accordance with the terms of this Agreement, Purchaser shall immediately return, and shall cause any depository acting on behalf of Purchaser to return, in accordance with applicable Legal Requirements, all tendered Shares to the
          registered holders thereof.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Offer Documents</font>. As promptly as practicable on the Offer Commencement Date, Parent and Purchaser shall (i) file with the SEC a tender offer statement on Schedule TO
            with respect to the Offer that will contain or incorporate by reference the Offer to Purchase and form of the related letter of transmittal (together with any exhibits, amendments or supplements thereto, the &#8220;<font style="font-family: 'Times New Roman';"><u>Offer Documents</u></font>&#8221;) and (ii) cause the Offer to Purchase and related documents to be disseminated to holders of Shares as and to the extent required by applicable Legal Requirements. Parent and Purchaser shall cause
            the Offer Documents to permit holders of Shares to tender Shares pursuant to the Offer pursuant to guaranteed delivery procedures. Parent and Purchaser agree that they shall cause the Offer Documents filed by either Parent or Purchaser with the
            SEC (x) to comply in all material respects with the Exchange Act and other applicable Legal Requirements and (y) to not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
            necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>,<font style="font-family: 'Times New Roman'; font-style: italic;"> however</font>, that no covenant is made by Parent or Purchaser with respect to information supplied by or on behalf of the Acquired Corporations for inclusion or incorporation by reference in the Offer
            Documents. Each of Parent, Purchaser and the Company agrees to respond promptly to any comments (including oral comments) of the SEC or its staff and to promptly correct any information provided by it for use in the Offer Documents if and to
            the extent that such information shall have become false or misleading in any material respect, and Parent and Purchaser further agree to take all steps necessary to cause the Offer Documents as so corrected to be filed with the SEC and to be
            disseminated to holders of Shares, in each case as and to the extent required by applicable Legal Requirements. The Company consents to the inclusion of the Company Board Recommendation in the Offer Documents; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that there has not been a Company Adverse Change Recommendation. The Company shall promptly furnish or otherwise make available to Parent and Purchaser or Parent&#8217;s legal counsel all information
            concerning the Acquired Corporations and the Company&#8217;s stockholders that may be required or reasonably requested in connection with any action contemplated by this <font style="font-family: 'Times New Roman';"><u>Section 1.1(e)</u></font>. The
            Company and its counsel shall be given reasonable opportunity to review and comment on the Offer Documents (including any response to any comments (including oral comments) of the SEC or its staff with respect thereto) prior to the filing
            thereof with the SEC, and Parent and Purchaser shall give reasonable and good faith consideration to any such comments made by the Company or its counsel. Parent and Purchaser agree to provide the Company and its counsel with any comments
            (including oral comments) Parent, Purchaser or their counsel may receive from the SEC or its staff with respect to the Offer Documents promptly after receipt of those comments (including oral comments).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref131543319"></a><a name="z_Ref196941420"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Funds</font>. Without limiting the generality of <font style="font-family: 'Times New Roman';"><u>Section 9.11</u></font>, Parent shall provide or
          cause to be provided to Purchaser, on a timely basis, all of the funds necessary to purchase all Shares that Purchaser becomes obligated to purchase pursuant to the Offer, and shall cause Purchaser to perform, on a timely basis, all of
          Purchaser&#8217;s obligations under this Agreement. Parent and Purchaser shall, and each of Parent and Purchaser shall ensure that all of their respective controlled Affiliates shall, tender any Shares held by them into the Offer.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473477446"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Adjustments</font>. If, between the date of this Agreement and the Offer Acceptance Time, the outstanding Shares are changed into a different number or class of shares by reason of any
          stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction, then the Offer Price shall be appropriately adjusted.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Acceptance</font>. <a name="z_Hlk131580713"></a>Subject only to the satisfaction or, to the extent waivable by Purchaser or Parent, waiver by Purchaser or Parent of each of
            the Offer Conditions, Purchaser shall (i) promptly after the expiration of the Offer irrevocably accept for payment all Shares tendered (and not validly withdrawn) pursuant to the Offer (the time of such acceptance, the &#8220;<font style="font-family: 'Times New Roman';"><u>Offer Acceptance Time</u></font>&#8221;) and (ii) promptly after the Offer Acceptance Time pay for such Shares.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref131542769"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Transfer Taxes</font>. If the payment of the Offer Price is to be made to a Person other than the Person in whose name the tendered Shares are registered on the stock transfer books of
          the Company, it shall be a condition of payment that the Person requesting such payment shall have paid all transfer and other similar Taxes required by reason of the payment of the Offer Price to a Person other than the registered holder of the
          Shares tendered, or shall have established to the satisfaction of Purchaser that such Taxes either have been paid or are not applicable. None of Parent, Purchaser or the Surviving Corporation shall have any liability for the transfer and other
          similar Taxes described in this <font style="font-family: 'Times New Roman';"><u>Section 1.1(i)</u></font> under any circumstance.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-size: 10pt;"><a name="z_Toc228288314"></a><a name="z_Toc227238376"></a><a name="z_Toc227238495"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">1.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;






        <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Company Actions</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473200333"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Schedule 14D-9</font>. As promptly as practicable on the Offer Commencement Date, following the filing of the Offer Documents, the Company shall (i) file with the SEC a <a name="z_9kR3WTr26645AeMnnfufOmmzog61tuC56FBH"></a>Tender Offer Solicitation/<a name="z_9kR3WTr26645BdKcnyxqssgx628no349346M"></a>Recommendation Statement on Schedule 14D-9 (together with any exhibits, amendments or supplements thereto, the &#8220;<font style="font-family: 'Times New Roman';"><u>Schedule 14D-9</u></font>&#8221;) that, subject to <font style="font-family: 'Times New Roman';"><u>Section 6.1(b)</u></font>, shall reflect the Company Board Recommendation and include the notice and other
          information required by Section 262(d)(2) of the DGCL and (ii) cause the Schedule 14D-9 and related documents to be disseminated to holders of Shares as and to the extent required by applicable Legal Requirements, including by setting the
          Stockholder List Date as the record date for purposes of receiving the notice required by Section 262(d)(2) of the DGCL. The Company agrees that it shall cause the Schedule 14D-9 (x) to comply in all material respects with the Exchange Act and
          other applicable Legal Requirements and (y) to not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the
          circumstances under which they were made, not misleading; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>,<font style="font-family: 'Times New Roman'; font-style: italic;"> however</font>, that no covenant is
          made by the Company with respect to information supplied by or on behalf of Parent or Purchaser for inclusion or incorporation by reference in the Schedule 14D-9. Each of Parent, Purchaser and the Company agrees to respond promptly to any
          comments (including oral comments) of the SEC or its staff and to promptly correct any information provided by it for use in the Schedule 14D-9 if and to the extent that such information shall have become false or misleading in any material
          respect, and the Company further agrees to take all steps necessary to promptly cause the Schedule 14D-9 as so corrected to be filed with the SEC and to be disseminated to holders of Shares, in each case as and to the extent required by
          applicable Legal Requirements. Parent and Purchaser shall promptly furnish or otherwise make available to the Company or the Company&#8217;s legal counsel all information concerning Parent or Purchaser that may be required or reasonably requested in
          connection with any action contemplated by this <font style="font-family: 'Times New Roman';"><u>Section 1.2(a)</u></font>. Parent and its counsel shall be given reasonable opportunity to review and comment on the Schedule 14D-9 (including any
          response to any comments (including oral comments) of the SEC or its staff with respect thereto) prior to the filing thereof with the SEC, and the Company shall give reasonable and good faith consideration to any such comments made by Parent or
          its counsel. The Company agrees to provide Parent and its counsel with any comments (including oral comments) the Company or its counsel may receive from the SEC or its staff with respect to the Schedule 14D-9 promptly after receipt of those
          comments (including oral comments).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473194475"></a><a name="z_Ref473291468"></a><a name="z_Ref196941413"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Stockholder Lists</font>. The Company shall, promptly after the date hereof, furnish Parent, and, if requested by
          Parent, furnish the Paying Agent and the Depository Agent, with a list of its stockholders of record, mailing labels and any available listing or computer file containing the names and addresses of all record holders of Shares and lists of
          securities positions of Shares held in stock depositories, in each case accurate and complete as of the most recent practicable date, and shall provide to Parent, and if requested by Parent, provide to the Paying Agent and the Depository Agent,
          such additional information (including updated lists of stockholders of record, mailing labels and lists of securities positions) and such other assistance as Parent may reasonably request in connection with disseminating the Offer Documents, and
          any other documents necessary to consummate the Transactions, to the holders of Shares (the date of the list used to determine the Persons to whom the Offer Documents and the Schedule 14D-9 are first disseminated, which date shall not be more
          than ten (10) days prior to the date the Offer Documents and the Schedule 14D-9 are first disseminated, the &#8220;<font style="font-family: 'Times New Roman';"><u>Stockholder List Date</u></font>&#8221;). Except for such steps as are necessary to
          disseminate the Offer Documents and any other documents necessary to consummate the Transactions, Parent and Purchaser and their Representatives shall hold in confidence in accordance with the Mutual Confidentiality Agreement dated January 23,
          2026, between the Company and Parent (as amended, the &#8220;<font style="font-family: 'Times New Roman';"><u>Confidentiality Agreement</u></font>&#8221;) the information contained in any such labels, listings and files, shall use such information only in
          connection with the Offer and the Merger and, if this Agreement shall be terminated, shall deliver, and shall use their reasonable best efforts to cause their agents to deliver, to the Company (or destroy) all copies and any extracts or summaries
          from such information then in their possession or control, and, if requested by the Company, promptly certify to the Company in writing that all such material has been returned or destroyed.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; font-weight: bold;">Share Registry</font>. The Company shall register (and shall instruct its transfer agent to register) the transfer of the Shares accepted for payment by Purchaser in the
            Offer effective immediately after the Offer Acceptance Time.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Toc227238377"></a><a name="z_Toc227238496"></a><a name="z_Toc228288315"></a>SECTION 2</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref460608480"></a><font style="font-family: 'Times New Roman';"><u>MERGER TRANSACTION</u></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608468"></a><a name="z_Toc227238378"></a><a name="z_Toc227238497"></a><a name="z_Toc228288316"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">2.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Merger of Purchaser into the Company</font>. Upon the terms and subject to the
        conditions set forth in this Agreement and in accordance with Section 251(h) of the DGCL, at the Effective Time, the Company and Parent shall consummate the Merger, whereby Purchaser shall be merged with and into the Company, the separate existence
        of Purchaser shall cease, and the Company will continue as the Surviving Corporation.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238379"></a><a name="z_Toc227238498"></a><a name="z_Toc228288317"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">2.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Effect of the Merger</font>. The Merger shall have the effects set forth in this Agreement and in the applicable
        provisions of the DGCL. Without limiting the generality of the foregoing, at the Effective Time, all of the property, rights, privileges, immunities, powers and franchises of the Company and Purchaser shall vest in the Surviving Corporation, and
        all of the debts, liabilities and duties of the Company and Purchaser shall become the debts, liabilities and duties of the Surviving Corporation.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><a name="z_Toc228288318"></a><a name="z_Toc227238380"></a><a name="z_Toc227238499"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">2.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Closing; Effective Time</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473293137"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Unless





          this Agreement shall have been terminated pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8</u></font>, and unless otherwise mutually agreed in writing between the Company, Parent and Purchaser, the consummation of the
          Merger (the &#8220;<font style="font-family: 'Times New Roman';"><u>Closing</u></font>&#8221;) shall take place via the electronic exchange of documents and signatures by the Parties, as soon as practicable (and in no event later than one (1) business day)
          following the consummation of the Offer except if the conditions set forth in <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> shall not be satisfied or, to the extent permissible by applicable Legal Requirements, waived as
          of such date, in which case the Closing shall take place on the first (1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>) business day on which all conditions set forth in <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> are satisfied or, to the extent permissible by applicable Legal Requirements, waived. The date on which the Closing occurs is referred to in this Agreement as the &#8220;<font style="font-family: 'Times New Roman';"><u>Closing





              Date</u></font>&#8221;.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473293544"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Subject





          to the provisions of this Agreement, as soon as practicable on the Closing Date, the Company and Purchaser shall file or cause to be filed a certificate of merger with the Secretary of State of the State of Delaware with respect to the Merger, in
          such form reasonably agreed upon between the Parties and as required by, and executed and acknowledged in accordance with, the relevant provisions of the DGCL, and the Parties shall take all such further actions as may be required by applicable
          Legal Requirements to make the Merger effective. The Merger shall become effective upon the date and time of the filing of that certificate of merger with the Secretary of State of the State of Delaware or such later date and time as is agreed
          upon in writing by the Parties and specified in the certificate of merger (such date and time the Merger is effective, the &#8220;<font style="font-family: 'Times New Roman';"><u>Effective Time</u></font>&#8221;).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><a name="z_Toc227238381"></a><a name="z_Toc227238500"></a><a name="z_Toc228288319"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">2.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Certificate of Incorporation and Bylaws; Directors and Officers</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As of the Effective Time, the certificate of incorporation of the Company shall by virtue of the Merger and without any further action, be amended and restated to read in its entirety as set forth on <font style="font-family: 'Times New Roman';"><u>Annex II</u></font> and, as so amended and restated, shall be the certificate of incorporation of the Surviving Corporation until thereafter changed or amended as provided therein or by applicable Legal Requirements, subject to <font style="font-family: 'Times New Roman';"><u>Section 6.4(a)</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As of the Effective Time, the bylaws of the Surviving Corporation shall be amended and restated to conform to the bylaws of Purchaser as in effect immediately prior to the Effective Time, until thereafter changed or amended as provided
            therein or by applicable Legal Requirements, subject to <font style="font-family: 'Times New Roman';"><u>Section 6.4(a)</u></font>, except that references to the name of Purchaser shall be replaced by references to the name of the Surviving
            Corporation.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As of the Effective Time, the directors and officers of the Surviving Corporation shall be the respective individuals who served as the directors and officers of Purchaser as of immediately prior to the Effective Time, until their
            respective successors are duly elected and qualified, or their earlier death, resignation or removal. Prior to the Effective Time, each director and, if so requested by Parent, each officer of the Company immediately prior to the Effective Time
            shall execute and deliver a letter effectuating such director&#8217;s resignation as a member of the Board of Directors and an officer of the Company (but for the avoidance of doubt, not as an employee of the Company), respectively, conditioned upon
            and effective as of the Effective Time.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><a name="z_Ref131492283"></a><a name="z_Toc227238382"></a><a name="z_Toc227238501"></a><a name="z_Toc228288320"></a><a name="z_Ref460608462"></a><a name="z_Ref460608463"></a><a name="z_Ref460608464"></a><a name="z_Ref460608465"></a><a name="z_Ref460608466"></a><a name="z_Ref460608467"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">2.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
        <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Conversion of Shares</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref131491939"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">At





          the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Purchaser, the Company or any stockholder of the Company:</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref473194524"></a><a name="z_Ref_ContractCompanion_9kb9Ur13A"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Shares held immediately prior to the Effective Time by the Company (or held in the Company&#8217;s treasury) shall be cancelled and retired and shall cease to exist, and no consideration
          shall be delivered in exchange therefor;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref473194529"></a><a name="z_Ref_ContractCompanion_9kb9Ur13C"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Shares held immediately prior to the Effective Time by Parent, Purchaser or any other direct or indirect wholly owned Subsidiary of Parent or Purchaser (including, for the avoidance
          of doubt, any Shares acquired by Purchaser in the Offer) shall be cancelled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref473295049"></a><a name="z_Ref196941414"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">subject to <font style="font-family: 'Times New Roman';"><u>Section 2.5(b)</u></font>, each Share outstanding immediately prior to the Effective Time (other than (A) any Excluded Shares and (B) any Dissenting
          Shares, which Dissenting Shares shall have only those rights set forth in <font style="font-family: 'Times New Roman';"><u>Section 2.7</u></font>) shall be converted into the right to receive the Offer Price (the &#8220;<font style="font-family: 'Times New Roman';"><u>Merger Consideration</u></font>&#8221;), without any interest thereon and subject to any withholding of Taxes in accordance with <font style="font-family: 'Times New Roman';"><u>Section 2.6(e)</u></font>; and</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iv)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">each share of the common stock, $0.001 par value per share, of Purchaser then outstanding shall be converted into one share of common stock of the Surviving Corporation.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">From and after the Effective Time, subject to this <font style="font-family: 'Times New Roman';"><u>Section 2.5(a)</u></font>, all Shares shall no
        longer be outstanding and shall automatically be cancelled and shall cease to exist, and each applicable holder of such Shares (other than Dissenting Shares) shall cease to have any rights with respect thereto, except the right to receive the
        Merger Consideration therefor upon the surrender of such Shares in accordance with <font style="font-family: 'Times New Roman';"><u>Section 2.6</u></font>, or, in the case of Dissenting Shares, the rights set forth in <font style="font-family: 'Times New Roman';"><u>Section 2.7</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608378"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">If,





          between the date of this Agreement and the Effective Time, the outstanding Shares are changed into a different number or class of shares by reason of any stock split, division or subdivision of shares, stock dividend, reverse stock split,
          consolidation of shares, reclassification, recapitalization or other similar transaction, then the Merger Consideration shall be appropriately adjusted.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">2.6</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;





          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Surrender of Certificates; Stock Transfer Books</font></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473293491"></a><a name="z_Ref196941415"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Prior to the commencement of the Offer, Parent shall designate a bank or trust company reasonably acceptable to the Company to act as agent (the &#8220;<font style="font-family: 'Times New Roman';"><u>Depository Agent</u></font>&#8221;)





          for the holders of Shares to receive the aggregate Offer Price to which holders of such Shares shall become entitled pursuant to <font style="font-family: 'Times New Roman';"><u>Section 1.1(h)</u></font> and to act as agent (the &#8220;<font style="font-family: 'Times New Roman';"><u>Paying Agent</u></font>&#8221;) for the holders of Shares to receive the aggregate Merger Consideration to which holders of such Shares shall become entitled pursuant to <font style="font-family: 'Times New Roman';"><u>Section 2.5</u></font>. As and when necessary to comply with its and Purchaser&#8217;s obligations hereunder, Parent shall deposit, or shall cause to be deposited, with the Depository Agent or Paying Agent cash sufficient to make the
          payment of the aggregate Offer Price payable pursuant to <font style="font-family: 'Times New Roman';"><u>Section 1.1(h)</u></font> and to pay the aggregate Merger Consideration payable pursuant to <font style="font-family: 'Times New Roman';"><u>Section





              2.5</u></font> (together, the &#8220;<font style="font-family: 'Times New Roman';"><u>Payment Fund</u></font>&#8221;). The Payment Fund shall not be used for any purpose other than to pay the aggregate Offer Price in the Offer and the aggregate Merger
          Consideration in the Merger. The Payment Fund shall be invested by the Paying Agent as directed by Parent;<font style="font-family: 'Times New Roman'; font-style: italic;"> provided</font> that no such investments or losses thereon shall relieve
          Parent and Purchaser from making (or shall have terms that could prevent or delay) the payments required by <font style="font-family: 'Times New Roman';"><u>Section 1.1(h)</u></font> and <font style="font-family: 'Times New Roman';"><u>Section
              2.5</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608377"></a><a name="z_Ref473292768"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Promptly after the Effective Time (but in no event later than three (3) business days thereafter), the Surviving Corporation shall cause to be delivered to each Person who was, at the Effective Time, a holder of
          record of (i) Shares represented by a certificate evidencing such Shares (the &#8220;<font style="font-family: 'Times New Roman';"><u>Certificated Shares</u></font>&#8221;) or (ii) Book-Entry Shares, who, in each case (i) and (ii) was entitled to receive the
          Merger Consideration pursuant to <font style="font-family: 'Times New Roman';"><u>Section 2.5</u></font>, (A) a form of letter of transmittal, which shall be in reasonable and customary form and shall specify that delivery shall be effected, and
          risk of loss and title to the Certificated Shares shall pass, only upon proper delivery of the certificates evidencing such Certificated Shares (the &#8220;<font style="font-family: 'Times New Roman';"><u>Certificates</u></font>&#8221;) (or affidavits of
          loss in lieu thereof in accordance with <font style="font-family: 'Times New Roman';"><u>Section 2.6(f)</u></font>, if applicable) to the Paying Agent, or a customary agent&#8217;s message with respect to Book-Entry Shares, and (B) instructions for
          use in effecting the surrender of the Certificates or Book-Entry Shares in exchange for the Merger Consideration issuable and payable in respect of such Shares pursuant to <font style="font-family: 'Times New Roman';"><u>Section 2.5</u></font>.
          Upon surrender to the Paying Agent of Certificates (or affidavits of loss in lieu thereof in accordance with <font style="font-family: 'Times New Roman';"><u>Section 2.6(f)</u></font>, if applicable) or Book-Entry Shares, together with such
          letter of transmittal in the case of Certificates, duly completed and validly executed in accordance with the instructions thereto, and such other documents as may be required pursuant to the instructions, the holder of such Certificated Shares
          or Book-Entry Shares shall be entitled to receive in exchange therefor the Merger Consideration for each Certificated Share or Book-Entry Share, and such Certificates and Book-Entry Shares shall then be cancelled. No interest shall accrue or be
          paid on the Merger Consideration payable upon the surrender of any Certificates or Book-Entry Shares for the benefit of the holder thereof. If the payment of any Merger Consideration is to be made to a Person other than the Person in whose name
          the surrendered Certificates formerly evidencing the Certificated Shares is registered on the stock transfer books of the Company, it shall be a condition of payment that the Certificate so surrendered shall be endorsed properly or otherwise be
          in proper form for transfer and that the Person requesting such payment shall have paid all transfer and other similar Taxes required by reason of the payment of the Merger Consideration to a Person other than the registered holder of the
          Certificate surrendered, or shall have established to the satisfaction of the Surviving Corporation that such transfer or other similar Taxes either have been paid or are not applicable. None of Parent, Purchaser or the Surviving Corporation
          shall have any liability for the transfer and other similar Taxes described in this <font style="font-family: 'Times New Roman';"><u>Section 2.6(b)</u></font> under any circumstance. Payment of the applicable Merger Consideration with respect to
          Book-Entry Shares shall only be made to the Person in whose name such Book-Entry Shares are registered. Until surrendered as contemplated by this <font style="font-family: 'Times New Roman';"><u>Section 2.6</u></font>, each Certificated Share
          and Book-Entry Share (in each case, other than Dissenting Shares) shall be deemed at any time after the <a name="El2_wO"></a>Effective Time to represent only the right to receive the applicable <a name="El20xO"></a>Merger Consideration as
          contemplated by <font style="font-family: 'Times New Roman';"><u>Section 2.5</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">At any time following twelve (12) months after the Effective Time, Parent shall be entitled to require the Paying Agent to deliver to it any funds (with respect to the aggregate Merger Consideration to which holders of Shares shall become
            entitled pursuant to <font style="font-family: 'Times New Roman';"><u>Section 2.5</u></font>) which had been made available to the Paying Agent and not disbursed to holders of Certificated Shares or Book-Entry Shares (including all interest
            and other income received by the Paying Agent in respect of all funds made available to it), and, thereafter, such holders shall be entitled to look to the Surviving Corporation (subject to abandoned property, escheat and other similar Legal
            Requirements) only as general creditors thereof with respect to the Merger Consideration that may be payable upon due surrender of the Certificates or Book-Entry Shares held by them, without any interest thereon. Notwithstanding the foregoing,
            neither the Surviving Corporation nor the Paying Agent shall be liable to any holder of Certificated Shares or Book-Entry Shares for the Merger Consideration delivered in respect of such Share to a public official pursuant to any abandoned
            property, escheat or other similar Legal Requirements. Any amounts remaining unclaimed by such holders at such time at which such amounts would otherwise escheat to or become property of any Governmental Body shall become, to the extent
            permitted by applicable Legal Requirements, the property of the Surviving Corporation or its designee, free and clear of all claims or interest of any Person previously entitled thereto.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">At the close of business on the day of the Effective Time, the stock transfer books of the Company with respect to the Shares shall be closed and thereafter there shall be no further registration of transfers of Shares on the records of
            the Company. From and after the Effective Time, the holders of the Shares outstanding immediately prior to the Effective Time shall cease to have any rights with respect to such Shares except as otherwise provided herein or by applicable Legal
            Requirements. If, after the <a name="El2wzO"></a>Effective Time, <a name="El2xzO"></a>Certificates or <a name="El2yzO"></a><a name="Elv5_O"></a>Book-Entry Shares are presented to the <a name="El2zzO"></a>Surviving Corporation for any
            reason, they shall be cancelled and exchanged as provided in this <a name="El2_zO"></a>Agreement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608376"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Each





          withholding agent shall be entitled to deduct and withhold from the Offer Price, the Merger Consideration, including payable to any holder of the Shares or any holder of Company Equity Awards, or any other consideration otherwise payable pursuant
          to this Agreement, in each case, such amounts as it is required by any Legal Requirement to deduct and withhold with respect to Taxes. Other than in respect of payments subject to compensatory withholding and paid through the relevant entity&#8217;s
          payroll system or backup withholding under Section 3406 of the Code, each such withholding agent shall use commercially reasonable efforts to reduce or eliminate any such withholding, including by requesting any necessary Tax forms, including <a name="z_9kR3WTr26645CVy9yL43"></a>IRS Form W-9 or the appropriate <a name="z_9kMHG5YVt48867EX0B0N65"></a>IRS Form W-8, as applicable, or any similar information. Each such withholding agent shall take all action that may be necessary to ensure
          that any such amounts so withheld are timely and properly remitted to the appropriate Governmental Body and such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the holder of the Shares, holder of
          Company Equity Awards or other recipient of consideration hereunder in respect of which such deduction and withholding was made.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the holder of the Certificated Shares formerly represented by that Certificate, or by a representative of that holder, claiming
            that Certificate to be lost, stolen or destroyed and, if required by the Surviving Corporation, the posting by that holder of a bond, in such reasonable amount as Parent may direct, as indemnity against any claim that may be made against it
            with respect to such Certificate (which amount shall not exceed the Merger Consideration payable with respect to such Certificated Shares), the Paying Agent will pay (less any Taxes required to be deducted or withheld pursuant to <font style="font-family: 'Times New Roman';"><u>Section 2.6(e)</u></font>), in exchange for such lost, stolen or destroyed Certificate, the applicable Merger Consideration to be paid in respect of the Certificated Shares formerly represented by
            such Certificate, as contemplated by this <font style="font-family: 'Times New Roman';"><u>Section</u></font><u> 2</u>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref473204114"></a><a name="z_Ref473287271"></a><a name="z_Ref473293519"></a><a name="z_Ref473295036"></a><a name="z_Toc227238384"></a><a name="z_Toc227238503"></a><a name="z_Toc228288322"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">2.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Dissenters&#8217;





          Rights</font>. Notwithstanding anything to the contrary in this Agreement, any Shares outstanding immediately prior to the Effective Time which are held by holders who are entitled to appraisal rights under Section 262 of the DGCL and have
        properly exercised and perfected their respective demands for appraisal of such Shares in the time and manner provided in Section 262 of the DGCL and, as of the Effective Time, have neither effectively withdrawn nor lost their rights to such
        appraisal and payment under the DGCL (the &#8220;<font style="font-family: 'Times New Roman';"><u>Dissenting Shares</u></font>&#8221;), shall not be converted into the right to receive the Merger Consideration, but shall, by virtue of the Merger, be
        automatically cancelled and no longer outstanding, shall cease to exist and the holder thereof shall be entitled to only such consideration as shall be determined pursuant to Section 262 of the DGCL in respect of such Dissenting Shares; <font style="font-family: 'Times New Roman'; font-style: italic;">provided </font>that if any such holder shall have failed to perfect or shall have effectively withdrawn or lost such holder&#8217;s right to appraisal and payment under the DGCL, such
        holder&#8217;s Shares shall be deemed to have been converted as of the Effective Time into the right to receive the Merger Consideration (less any Taxes required to be deducted or withheld pursuant to <font style="font-family: 'Times New Roman';"><u>Section





            2.6(e)</u></font>), and such Shares shall no longer be deemed to be Dissenting Shares. The Company shall give prompt notice to Parent and Purchaser of any demands received by the Company for appraisal of any Shares, withdrawals of such demands
        and any other instruments served pursuant to Section 262 of the DGCL, in each case prior to the Effective Time, and, at or prior to the Effective Time, the Company shall provide the Paying Agent with a list of the names and addresses of the holders
        of Dissenting Shares, if any, and such other information regarding the Dissenting Shares as the Paying Agent reasonably requests. Parent and Purchaser shall have the right to direct and to participate in all negotiations and proceedings with
        respect to such demands, and the Company shall not, without the prior written consent of Parent and Purchaser (which consent shall not be unreasonably withheld, conditioned or delayed), settle or offer to settle, or make any payment with respect
        to, any such demands, approve any withdrawal of any such demands or agree or commit to do any of the foregoing.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><a name="z_Toc228288323"></a><a name="z_Ref460608453"></a><a name="z_Ref460608454"></a><a name="z_Ref460608455"></a><a name="z_Ref460608456"></a><a name="z_Ref460608457"></a><a name="z_Ref460608458"></a><a name="z_Toc227238385"></a><a name="z_Toc227238504"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">2.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Treatment of Company Equity Awards and Company ESPP</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref228224472"></a><a name="z_Ref196927800"></a><a name="z_Hlk224559018"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">At the Effective Time, each Company Option that is then outstanding and unexercised, and which has a per Share exercise price that is less than the Merger Consideration, shall be (i) to
          the extent not then vested, deemed fully vested and (ii) cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the
          per Share exercise price of such Company Option, multiplied by (B) the total number of Shares subject to such Company Option immediately prior to the Effective Time, which shall be payable in accordance with <font style="font-family: 'Times New Roman';"><u>Section 2.8(c)</u></font>. Notwithstanding anything herein to the contrary, any Company Option with a per Share exercise price equal to or greater than the Merger Consideration shall be cancelled at the Effective Time without any
          consideration payable in respect thereof and shall have no further force or effect.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196927909"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">At





          the Effective Time, each then outstanding Company RSU shall be (i) deemed fully vested and (ii) cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger
          Consideration multiplied by (B) the number of Shares subject to such Company RSU immediately prior to the Effective Time, which shall be payable in accordance with <a name="z_Ref196921172"></a><a name="z_Ref460608373"></a><a name="z_Ref473206197"></a><font style="font-family: 'Times New Roman';"><u>Section 2.8(c)</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196922998"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As





          soon as reasonably practicable (but in any event no later than the second payroll date) after the Effective Time, the Surviving Corporation shall pay the Company Equity Award holders through its payroll system, payroll provider or the Company&#8217;s
          standard accounts payable procedures, as applicable, all amounts required to be paid to such holders in respect of Company Equity Awards that are canceled and converted pursuant to this <font style="font-family: 'Times New Roman';"><u>Section
              2.8</u></font>, less applicable Tax withholdings and other authorized deductions.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">To the extent a payment made pursuant to the timing set forth in this <u>Section 2.8</u> would trigger a Tax or penalty under Section 409A of the Code, such payment shall instead
              be made at such a time that such payment would not trigger such Tax or penalty.</font></font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Prior to the Effective Time, the Company, the Board of Directors (or the applicable committee thereof) shall take all actions appropriate or necessary to (i) effectuate the transactions described in this <font style="font-family: 'Times New Roman';"><u>Section 2.8</u></font> and (ii) terminate each Company Equity Plan effective as of, and contingent upon, the Effective Time. Parent shall have a reasonable opportunity to review and comment on any resolutions related to such
            actions and the Company shall not unreasonably omit comments provided by Parent with respect to such materials.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196941422"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The





          Board of Directors (or the applicable committee thereof), shall adopt resolutions or take such other actions as may be required to provide that (A) the commencement of any future offering period will be suspended following the date of this
          Agreement under the Company ESPP unless and until this Agreement is terminated, (B) there will be no increase in the amount of participants&#8217; payroll deduction elections under the Company ESPP during the current offering period from those in
          effect as of the date of this Agreement, (C) except to the extent required by applicable Legal Requirements, no individual participating in the Company ESPP shall be permitted to make separate non-payroll contributions to the Company ESPP, (D) no
          individuals shall commence participation in the Company ESPP during the period from the date of this Agreement through the Effective Time, and (E) each outstanding purchase right issued pursuant to the Company ESPP shall be fully exercised on the
          earlier of (x) the scheduled purchase date for such offering period and (y) the date that is no later than five (5) business days prior to the Effective Time (with any participant payroll deductions not applied to the purchase of Shares returned
          to the participant), and (ii) terminate the Company ESPP effective immediately prior to, and contingent upon, the Effective Time.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">2.9</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;





          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Further Action</font></font>. The Parties agree to take all necessary action to cause the Merger to become effective in accordance with this <font style="font-family: 'Times New Roman';"><u>Section 2</u></font> as soon as practicable following the consummation of the Offer without a meeting of the Company&#8217;s stockholders, as provided in Section 251(h) of the DGCL. If, at any time after the
        Effective Time, any further action is reasonably determined by Parent to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and
        property of Purchaser and the Company, the officers and directors of the Surviving Corporation and Parent shall be fully authorized (in the name of Purchaser, in the name of the Company and otherwise) to take such action.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Toc227238387"></a><a name="z_Toc227238506"></a><a name="z_Toc228288325"></a>SECTION 3</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref460608479"></a><font style="font-family: 'Times New Roman';"><u>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</u></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company hereby represents and warrants to Parent and Purchaser as follows (it being understood that each representation and warranty contained in
        this <font style="font-family: 'Times New Roman';"><u>Section 3</u></font> is subject to (a) exceptions and disclosures set forth in the section or subsection of the Company Disclosure Schedule corresponding to the particular section or subsection
        in this <font style="font-family: 'Times New Roman';"><u>Section 3</u></font>; (b) any exception or disclosure set forth in any other section or subsection of the Company Disclosure Schedule to the extent it is reasonably apparent on the face of
        such disclosure that such exception or disclosure is applicable to qualify such representation and warranty; and (c) disclosure in the Company SEC Documents filed and publicly available at least one (1) business day prior to the date of this
        Agreement (other than any information in the &#8220;<a name="ignore5"></a><a name="z_9kR3WTr26645DfOwzN8cw98D"></a>Risk Factors&#8221; or &#8220;<a name="ignore6"></a><a name="z_9kR3WTr26645EUI1AuquPV52x10go349346MS"></a>Forward-Looking Statements&#8221; sections of such
        Company SEC Documents or other general cautionary or forward-looking statements in any other sections of such Company SEC Documents)); <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that this <font style="font-family: 'Times New Roman';"><u>clause (c)</u></font> shall not be applicable to <font style="font-family: 'Times New Roman';"><u>Sections 3.3</u></font> and <font style="font-family: 'Times New Roman';"><u>3.21</u></font>:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><a name="z_Toc228288326"></a><a name="z_Ref473295354"></a><a name="z_Ref473295382"></a><a name="z_Toc227238388"></a><a name="z_Toc227238507"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Due Organization; Subsidiaries, Etc</font>.<a name="z_Ref460608371"></a></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref10099780"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The





          Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, and the Company&#8217;s Subsidiaries are set forth on <font style="font-family: 'Times New Roman';"><u>Section 3.1</u></font> of
          the Company Disclosure Schedule (the Company and its Subsidiaries, each an &#8220;<font style="font-family: 'Times New Roman';"><u>Acquired Corporation</u></font>&#8221; and collectively, the &#8220;<font style="font-family: 'Times New Roman';"><u>Acquired
              Corporations</u></font>&#8221;). Each Subsidiary of the Company is duly organized, validly existing and in good standing (with respect to jurisdictions that recognize such concept) under the laws of its jurisdiction of organization. Each Acquired
          Corporation has all necessary power and authority: (i) to conduct its business in the manner in which its business is currently being conducted and (ii) to own and use its assets in the manner in which its assets are currently owned and used.
          Each Acquired Corporation is qualified or licensed to do business as a foreign corporation or other entity, and is in good standing, in each jurisdiction where the nature of its business requires such qualification or licensing, except where such
          failure has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Company owns beneficially and of record all of the outstanding shares of capital stock of the other Acquired Corporations, free and clear of all Encumbrances and transfer restrictions, except for Encumbrances or transfer restrictions
            of general applicability as may be provided under the Securities Act or applicable securities laws. Except for the shares of capital stock of the other Acquired Corporations held by the Company, no Acquired Corporation owns, directly or
            indirectly, any capital stock or equity interests of, or subscriptions, options, calls, warrants or rights (whether or not currently exercisable) to acquire, or other securities convertible into or exchangeable or exercisable for, any capital
            stock or equity interests of, any Entity.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref473295388"></a><a name="z_Ref473295446"></a><a name="z_Toc227238389"></a><a name="z_Toc227238508"></a><a name="z_Toc228288327"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Certificate of Incorporation and Bylaws</font>. The Company
        has delivered or made available to Parent accurate and complete copies of the certificate of incorporation, bylaws and other charter and organizational or governing documents of each Acquired Corporation, including all amendments thereto, as in
        effect on the date hereof.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><a name="z_Toc228288328"></a><a name="z_Ref460608451"></a><a name="z_Ref460608452"></a><a name="z_Toc227238390"></a><a name="z_Toc227238509"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Capitalization, Etc</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608370"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The





          authorized capital stock of the Company consists of: (i) 100,000,000 Shares, of which 53,167,988 Shares had been issued and were outstanding as of the close of business on April 24, 2026 (the &#8220;<font style="font-family: 'Times New Roman';"><u>Capitalization





              Date</u></font>&#8221;); and (ii) 5,000,000 shares of Company Preferred Stock, of which no shares are outstanding. From the Capitalization Date to the execution of this Agreement, the Company has not issued any Shares except pursuant to the
          exercise of Company Options or the vesting or settlement of Company RSUs, in each case outstanding as of the Capitalization Date in accordance with their terms as in effect on the Capitalization Date and, from the Capitalization Date to the
          execution of this Agreement, the Company has not issued any warrants to acquire Shares or any Company Options, Company RSUs or other equity or equity-based awards. All of the outstanding shares of the capital stock of the Company have been duly
          authorized and validly issued, and are fully paid and nonassessable.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Company owns all of the authorized and outstanding capital stock and other equity interests of each of the Company&#8217;s Subsidiaries. All of the outstanding shares of the capital stock of the Company&#8217;s Subsidiaries have been duly
            authorized and validly issued and are fully paid and nonassessable. The Company does not own, directly or indirectly, any capital stock or other equity interests in, or subscriptions, options, calls, warrants or rights (whether or not currently
            exercisable) to acquire, or other securities convertible into or exchangeable or exercisable for, any capital stock or other equity interests of any other Entity.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608369"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)





          None of the outstanding shares of capital stock of the Acquired Corporations are entitled or subject to any preemptive right, right of repurchase or forfeiture, right of participation, right of maintenance or any similar right; (ii) none of the
          outstanding shares of capital stock of the Acquired Corporations are subject to any right of first refusal in favor of any Acquired Corporation; (iii) there are no outstanding bonds, debentures, notes or other indebtedness of any Acquired
          Corporation having a right to vote on any matters on which the stockholders of the Acquired Corporations have a right to vote; and (iv) there is no Contract relating to the voting or registration of, or restricting any Person from purchasing,
          selling, pledging or otherwise disposing of (or from granting any option or similar right with respect to), any shares of capital stock of the Acquired Corporations. No Acquired Corporation is under any obligation, or bound by any Contract
          pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of capital stock of the Acquired Corporations, except in connection with any acquisitions, or deemed acquisitions, of Shares or other
          equity securities of the Company in connection with (x) the withholding of Taxes in connection with the exercise, vesting or settlement of Company Equity Awards and (y) forfeitures of Company Equity Awards. The Shares constitute the only
          outstanding class of securities of the Company registered under the Securities Act. No Subsidiary of the Company owns any Shares.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As of the Capitalization Date: (i) 4,789,390 Shares were issuable upon the exercise of outstanding Company Options; (ii) 3,759,452 Shares were issuable upon the vesting or settlement of outstanding Company RSUs; (iii) 46,104 Shares were
            subject to outstanding purchase rights under the Company ESPP (assuming a purchase price equal to the fair market value of a Share on the first day of the current offering period); (iv) 1,990,364 Shares were reserved for future issuance under
            the Company ESPP; (v) 1,630,000 Shares were issuable upon the exercise of the Company Warrants; and (vi) 8,551,960 Shares were reserved for future issuance upon conversion of the Convertible Senior Notes. Other than as set forth in this <font style="font-family: 'Times New Roman';"><u>Section 3.3</u></font>, there are no issued, reserved for issuance, outstanding or authorized stock option, stock appreciation, phantom stock, profit participation or similar rights or equity-based
            awards with respect to the Company.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref226991442"></a><a name="z_Ref131684172"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Section 3.3(e)</u></font> of the Company Disclosure Schedule sets forth a schedule of each outstanding Company Equity Award as of the Capitalization Date, including,
          as applicable, (i) the type of award (e.g., incentive stock option, non-statutory stock option, restricted stock unit, etc.); (ii) the name of the holder; (iii) the number of Shares underlying such Company Equity Award; (iv) the grant date; (v)
          the exercise price; (vi) the vesting terms; and (vii) the expiration date. Each outstanding Company Equity Award (A) was granted in compliance with applicable Legal Requirements and the terms and conditions of the applicable Company Equity Plan
          and award agreement under which it was granted and (B) if held by a U.S. employee or other service provider (current or former), has continuously since grant met all requirements for exemption from Section 409A of the Code. Each Company Option
          has a per Share exercise price equal to or greater than the fair market value of a Share on the date of grant as determined in accordance with Section 409A of the Code and Section 422 of the Code, as applicable. Each Company Option that is
          intended to qualify as an &#8220;incentive stock option&#8221; satisfies the requirements of Section 422 of the Code.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">There are no issued, reserved for issuance, outstanding or authorized stock option, stock appreciation, phantom stock, profit participation or similar rights or equity-based awards with respect to any Subsidiary of the Company.<a name="z_Ref460608367"></a></font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196941424"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Except





          (x) as set forth in this <font style="font-family: 'Times New Roman';"><u>Section 3.3</u></font>, (y) for the Company Equity Awards, Company Warrants and Convertible Senior Notes outstanding as of the date of this Agreement (or issued after the
          date hereof in compliance with <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)(iii)</u></font> or <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)(iv)</u></font>) and (z) for the purchase rights under the Company
          ESPP, there are no: (i) outstanding shares of capital stock or other securities of any Acquired Corporation; (ii) outstanding subscriptions, options, calls, warrants or rights (whether or not currently exercisable) to acquire any shares of the
          capital stock, restricted stock unit, performance stock unit, stock appreciation rights, incentive award measured based on the Shares, stock-based performance unit or any other right that is linked to, or the value of which is in any way based on
          or derived from the value of any shares of capital stock or other securities of any Acquired Corporation, in each case other than derivative securities not issued by an Acquired Corporation; (iii) outstanding securities, instruments, bonds,
          debentures, notes or obligations that are or may become convertible into or exchangeable for any shares of the capital stock or other securities of any Acquired Corporation; (iv) stockholder rights plans (or similar plans commonly referred to as
          a &#8220;<a name="ignore7"></a>poison pill&#8221;) or Contracts under which any Acquired Corporation is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities; or (v) voting trusts or other Contract to
          which any Acquired Corporation is a party with respect to the voting of capital stock of any Acquired Corporation.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">15</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><a name="z_Toc228288329"></a><a name="z_Toc227238391"></a><a name="z_Toc227238510"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">SEC Filings; Financial Statements</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473221215"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Since





          January 1, 2023, the Company has filed or furnished on a timely basis all reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated therein) required to be filed or furnished by the
          Company with the SEC (as supplemented, modified or amended since the time of filing, the &#8220;<font style="font-family: 'Times New Roman';"><u>Company SEC Documents</u></font>&#8221;). As of the respective date each of the Company SEC Documents was filed
          or furnished by the Company with the SEC, or, if amended prior to the date of this Agreement, as of the date of (and giving effect to) the last such amendment (and, in the case of registration statements and proxy statements, on the date of
          effectiveness and the dates of the relevant meetings, respectively), the Company SEC Documents complied in all material respects with the requirements of the Securities Act, the Exchange Act or the Sarbanes-Oxley Act, as the case may be, and the
          rules and regulations of the SEC promulgated thereunder applicable to those Company SEC Documents, and, except to the extent that information contained in such Company SEC Document has been revised, amended, modified or superseded (prior to the
          date of this Agreement) by a later filed Company SEC Document, none of the Company SEC Documents when filed or furnished contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or
          necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473293614"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The





          financial statements (including any related notes and schedules) contained or incorporated by reference in the Company SEC Documents when filed: (i) complied as to form in all material respects with the published rules and regulations of the SEC
          applicable thereto; (ii) were prepared in accordance with United States generally accepted accounting principles (&#8220;<font style="font-family: 'Times New Roman';"><u>GAAP</u></font>&#8221;) applied on a consistent basis throughout the periods covered
          (except as may be indicated in the notes to such financial statements or, in the case of unaudited interim financial statements, as may be permitted by the SEC on <a name="z_9kR3WTr26645FVI10BDd"></a>Form 10-Q, 8-K or any successor form under
          the Exchange Act); and (iii) fairly presented, in all material respects, the financial position of the Acquired Corporations as of the respective dates thereof and the results of operations and cash flows of the Acquired Corporations for the
          periods covered thereby (subject, in the case of the unaudited financial statements, to the absence of notes and to normal and recurring year-end adjustments).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">16</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Company maintains a system of &#8220;internal control over financial reporting&#8221; (as defined in Rule 13a-15 under the Exchange Act), which is designed to provide reasonable assurance regarding the reliability of financial reporting and the
            preparation of financial statements for external purposes in accordance with GAAP, and includes those policies and procedures that: (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the
            transactions and dispositions of the consolidated assets of the Acquired Corporations; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and that
            receipts and expenditures are being made only in accordance with authorizations of management and the Board of Directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or
            disposition of the consolidated assets of the Acquired Corporations that could have a material effect on its financial statements. The Company&#8217;s management has completed an assessment of the effectiveness of the Company&#8217;s system of internal
            control over financial reporting in compliance with the requirements of Section 404 of the Sarbanes-Oxley Act for the fiscal year ended December 31, 2025, and, except as set forth in the Company SEC Documents filed at least one (1) business day
            prior to the date of this Agreement, that assessment concluded that those controls were effective. Since January 1, 2026, neither the Company nor, to the knowledge of the Company, the Company&#8217;s independent registered accountant has identified
            or been made aware of: (1) any significant deficiency or material weakness in the design or operation of the internal control over financial reporting utilized by the Company, which is reasonably likely to adversely affect the Company&#8217;s ability
            to record, process, summarize and report financial information; or (2) any fraud, whether or not material, that involves the management or other employees of the Company who have a significant role in the Company&#8217;s internal control over
            financial reporting.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Company maintains disclosure controls and procedures as defined in and required by Rule 13a-15 or 15d-15 under the Exchange Act that are reasonably designed to ensure that all information required to be disclosed in the Company&#8217;s
            reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that all such information is accumulated and communicated to the
            Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure and to enable the principal executive officer of the Company and the principal financial officer of the Company to make the certifications required
            under the Exchange Act with respect to such reports. The Company is in compliance in all material respects with all current listing and corporate governance requirements of Nasdaq.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Company is not a party to, nor does it have any obligation or other commitment to become a party to, &#8220;<a name="ignore8"></a>off-balance sheet arrangements&#8221; (as defined in Item 303(a) of Regulation S-K under the Exchange Act) where the
            result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, the Acquired Corporations in the Company SEC Documents.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the Company SEC Documents. None of the Company SEC Documents is the subject of ongoing SEC review,
            and there are no inquiries or investigations by the SEC or any internal investigations pending or threatened, in each case regarding any accounting practices of the Company.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">17</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473293180"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Each





          document required to be filed by the Company with the SEC in connection with the Offer, including the Schedule 14D-9 (the &#8220;<font style="font-family: 'Times New Roman';"><u>Company Disclosure Documents</u></font>&#8221;), and any amendments or
          supplements thereto, when filed, distributed or otherwise disseminated to the Company&#8217;s stockholders, as applicable, will comply as to form in all material respects with the applicable requirements of the Exchange Act. The Company Disclosure
          Documents, at the time of the filing of such Company Disclosure Documents or any supplement or amendment thereto with the SEC and at the time such Company Disclosure Documents or any supplements or amendments thereto are first distributed or
          otherwise disseminated to the Company&#8217;s stockholders, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of
          the circumstances under which they were made, not misleading.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The information with respect to the Acquired Corporations that the Company furnishes to Parent or Purchaser specifically for use in the Offer Documents, (x) at the time of the filing of, (y) at any time such document is amended or
            supplemented, and (z) at the time of any distribution or dissemination of the Offer Documents, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to
            make the statements made therein, in light of the circumstances under which they were made, not misleading.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(ii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Notwithstanding the foregoing, the Company makes no representation with respect to statements made or incorporated by reference therein based on information supplied by or on behalf of Parent or Purchaser for inclusion or incorporation by
            reference in the Company Disclosure Documents.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608450"></a><a name="z_Toc227238392"></a><a name="z_Toc227238511"></a><a name="z_Toc228288330"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Absence of Changes; No Material Adverse Effect</font>. Except as expressly contemplated
        by this Agreement, from January 1, 2026 through the date of this Agreement:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">except for discussions, negotiations and activities related to this Agreement or other potential strategic transactions, the Acquired Corporations have operated in all material respects in the ordinary course of business consistent with
            past practice and none of the Acquired Corporations has taken any action that would have required the consent of Parent under <font style="font-family: 'Times New Roman';"><u>clauses (i)</u></font>, <font style="font-family: 'Times New Roman';"><u>(ii)</u></font>, <font style="font-family: 'Times New Roman';"><u>(vii)</u></font>, <font style="font-family: 'Times New Roman';"><u>(ix)</u></font>, <font style="font-family: 'Times New Roman';"><u>(x)</u></font>, <font style="font-family: 'Times New Roman';"><u>(xi)</u></font>, <font style="font-family: 'Times New Roman';"><u>(xii)</u></font>, <font style="font-family: 'Times New Roman';"><u>(xiv)</u></font>, <font style="font-family: 'Times New Roman';"><u>(xvi)</u></font>,
            <font style="font-family: 'Times New Roman';"><u>(xvii)</u></font>, <font style="font-family: 'Times New Roman';"><u>(xviii)</u></font>, <font style="font-family: 'Times New Roman';"><u>(xix)</u></font>, <font style="font-family: 'Times New Roman';"><u>(xx)</u></font> and <font style="font-family: 'Times New Roman';"><u>(xxi)</u></font> (solely as relates to the foregoing) of <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)</u></font> had such action occurred
            after the date of this Agreement; and</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473295470"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">there





          has not occurred any event, occurrence, circumstance, change or effect that, individually or in the aggregate, has had or would reasonably be expected to have, a Material Adverse Effect.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref196941432"></a><a name="z_Toc227238393"></a><a name="z_Toc227238512"></a><a name="z_Toc228288331"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Title to Assets</font>. Each Acquired Corporation has good and valid title to all
        material assets (excluding Intellectual Property Rights) owned by it as of the date of this Agreement, and such assets are owned by the Acquired Corporations free and clear of any Encumbrances (other than Permitted Encumbrances).</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288332"></a><a name="z_Toc227238394"></a><a name="z_Toc227238513"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Real Property</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Acquired Corporations do not own any real property.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">18</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Section 3.7(b)</u></font> of the Company Disclosure Schedule sets forth an accurate and complete list in all material respects of all real property currently leased, subleased or licensed by
            or from the Acquired Corporations or otherwise used or occupied by the Acquired Corporations. The Acquired Corporations hold valid and existing leasehold interests in the real property that is leased or subleased by the Acquired Corporations
            from another Person (the &#8220;<font style="font-family: 'Times New Roman';"><u>Leased Real Property</u></font>&#8221;), free and clear of all Encumbrances other than Permitted Encumbrances, in each case, except as would not reasonably be expected to
            have, individually or in the aggregate, a Material Adverse Effect. Since January 1, 2023, no Acquired Corporation has received any written notice regarding (i) any material violation or breach or default under any lease related to the Leased
            Real Property that has not since been cured; (ii) any pending or threatened in writing condemnation of any portion of the Leased Real Property; or (iii) building, fire or zoning code violations with respect to the Leased Real Property, in each
            case in <font style="font-family: 'Times New Roman';"><u>clauses (i)</u></font> through <font style="font-family: 'Times New Roman';"><u>(iii)</u></font>, that is material to the Acquired Corporations, taken as a whole.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288333"></a><a name="z_Ref10468779"></a><a name="z_Ref10468805"></a><a name="z_Ref10469315"></a><a name="z_Ref10469347"></a><a name="z_Toc227238395"></a><a name="z_Toc227238514"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Intellectual





          Property</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref227253841"></a><a name="z_Ref473278781"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Section 3.8(a)</u></font> of the Company Disclosure Schedule sets forth a complete and accurate list, as of the date of this Agreement, of each item of Company IP that
          is Registered IP (&#8220;<font style="font-family: 'Times New Roman';"><u>Company Registered IP</u></font>&#8221;) and Registered IP that is Exclusively Licensed IP, including for each item (as applicable):</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">with respect to Patents: (i) the name of <a name="z_cp_text_1_8"></a>the current registered owner(s) and, with respect to Patents exclusively related to Ekterly (sebetralstat) if different, the owner(s) at the time of filing, (ii) the
            jurisdiction of application or registration, (iii) the application or registration number<a name="z_cp_text_1_12"></a>, <a name="z_cp_text_1_18"></a>(iv) the application filing date, (v) the name of each inventor, (vi) the priority application
            numbers and dates, (vii) the registration or issuance date, (viii) the current expiration date (including any patent term extension under 35 U.S.C. &#167; 156 or similar foreign Legal Requirement, and whether the patent is subject to any terminal
            disclaimer), (ix) the next renewal or maintenance fee due date, any patent term adjustment under 35 U.S.C. &#167; 154(b) or similar foreign Legal Requirement, and whether the patent is subject to any terminal disclaimer, and (x) the current
            prosecution or registration status;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(ii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">with respect to Trademarks: (i) the name of the current registered owner(s), (ii) the jurisdiction of application or registration, (iii) the application or registration number, (iv) the application filing date, (v) the international
            class(es) and the list of goods and services covered thereby, (vi) the registration date, (vii) the next renewal date, and (viii) the current prosecution or registration status.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">All such Company Registered IP and Registered IP exclusively licensed to the Company is subsisting and, other than pending applications therefor,
        valid and enforceable.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 3.8(a)</u></font><font style="font-size: 10pt;"> of the Company Disclosure
          Schedule sets forth a separate list identifying all Patents and Trademarks that were owned or held by any Acquired Corporation at any time during the five (5) years prior to the date of this Agreement and that have lapsed, expired, or been
          abandoned, including for each such item (i) the applicable jurisdiction and (ii) the application or registration number. For the avoidance of doubt, such lapsed, expired, or abandoned items shall not constitute Company Registered IP for purposes
          of this Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">19</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-size: 10pt;"><a name="z_Ref227050563"></a></div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The ownership of each item of Company Registered IP is recorded with the applicable Governmental Body solely in the name of the applicable Acquired Corporation, or an Acquired Corporation is the applicant of record with respect thereto.
            The Acquired Corporations do not own or purport to own any proprietary software. An Acquired Corporation has timely made all filings and payments with Governmental Bodies as may be necessary or appropriate to preserve, maintain and protect the
            Company Registered IP and all such filings and payments with Governmental Bodies have been timely paid with respect to Registered IP that is Exclusively Licensed IP.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No interference, opposition, reissue, reexamination proceeding, cancellation proceeding, or other Legal Proceeding (other than routine examination proceedings with respect to pending applications) is pending or threatened in writing
            against any Acquired Corporation, in which the scope, title, validity, enforceability, priority, inventorship or ownership of any Company Registered IP or Exclusively Licensed IP that is Registered IP is being contested or challenged. No
            interference, opposition, reissue, reexamination proceeding, cancellation proceeding, or other Legal Proceeding related to the scope, title, validity, enforceability, priority, inventorship or ownership of any Intellectual Property Rights has
            been commenced or threatened in writing by or on behalf of any Acquired Corporation against any third party.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Acquired Corporations are the sole and exclusive owners of all Company IP, free and clear of all Encumbrances other than Permitted Encumbrances. The Acquired Corporations have the valid and enforceable right to use or otherwise
            practice all Intellectual Property Rights used in the business of the Acquired Corporations and will continue to own, license or have the right to use, practice and transfer all such material Intellectual Property Rights, including all Company
            IP and Exclusively Licensed IP immediately following the Closing in the same manner and to the same extent as prior to the Closing.<a name="z_Ref460608364"></a></font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No funding, facilities or personnel of any Governmental Body, university, research institute or other educational institution has been used to develop any of the Company IP or Exclusively Licensed IP.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Acquired Corporations have maintained and currently maintain commercially reasonable steps to maintain the confidentiality of Trade Secrets included in the Company IP and Exclusively Licensed IP. The Acquired Corporations are not in
            breach of and have not breached any obligations or undertakings of confidentiality which they owe or have owed to any Person. Each current and former employee, consultant, and contractor of any Acquired Corporation who has contributed to the
            creation or development of any Company IP has executed a valid and enforceable written agreement assigning to an Acquired Corporation all rights, title, and interest in and to such Intellectual Property Rights, and no such Person has retained
            any ownership rights or has any claim to any Company IP<a name="z_Ref460608363"></a><a name="z_Ref131686063"></a>.<a name="z_Ref460608362"></a></font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref189692062"></a><a name="z_Ref222764611"></a><a name="z_Ref226992742"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Section 3.8(g)</u></font> of the Company Disclosure Schedule sets forth each Contract that is a license agreement or other agreement
          pursuant to which an Acquired Corporation licenses, obtains a covenant not to sue, or otherwise receives a right from a third Person in or to any Intellectual Property Right (each an &#8220;<font style="font-family: 'Times New Roman';"><u>In-bound IP
              Contract</u></font>&#8221;) or licenses, grants a covenant not to sue, or otherwise grants a right to a third Person in or to any Company IP (each an &#8220;<font style="font-family: 'Times New Roman';"><u>Out-bound IP Contract</u></font>&#8221;, and
          collectively with the In-bound IP Contracts, &#8220;<font style="font-family: 'Times New Roman';"><u>IP Contracts</u></font>&#8221;) (<font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">that</font>, (a) In-bound IP Contracts shall exclude commercially available off-the-shelf software, clinical trial agreements, non-disclosure agreements, service agreements (other than material service agreements),
          employee invention assignment agreements or material transfer agreements, in each case, entered into in the ordinary course of business, (b) Out-bound IP Contracts shall exclude non-exclusive outbound licenses entered into in the ordinary course
          of business contained in clinical trial agreements, non-disclosure agreements, sales or marketing agreements, material transfer agreements, service agreements (other than material service agreements), or agreements where such license is ancillary
          to the primary purpose of the Contract, and (c) IP Contracts shall exclude Contracts in which the license of Intellectual Property Rights is incidental to the performance of such Contract (such Contracts excluded from IP Contracts pursuant to <font style="font-family: 'Times New Roman';"><u>clauses (a)</u></font> through <font style="font-family: 'Times New Roman';"><u>(c)</u></font>, &#8220;<font style="font-family: 'Times New Roman';"><u>Standard IP Contracts</u></font>&#8221;)).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">20</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196941430"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">To





          the knowledge of the Company, the operation of the Acquired Corporations&#8217; business as currently conducted or the use of the Company IP, has not infringed, misappropriated or otherwise violated, and does not infringe, misappropriate or otherwise
          violate any Intellectual Property Rights of any other Person. As of the date of this Agreement, (i) no Legal Proceeding is pending (or, threatened in writing) against an Acquired Corporation alleging infringement, misappropriation or other
          violation of any Intellectual Property Rights of another Person and (ii) since January 1, 2023, no Acquired Corporation has received any written notice or other written communication alleging infringement, misappropriation or other violation of
          any Intellectual Property Right of another Person by an Acquired Corporation.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_cp_text_1_101"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">To





          the knowledge of the Company, no Person has infringed, misappropriated or otherwise violated, nor is any Person infringing, misappropriating or otherwise violating, any Company IP or the Exclusively Licensed IP. As of the date of this Agreement,
          no Legal Proceeding is pending or threatened in writing by an Acquired Corporation alleging infringement, misappropriation or other violation of any Company IP or Exclusively Licensed IP, and, in the last six (6) years, no Legal Proceeding has
          been brought by an Acquired Corporation alleging infringement, misappropriation or other violation of any Company IP or the Exclusively Licensed IP.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref10092153"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(j)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)





          An Acquired Corporation lawfully owns, leases, licenses or has the right to use the Company IT Assets, and will continue to own, lease, license or have the right to use all material Company IT Assets at the Effective Time; (ii) such systems and
          Company IT Assets are sufficient for the immediate and currently anticipated needs of the Acquired Corporations and operate and perform in a manner that permits the Acquired Corporations to conduct their respective business as currently
          conducted; (iii) the Acquired Corporations have taken commercially reasonable actions, consistent with current industry standards, to protect the confidentiality, integrity and security of the Company IT Assets (and all information and
          transactions stored therein or transmitted thereby) against any unauthorized use, access, interruption, modification or corruption; (iv) to the knowledge of the Company, there has been no unauthorized use, access, interruption, modification or
          corruption of any Company IT Assets (or any information or transactions stored therein or transmitted thereby); (v) the Company IT Assets do not contain any viruses, bugs, vulnerabilities, faults or other disabling code; to the knowledge of the
          Acquired Corporations, the Company IT Assets do not contain any &#8220;back door&#8221;, &#8220;time bomb&#8221;, &#8220;<a name="z_9kR3WTr266467aZ1uhm"></a>Trojan horse&#8221;, &#8220;worm&#8221;, &#8220;drop dead device&#8221;, &#8220;virus&#8221;, malware or other software routines or components intentionally
          designed to permit unauthorized access to, maliciously disable, maliciously encrypt or erase software, hardware, or data; (vi) the Acquired Corporations are not in material breach of any of their material Contracts relating to any Company IT
          Assets; (vii) since January 1, 2023, the Acquired Corporations have not been subjected to an audit of any kind in connection with any Contract pursuant to which they use any Company IT Assets, nor received any notice of intent to conduct any such
          audit, except to the extent such audit did not result in liability that remains outstanding.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">21</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(k)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">With respect to all Patents included in the Company Registered IP: (i) no application to reissue or reexamination proceeding for any issued Patents is pending; (ii) no statutory disclaimer has been filed as to any issued Patents; (iii) no
            declaratory judgment action relating to the validity, enforceability or infringement of any issued Patents has been served on any Acquired Corporation; and (iv) no claim of any issued Patent has been cancelled or held invalid or unenforceable
            by any Governmental Body.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(l)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Acquired Corporations use all Artificial Intelligence Tools in compliance with the applicable license terms and Legal Requirements applicable to such use, including Regulation (EU) 2024/1689 of the European Parliament and of the <a name="z_9kR3WTr266468KF44njt"></a>Council of 13 June 2024 (<a name="z_9kR3WTr266469Nxujk5v"></a>EU AI Act). Since January 1, 2023, no Acquired Corporation has included or includes any Trade Secret, Personal Data, material confidential or
            proprietary information of any Acquired Corporation, or of any third party to which any Acquired Corporation is under an obligation of confidentiality, in any prompts or inputs into any Artificial Intelligence Tools, except in cases where such
            Artificial Intelligence Tools do not use such prompts or inputs to train such Artificial Intelligence Tools or improve the services of the provider of such Artificial Intelligence Tools. No Acquired Corporation has used Artificial Intelligence
            Tools to develop any Company Registered IP or any other material Company IP.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(m)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Since January 1, 2023, (i) the Acquired Corporations are and have been in compliance with all Privacy and Data Security Requirements that apply to each of them in all material respects, (ii) the Acquired Corporations have implemented a
            commercially reasonable information security program comprising appropriate procedures, policies and administrative, technical and physical safeguards designed to prevent a Security Incident, (iii) no Acquired Corporation has been legally
            required to provide any notice to any Person in connection with a Security Incident, nor has any Acquired Corporation actually provided any such notice, (iv) there are no Legal Proceedings pending or, to the knowledge of the Company, threatened
            against any Acquired Corporation alleging a violation of any Person&#8217;s Personal Data or privacy rights and (v) there has not been any Security Incident. Personal <a name="z_9kR3WTr26646BO2pqNZ5rizE1n"></a>Data Processed by any Acquired
            Corporation can be used after the Closing by the Surviving Corporation or any Acquired Corporation in the manner substantially the same as currently used by the Acquired Corporations.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288334"></a><a name="z_Toc227238396"></a><a name="z_Toc227238515"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Contracts</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608361"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Section 3.9(a)</u></font> of the Company Disclosure Schedule identifies each Contract to which any Acquired Corporation is a party, or by which it is bound, that constitutes a Material Contract as of
          the date of this Agreement and identifies each such Material Contract under the applicable clause of <font style="font-family: 'Times New Roman';"><u>Section 3.9(a)</u></font> to which it applies. For purposes of this Agreement, each of the
          following Contracts to which any Acquired Corporation is a party or by which it is bound as of the date of this Agreement (other than an Employee Plan) constitutes a &#8220;<font style="font-family: 'Times New Roman';"><u>Material Contract</u></font>&#8221;:</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">22</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract that is a settlement, conciliation or similar agreement between any Acquired Corporation and any Governmental Body and pursuant to which (A) an Acquired Corporation will be required after the date of this Agreement to pay any
            monetary obligations or (B) that contains material obligations or limitations on such Acquired Corporation&#8217;s conduct;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(ii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract between any Acquired Corporation and any third Person (A) limiting the freedom or right of any Acquired Corporation to engage in any line of business or to compete with any other Person in any location or line of business, (B)
            containing any &#8220;<a name="ignore9"></a>most favored nations&#8221; terms and conditions (including with respect to pricing) granted by any Acquired Corporation, or (C) containing exclusivity obligations or otherwise materially limiting the freedom or
            right of any Acquired Corporation to sell, distribute or manufacture any products or services for any other Person;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref196941437"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract with payments to any Acquired Corporation that exceeded $1,000,000 in the fiscal year ending December 31, 2025 or payments by any Acquired Corporation that exceeded $1,000,000 for the fiscal year ending December 31, 2025 and in
          each case which cannot be cancelled by such Acquired Corporation without penalty or further payment without more than ninety (90) days&#8217; notice;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iv)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract under which any Acquired Corporation has obtained Indebtedness for borrowed money in an aggregate principal amount in excess of $100,000 (whether incurred, assumed, guaranteed or secured by any asset);</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(v)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract between an Acquired Corporation and a third Person (A) for the disposition of any material assets or business of the Acquired Corporations or (B) for the acquisition of a material portion of the assets or business of any third
            Person (whether by merger, sale of stock or assets or otherwise), in each case (A) or (B) that contains continuing indemnities or other material obligations or any continuing &#8220;earn out&#8221; or other contingent payment obligations on the part of an
            Acquired Corporation;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(vi)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract between any Acquired Corporation and any third Person constituting a material joint venture, collaboration, partnership or similar revenue sharing arrangement, in each case, pursuant to which an Acquired Corporation has an
            obligation (contingent or otherwise) to make a material investment in or material extension of credit to any third Person;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref473293122"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any




          Contract that by its express terms requires an Acquired Corporation, or any successor to, or acquirer of, an Acquired Corporation, to make any payment to another Person as a result of a change of control of such Acquired Corporation (a &#8220;<font style="font-family: 'Times New Roman';"><u>Change of Control Payment</u></font>&#8221;) or gives another Person a right to receive or elect to receive a Change of Control Payment;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(viii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract that prohibits the declaration or payment of dividends or distributions in respect of the capital stock of an Acquired Corporation, the pledging of the capital stock or other equity interests of an Acquired Corporation or the
            issuance of any guaranty by an Acquired Corporation;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">23</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(ix)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any collective bargaining agreement or other Contract with any Union;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref222761195"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(x)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any





          IP Contract;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xi)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract pursuant to which any Acquired Corporation has continuing obligations or interests involving (A) &#8220;milestone&#8221; or other similar contingent payments, including upon the achievement of research, development, regulatory or
            commercial milestones or (B) payment of royalties or other amounts calculated based upon any revenues or income of any Acquired Corporation, in each case of <font style="font-family: 'Times New Roman';"><u>clauses (A)</u></font> and <font style="font-family: 'Times New Roman';"><u>(B)</u></font> that cannot be terminated by such Acquired Corporation without penalty without more than sixty (60) days&#8217; notice and requires by its terms, or is reasonably expected to require, the
            payment or delivery of cash by any Acquired Corporation in an aggregate amount having a value in excess of $500,000 in the fiscal year ended December 31, 2025 or ending December 31, 2026;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract that relates to any swap, forward, futures or other similar derivative transaction with a notional value in excess of $150,000;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xiii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract that contains a put, call, right of first refusal, right of first negotiation or similar right pursuant to which any Acquired Corporation could be required to purchase or sell, or offer for purchase or sale, or exclusively
            license, as applicable, any (A) equity interests of any Person or (B) material assets (excluding ordinary course commitments to purchase goods, products and off-the-shelf software) or businesses, in each case (A) and (B) for an amount in excess
            of $500,000;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xiv)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract with a sole source supplier material to the conduct of the business of an Acquired Corporation as currently conducted and in which a reasonable alternative supplier is not available;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xv)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract, the primary purpose of which is to provide for indemnification or guarantee of the obligations of any other Person that would be material to an Acquired Corporation;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xvi)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract with any Affiliate (other than another Acquired Corporation), director, executive officer (as such term is defined in the Exchange Act), Person holding 5% or more of the Shares, or, to the knowledge of the Company, any
            Affiliate (other than the Company) or immediate family member of any of the foregoing;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xvii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any other Contract that is currently in effect and has been filed (or is required to be filed) by the Company as an exhibit pursuant to Item 601(b)(10) of Regulation S-K under the Securities Act or that would be required to be disclosed
            under Item 404 of Regulation S-K under the Securities Act; and</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xviii)</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any Contract that is a lease of which the Leased Real Property is subject thereto.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">24</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As of the date of this Agreement, the Company has either delivered or made available to Parent an accurate and complete copy of each Material Contract or has publicly made available such Material Contract (without redactions or omissions)
            in the <a name="z_9kR3WTr26646CQEldt952xnJCz0OJ3Bx8DA9"></a>Electronic Data Gathering, <a name="z_9kR3WTr26646DNCji7F01uquZV4I8wA7y"></a>Analysis and Retrieval (&#8220;<font style="font-family: 'Times New Roman';"><u>EDGAR</u></font>&#8221;) database of
            the SEC. No Acquired Corporation nor, to the knowledge of the Company, any other party thereto is in material breach of, or material default under, any Material Contract and no Acquired Corporation, or to the knowledge of the Company, any other
            party to a Material Contract has taken or failed to take any action that with or without notice, lapse of time or both would constitute a material breach of or material default under any Material Contract. Each Material Contract is, with
            respect to the Acquired Corporations and, to the knowledge of the Company, each other party thereto, a valid and binding agreement in full force and effect, enforceable in accordance with its terms, except as such enforcement may be subject to
            bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors&#8217; rights, and by general equitable principles. Since January 1, 2023, the Acquired
            Corporations have not received or delivered any written notice or, to the knowledge of the Company, oral notice, regarding any material violation or breach or default under any Material Contract that has not since been cured. None of the
            Acquired Corporations has waived in writing any rights under any Material Contract, the waiver of which would reasonably be expected to be material to the Acquired Corporations, taken as a whole.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref222773963"></a><a name="z_Toc227238397"></a><a name="z_Toc227238516"></a><a name="z_Toc228288335"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.10</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Liabilities</font>. The Acquired Corporations do not have any liabilities (whether
        accrued, absolute, contingent or otherwise), except for: (i) liabilities reflected or reserved against in the financial statements or notes thereto included in the Company SEC Documents filed at least one (1) business day prior to the date of this
        Agreement; (ii) liabilities or obligations incurred pursuant to the terms of this Agreement; (iii) liabilities for performance of obligations under Contracts binding upon the Acquired Corporations (other than resulting from any breach or
        acceleration thereof) either delivered or made available to Parent or entered into in the ordinary course of business consistent with past practice; (iv) liabilities incurred in the ordinary course of business consistent with past practice since
        January 1, 2025; and (v) liabilities that are not, and would not reasonably be expected to be, material to the Company. <font style="font-family: 'Times New Roman';"><u>Section 3.10</u></font> of the Company Disclosure Schedule sets forth a true
        and complete list of all outstanding Indebtedness for borrowed money of the Acquired Corporations.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238398"></a><a name="z_Toc227238517"></a><a name="z_Toc228288336"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.11</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Compliance with Legal Requirements</font>. <a name="z_Toc227238399"></a><a name="z_Toc227238518"></a>The Acquired
        Corporations are, and since January 1, 2023 have been, in material compliance with all applicable Legal Requirements, and, since January 1, 2023, no Acquired Corporation has been given written notice of, or been charged with, any alleged violation
        of, any applicable Legal Requirement.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><a name="z_Toc228288337"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.12</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Regulatory Matters</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Each Acquired Corporation is, and since January 1, 2023 has been, in compliance in all material respects with all Healthcare Regulatory Laws, in each case as applicable to such Acquired Corporation, the products of such Acquired
            Corporation and the operation of its business. Since January 1, 2023, no Acquired Corporation has been subject to any enforcement, regulatory, or administrative proceedings regarding alleged non-compliance with any Healthcare Regulatory Laws,
            or has received any written communication from any applicable Governmental Body, customer, wholesaler/distributor, payor, or other third party alleging actual or potential material non-compliance with any applicable Healthcare Regulatory Laws,
            and there are no facts and circumstances that would reasonably be expected to form the basis for any such non-compliance. Each Acquired Corporation has established and maintained an operational health care compliance program with the necessary
            policies and procedures materially designed to support performance of their respective contractual and regulatory obligations that: (i) governs all employees and contractors, (ii) is consistent with the standards and guidance promulgated by the
            Department of Health and Human Services Office of Inspector General, the Department of Justice, the <a name="z_9kR3WTr26646EiBxAfgvsngUwC4zyu65ZiH1y7C"></a>U.S. Federal Sentencing Guidelines for effective compliance programs, and the PhRMA
            Code, as applicable to the business of the Acquired Corporations, and (iii) addresses compliance with Healthcare Regulatory Laws.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">25</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Acquired Corporations hold all material Regulatory Permits required for their business as currently conducted, each such Regulatory Permit is valid and in full force and effect, and since January 1, 2023, (i) have been in compliance
            with the terms and requirements of the material Regulatory Permits required for the business of the Acquired Corporations as currently conducted and no material violation of or default under any such Regulatory Permits has occurred and (ii)
            have not received any written notice by any applicable Governmental Body asserting any deficiency with respect to any such Regulatory Permits of the Acquired Corporations. No material limitation, adverse modification, revocation, withdrawal,
            cancellation, lapse, integrity review, suspension, or other adverse action against any such material Regulatory Permit is pending, under investigation, or, to the knowledge of the Company, threatened.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref227760141"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Since





          January 1, 2023, all material filings, declarations, listings, registrations, reports, submissions, records, notices, supplements, amendments, modifications, Regulatory Permits, Governmental Authorizations, and other pricing, product attribute,
          or other data required under applicable Healthcare Regulatory Laws to be filed, maintained, or furnished to the FDA, DEA, CMS, HRSA, VA or any other Governmental Body by the Acquired Corporations, including all adverse event reports, periodic and
          annual drug reports, all advertising and promotional materials, and all registrations and reports required to be filed with clinicaltrials.gov (&#8220;<font style="font-family: 'Times New Roman';"><u>Healthcare Regulatory Filings</u></font>&#8221;), in each
          case to the extent applicable to the business of the Acquired Corporations, have been so filed, maintained, or furnished and have been accurate and complete, to the best of the Acquired Corporations&#8217; knowledge. All such Healthcare Regulatory
          Filings have been made available to Parent, were in material compliance with applicable Healthcare Regulatory Laws when filed (or were corrected or completed in a subsequent filing) and were made in good faith upon all information available to
          the Acquired Corporations at such time. No material deficiencies have been asserted in writing by any applicable Governmental Body with respect to any such Healthcare Regulatory Filings.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Since January 1, 2023, all products of the Acquired Corporations have been and are being designed, developed, researched, tested, manufactured, processed, stored, imported, exported, labeled, packaged, advertised, promoted, distributed,
            supplied, commercialized, offered for sale, sold, and marketed in material compliance with the Healthcare Regulatory Laws and applicable Regulatory Permits. Since January 1, 2023, no products of the Acquired Corporations have been (i)
            adulterated, misbranded, or prohibited from introduction into interstate commerce under applicable Healthcare Regulatory Laws, or (ii) been subject to any recall, field notification, market withdrawal or replacement, safety alert, warning,
            &#8220;dear doctor&#8221; letter, investigator notice, serious adverse event report or other notice of action relating to an efficacy or safety concern or alleged lack of regulatory compliance and, in each case (i) and (ii), to the knowledge of the
            Company, there are no facts or circumstances that would be reasonably likely to result in such action or otherwise require a change in the labeling or the termination or suspension of the research, development, manufacturing or distribution of
            any products of the Acquired Corporations.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">26</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Since January 1, 2023, the clinical and nonclinical studies conducted by or on behalf of the Acquired Corporations have been and, if still pending, are being conducted in material compliance with all applicable Healthcare Regulatory Laws,
            including Good Laboratory Practices and Good Clinical Practices, and no such studies have been placed on clinical hold or terminated or suspended prior to completion. Since January 1, 2023, no Acquired Corporation has received any written
            notice, correspondence or other communication from the FDA, other Governmental Body, institutional review board or clinical investigator alleging a lack of material compliance with any Healthcare Regulatory Laws or requiring the termination,
            suspension or material modification of any clinical studies conducted by or on behalf of any Acquired Corporation. There have been no allegations of, or investigations into, research misconduct (i.e., falsification or fabrication of data or
            plagiarism) with respect to any nonclinical studies, tests or clinical trials conducted by or on behalf of the Acquired Corporations.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Since January 1, 2023, no Acquired Corporation, nor to the knowledge of the Company, any Person acting on its behalf with respect to any products of the Acquired Corporations, has received any <a name="z_9kR3WTr26646FUI10Plh"></a>Form
            FDA-483, notice of inspectional observations, warning letter, untitled letter or similar written correspondence from any Governmental Body alleging or asserting material noncompliance with any Healthcare Regulatory Laws or Regulatory Permits.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196941421"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No





          Acquired Corporation nor any of their respective officers or employees, or, to the knowledge of the Company, agents has made an untrue statement of a material fact or fraudulent statement to the FDA or any Governmental Body, failed to disclose a
          material fact required to be disclosed to the FDA or committed any other act, made any statement or failed to make any statement, that (in any such case) establishes a reasonable basis for the FDA to invoke its Fraud, <a name="z_9kR3WTr26646GkW279xWgvw1vwyEKG4dT7CBG04"></a>Untrue Statements of Material Facts, <a name="z_9kR3WTr266478IHvgduF"></a>Bribery, and <a name="z_9kR3WTr266479QIsmiflSTuxI889v6iT810qoHC"></a>Illegal Gratuities Final Policy. As of the
          date of this Agreement, (i) no Acquired Corporation is the subject of any pending investigation by the FDA pursuant to its Fraud, <a name="z_9kMHG5YVt48868ImY49BzYixy3xy0GMI6fV9EDI"></a>Untrue Statements of Material Facts, <a name="z_9kMHG5YVt48869AKJxifwH"></a>Bribery, and <a name="z_9kMHG5YVt48869BSKuokhnUVwzKAABx8kVA32sq"></a>Illegal Gratuities Final Policy; and (ii) no Acquired Corporation nor any of its officers, employees, or agents of the Company has been
          (A) charged with or convicted of any criminal offense relating to the delivery of an item or service under any Federal Health Care Program, (B) had a civil monetary penalty assessed against it, him, or her under 42 U.S.C. &#167; 1320a-7a, (C) listed
          on the list of parties excluded from federal procurement programs and non-procurement programs as maintained in the <a name="z_9kR3WTr26647APJ5wt3zrt9pV1JBtq7eK39BCIU"></a>Government Services Administration&#8217;s System for Award Management, (D) the
          subject of or the target of any current or, to the knowledge of the Company, potential investigation relating to any <a name="z_9kR3WTr26647BP8detqlTHhp96QE05emI8C73LE"></a>Federal Health Care Program-related offense, or (E) debarred, excluded,
          or suspended from participation in any Federal Health Care Program or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. &#167; 335a or exclusion under 42 U.S.C. &#167; 1320a-7 or any similar Legal Requirement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">27</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Neither the Acquired Corporations nor any of their respective officers, employees, or agents have offered or paid any remuneration (including any kickback, bribe, rebate, payoff, influence payment or inducement) directly or indirectly,
            overtly or covertly, in cash or in kind, to any Person to induce such Person (i) to refer an individual to a Person for the furnishing or arranging for the furnishing of any item or service in violation of any Healthcare Regulatory Law or (ii)
            to purchase, lease, order, arrange for, or recommend purchasing, leasing, ordering any good, facility, service, or item in violation of any Healthcare Regulatory Law.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation has submitted, or caused the submission of, any false or fraudulent claim to any third party in violation of any Healthcare Regulatory Law, or has retained the proceeds of any such false claim, or has received any
            notice from any third party for any such violation or any allegation of a billing or coding mistake, overpayment, false claim, or fraud relating to the services of the Acquired Corporations.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(j)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Since January 1, 2023, no Acquired Corporation is or has been a party to any corporate integrity agreements, deferred prosecution agreements, non-prosecution agreements, monitoring agreements, consent decrees, settlement Orders,
            certification of compliance agreements, or similar agreements with or imposed by any Governmental Body under applicable Healthcare Regulatory Laws.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref227050596"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Each





          Acquired Corporation is, and since January 1, 2023 has been, in compliance with all applicable Healthcare Regulatory Laws relating to product pricing and attribute reporting, price reporting, discounts, and rebates. The Acquired Corporations have
          timely submitted all required pricing and other product-related submissions and other material filings pertaining to government pricing and price reporting, including any updates, changes, corrections, amendments, restatements, supplements, or
          modifications to such filings, and any 340B refunds to covered entities, as required by Governmental Bodies or required pursuant to a Healthcare Regulatory Law, in each case to the extent applicable to the business of the Acquired Corporations,
          and such filings have been complete and accurate as of their respective filing dates (or were corrected or completed in a subsequent filing). Except as set forth on <font style="font-family: 'Times New Roman';"><u>Section 3.12(k)</u></font> of
          the Company Disclosure Schedule, no Acquired Corporation as of the date hereof has filed any restatements or issued any material refunds under any Federal Health Care Program pursuant to applicable Healthcare Regulatory Laws relating to product
          pricing and attribute reporting, price reporting, discounts, and rebates.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(l)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">To the extent required, the Acquired Corporations (i) hold, and have held for all periods in which required, valid <a name="z_9kR3WTr26647CXFdiibimIRF5dWnk38fnJ9D84s"></a>Medicaid Drug Rebate Program National Drug Rebate Agreements, 340B
            <a name="z_9kR3WTr26647DbLdo1lch0G5pisij9vw87VQED1"></a>Pharmaceutical Pricing Agreements, <a name="z_9kR3WTr26647Eiu0koHDijyvqjnHDAK2bx0xEN8"></a>VA and Federal Supply Schedule Master Agreements and Pharmaceutical Pricing Agreements, and the
            <a name="z_9kR3WTr26647Fh9zleuz0R0xnzjXs9I2foE01DC"></a>TRICARE Retail Refund Pricing Agreement, in each case to the extent applicable to the business of the Acquired Corporations, and (ii) are, and since January 1, 2023 have been, as
            applicable, in compliance with all such agreements, including, without limitation, provisions in such agreements pertaining to the timely and accurate submission of pricing data to Governmental Bodies.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(m)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation (i) acts as a &#8220;<a name="z_9kR3WTr26647GRF5wtuhIN956N"></a>Covered Entity&#8221; or &#8220;<a name="z_9kR3WTr26647HRK8xtqwBUPEBwrq27"></a>Business Associate&#8221; as those terms are defined under HIPAA, (ii) uses, discloses, or
            otherwise processes protected health information (as defined under HIPAA) or other patient identifying information.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(n)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Acquired Corporations have developed and implemented patient or product support activities, such as, but not limited to, free drug programs, co-pay assistance, and access and insurance reimbursement support, in compliance with all
            applicable Healthcare Regulatory Laws.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">28</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.13</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;
          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Certain Business Practices</font></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">For the past five (5) years, no Acquired Corporation nor any of its officers, directors, or, to the knowledge of the Company, any of its employees or other Representatives (in each case, acting on behalf of such Acquired Corporation) has
            (i) used any funds (whether of an Acquired Corporation or otherwise) for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, (ii) made any unlawful payment to foreign or domestic government
            officials or employees or to foreign or domestic political parties or campaigns, (iii) accepted any unlawful payments, (iv) violated any provision of any Anti-Corruption Laws or any rules or regulations promulgated thereunder, anti-money
            laundering laws or any rules or regulations promulgated thereunder or any applicable Legal Requirement of similar effect, or (v) been party to any voluntary or directed disclosures or actual or threatened Legal Proceedings or enforcement
            actions, or otherwise received any written communication from a Governmental Body, relating to any of the foregoing (i) through (iv).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">For the past five (5) years, for U.S. economic sanctions matters and otherwise, no Acquired Corporation nor any of its officers, directors, or, to the knowledge of the Company, any of its employees or other Representatives (in each case,
            acting on behalf of such Acquired Corporation) (i) is or has been a Restricted Party, (ii) has, directly or indirectly, engaged in any dealings or transactions with or for the benefit of any Restricted Party, (iii) has violated any Global Trade
            Laws, or (iv) has been party to any voluntary or directed disclosures or actual or threatened Legal Proceedings or enforcement actions, or otherwise received any written communication from a Governmental Body, relating to any of the foregoing
            (i) through (iii).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref196941428"></a><a name="z_Toc227238401"></a><a name="z_Toc227238520"></a><a name="z_Toc228288339"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.14</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Governmental Authorizations</font>. The Acquired Corporations hold, and since January 1,
        2023 have held, all material Governmental Authorizations, including all material Regulatory Permits, necessary to enable the Acquired Corporations to conduct their business in the manner in which such business is currently being conducted. The
        Governmental Authorizations held by the Acquired Corporations are valid and in full force and effect. The Acquired Corporations are, and since January 1, 2023 have been, in material compliance with the terms and requirements of such Governmental
        Authorizations, and there are no facts or circumstances that would be reasonably likely to lead to the revocation, suspension, limitation, or cancellation of any such Governmental Authorizations. <font style="font-family: 'Times New Roman';"><u>Section





            3.14</u></font> of the Company Disclosure Schedule sets forth an accurate and complete list of all active state licenses that the Acquired Corporations have applied for and/or obtained, in each case as designated on the schedule, in connection
        with the sale of the Acquired Corporations&#8217; products into the United States.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref10468928"></a><a name="z_Toc228288340"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.15</font>&#160;&#160;&#160;&#160;&#160;&#160;





        <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Tax Matters</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608357"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">All





          income and other material Tax Returns required to be filed by or with respect to any Acquired Corporation with any Governmental Body (the &#8220;<font style="font-family: 'Times New Roman';"><u>Company Returns</u></font>&#8221;) have been timely filed
          (taking into account any extension of time within which to file) and all such Tax Returns are true, correct and complete in all material respects. All income and other material Taxes of each Acquired Corporation (whether or not shown to be due
          and payable on any such Tax Return) have been timely paid in full to the appropriate Governmental Body.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">29</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Each Acquired Corporation is, and at all times since its respective formation has been, treated as a corporation for U.S. federal, state and local income Tax purposes.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Each Acquired Corporation has withheld and paid all material Taxes required to have been withheld and paid in connection with amounts paid to any employee, independent contractor, creditor, equityholder or other third party (and such
            Acquired Corporation has complied in all material respects with related reporting and recordkeeping requirements).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196941419"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">
          (i) There is no pending or ongoing Legal Proceeding concerning any material Tax liability of any Acquired Corporation and no proposals, assessments or deficiencies for any material Taxes of such Acquired Corporation are, to the knowledge of the
          Company, being asserted or threatened, in each case, which have not been resolved in full, and (ii) no unresolved written claim has been made by any Governmental Body in any jurisdiction where such Acquired Corporation does not file Tax Returns
          that such Acquired Corporation is or may be subject to Taxes in that jurisdiction, or may be required to file material Tax Returns in that jurisdiction. No Acquired Corporation has granted or requested an extension or waiver of the applicable
          period for assessment or review under applicable Legal Requirement with respect to any material Company Returns, which period has not expired (taking into account such extension or waiver).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">For taxable years for which the applicable statute of limitations for an assessment of Taxes has not expired, no Acquired Corporation (i) has been a member of an affiliated group (within the meaning of Section 1504(a) of the Code) filing a
            consolidated federal income Tax Return (other than a group the common parent of which is or was the Company or another Acquired Corporation), or (ii) has any material liability for the Taxes of any other Person (other than another Acquired
            Corporation) under Section 1.1502-6 of the Treasury Regulations (or any similar provision of state, local or non-U.S. law), or as a transferee or successor or by contract (other than pursuant to agreements not primarily related to Taxes and
            entered into in the ordinary course of business) or otherwise pursuant to any Legal Requirement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">There are no material Encumbrances with respect to Taxes upon any of the assets or properties of any Acquired Corporation, other than for Taxes not yet due and payable.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation has engaged in any transaction that is a &#8220;listed transaction&#8221; under Section 1.6011-4(b)(2) of the Treasury Regulations or any other transaction requiring disclosure under any similar provision of state, local or <a name="z_9kR3WTr266489uwxeE6JliogU0HA85124K"></a>non-U.S. Legal Requirement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation has been either a &#8220;distributing corporation&#8221; or a &#8220;controlled corporation&#8221; in a distribution occurring during the last two (2) years or otherwise as part of a plan or series of related transactions with the
            Transactions in which the parties to such distribution treated the distribution as one to which Section 355 of the Code is applicable<font style="font-family: 'Times New Roman';">.</font></font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">30</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation has, or has ever had, a permanent establishment, or has ever engaged in a trade or business in any country other than the country of its organization, or is, or has ever been, subject to income Tax in a jurisdiction
            other than the country of its organization. The Acquired Corporations are, and have at all times been, a resident for Tax purposes only in the jurisdiction of their organization and have never been treated as resident in any other jurisdiction
            for any Tax purpose (including any double taxation arrangement).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(j)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation is a party to or bound by, nor has obligation under, any material Tax allocation, sharing, indemnity or similar agreement or arrangement, other than any such agreement that will terminate before the Closing Date or
            pursuant to any agreement not primarily related to Taxes.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(k)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation is required to include any material item of income in, or exclude any material item of deduction from, taxable income for any Tax period beginning after the Closing Date as a result of any: (i) change in method of
            accounting for any Tax period beginning on or after the Closing, including by reason of the application of Section 481 of the Code (or any corresponding or similar Legal Requirement) made prior to the Closing; (ii) &#8220;closing agreement&#8221; as
            described in Section 7121 of the Code (or any corresponding or similar provision of state, local or non-U.S. Legal Requirement) executed prior to the Closing; (iii) any intercompany transaction or excess loss account described in the Treasury
            Regulations promulgated under Section 1502 of the Code (or any similar or corresponding provision of state, local or non-U.S. Legal Requirement) arising prior to the Closing; (iv) installment sale or open transaction made prior to the Closing;
            or (v) prepaid amount received or deferred revenue prior to the Closing outside the ordinary course of business.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(l)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation has been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(m)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">All related party transactions involving an Acquired Corporation have been conducted on arm&#8217;s length terms in material compliance with Section 482 of the Code, the Treasury Regulations promulgated thereunder, and any similar provision of
            state, local, or other non-U.S. applicable law. Each Acquired Corporation has maintained, in all material respects, all necessary documentation in connection with such related party transactions in accordance with Section 482 of the Code and
            the Treasury Regulations promulgated thereunder.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(n)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation is a party to any material Tax exemption, Tax holiday or other Tax reduction agreement or Order of a Governmental Body.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(o)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No private letter rulings, technical advice memoranda or similar agreements or rulings have been requested, entered into or issued by any Governmental Body with respect to any of the Acquired Corporations. No Acquired Corporation has
            entered into a voluntary disclosure agreement or similar program pending with any jurisdiction. No power of attorney related or attributable to Taxes that is currently in effect has been granted by any Acquired Corporation.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">31</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(p)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Convertible Senior Notes are, and have at all times since issuance been, treated as indebtedness for U.S. federal income tax purposes. The Company has prepared and filed, and will continue to prepare and file, all tax returns and
            reports to the IRS and holders of the Convertible Senior Notes on a basis consistent with such treatment.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(q)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Since December 31, 2025, no Acquired Corporation has taken any of the actions set forth in <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)(xvi)</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288341"></a><a name="z_Toc227238403"></a><a name="z_Toc227238522"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.16</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Employee Matters</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608353"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The





          Acquired Corporations are, and since January 1, 2023 have been, in material compliance with all applicable<a name="z_cp_text_1_93"></a> Legal Requirements respecting employment and employment practices<a name="z_cp_text_2_94"></a> and terms and
          conditions of employment, including<a name="z_cp_text_1_96"></a> wages and hours and the classification and compensation of employees and independent contractors. Since January 1, 2023, the Acquired Corporations have not incurred, and no
          circumstances exist under which the Acquired Corporations would reasonably be expected to incur, any material liability arising from the failure to pay wages (including overtime wages), the misclassification of employees as consultants or
          independent contractors, and/or the misclassification of employees as exempt from the requirements of the U.S. Fair Labor Standards Act or applicable state <a name="z_cp_text_2_101"></a>or foreign Legal Requirements.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation is a party to, bound by, or otherwise subject to, any collective bargaining agreement or other Contract with a Union, and no such Contract is being negotiated by any Acquired Corporation, and no employees of the
            Acquired Corporations are represented by any Union with respect to their employment with the Acquired Corporations. No notice, consent or consultation obligations with respect to any employees of any Acquired Corporation, or any Union, is a
            condition precedent to, or triggered by, the execution of this Agreement or the consummation of the Transactions.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Since January 1, 2023, there have been no labor strikes, lockouts, work slowdowns, work stoppages, unfair labor practice charges, petitions for recognition, labor organizing efforts or drives, handbilling or picketing pending or, to the
            knowledge of the Company, threatened against or affecting any Acquired Corporation, and there have been no such activities for the past five (5) years.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">True and complete information as to the name, current job title and compensation (base salary and any bonus or commission opportunities for calendar year 2026) for all current employees of the Acquired Corporations has been provided to
            Parent, to the extent permitted under applicable Legal Requirements. No current executive or key employee of any of the Acquired Corporations or current group of employees of any of the Acquired Corporations (i) to the knowledge of the Company,
            has given notice of termination of employment or otherwise disclosed plans to terminate employment with any of the Acquired Corporations within the twelve (12) month period following the date hereof or (ii) is employed under a non-immigrant
            work visa or other work authorization that is limited in duration. No executive or key employee of any of the Acquired Corporations is or has been the subject of any sexual or other type of discrimination, harassment, or similar material
            misconduct allegations that could result in liability to the Acquired Corporations during his or her tenure at the applicable Acquired Corporation.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">32</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">There is not, and since January 1, 2023 has not been, any Legal Proceeding pending (or, to the knowledge of the Company, threatened), (i) by or before any Governmental Body with respect to the Acquired Corporations concerning
            employment-related matters or (ii) brought against any of the Acquired Corporations by or on behalf of any current or former applicant, employee or independent contractor of the Acquired Corporations.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation has, since January 1, 2023, (i) taken any action that would constitute a &#8220;<a name="z_9kR3WTr26648AUBo7bEyDvn"></a>Mass Layoff&#8221; or &#8220;<a name="z_9kR3WTr26648BYPhk4UH083zy"></a>Plant Closing&#8221; within the meaning of, or
            would otherwise trigger notice requirements or liability under, the WARN Act or (ii) been a party to a relevant transfer (as defined in the Transfer of Undertakings (Protection of Employment) Regulations 2006).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">All employees of the Acquired Corporations have the legal right to work in the jurisdiction in which they carry out their duties, and each of the Acquired Corporations have materially complied with all applicable immigration Legal
            Requirements in each applicable jurisdiction.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref196936311"></a><a name="z_Toc228288342"></a><a name="z_Toc227238404"></a><a name="z_Toc227238523"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.17</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Benefit Plans</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608352"></a><a name="z_Ref227011423"></a><a name="z_Ref196941425"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Section 3.17(a)</u></font> of the Company Disclosure Schedule sets forth an accurate and complete list of each material Employee Plan
          (other than (i) any employment agreement for non-officer employees of the Acquired Corporations that does not provide for severance or notice entitlements exceeding thirty (30) days other than as may be required by applicable law; (ii) equity
          grant notices and related documentation with respect to employees of the Acquired Corporations; and (iii) agreements with individual consultants entered into in the ordinary course of business consistent with past practice, in each case, <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> such agreements are on form provided to Parent that has been disclosed on <font style="font-family: 'Times New Roman';"><u>Section 3.17(a)</u></font> of the Company
          Disclosure Schedule).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">With respect to each material Employee Plan, accurate and complete copies of the following have been made available to Parent, as applicable: (i) the current plan documents and all material amendments thereto (or, if not reduced to
            writing, a written summary of all material plan terms, including any contributions required to be made by any of the Acquired Corporations), (ii) the current summary plan descriptions (including any summary of material modifications), (iii) the
            most recent determination letter or opinion letter issued by the IRS, (iv) the most recent annual report on <a name="z_9kR3WTr26648CPI10FMIE"></a>Form 5500, including all schedules and attachments, (v) any trust agreements, custodial
            agreements, insurance policies, administrative agreements, advisory agreements and similar Contract or funding arrangements, (vi) all <a name="z_9kR3WTr26648DQI102IENSW"></a>Forms 1094-C for any member of the Acquired Corporations that served
            as an employing entity for 2024 and 2025, and (vii) any non-routine correspondence (including any applications or submissions under any voluntary correction programs) with any Governmental Body within the last six (6) years.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">33</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Each Employee Plan, including any associated trust or fund, was established and has been maintained, operated, funded and administered in all material respects in compliance with its terms and in compliance with all applicable Legal
            Requirements.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">There is no pending or, to the knowledge of the Company, threatened Legal Proceeding or material claim with respect to any Employee Plan (other than routine claims for benefits), and to the knowledge of the Company, no fact or circumstance
            exists that would be reasonably likely to give rise to any such Legal Proceeding or material claim. <a name="z_Hlk164960336"></a>No Employee Plan is, or within the last six (6) years has been, the subject of an examination or audit by a
            Governmental Body, or the subject of an application or filing under, or a participant in, a government-sponsored amnesty, voluntary compliance, self-correction or similar program.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Section 3.17(a)</u></font> of the Company Disclosure Schedule sets forth a list of each Non-U.S. Plan. There is no Non-U.S. Plan in the nature of a defined benefit plan for the benefit of
            any Person in, or subject to any Legal Requirements of, a jurisdiction outside the United States, and none of the Acquired Corporations has ever maintained, sponsored, contributed to, operated, or been required to contribute to any such defined
            benefit plan except as required by applicable Legal Requirements. Each Non-U.S. Plan (i) if intended to qualify for special Tax treatment under applicable Legal Requirements, satisfies all requirements to obtain such Tax treatment, (ii) if
            required to be funded, book-reserved or secured by an insurance policy, is funded, book-reserved, or secured by such an insurance policy, as applicable, based on reasonable and appropriate actuarial assumptions in accordance with applicable
            accounting principles and applicable Legal Requirements, and (iii) has been maintained in compliance in all material respects with applicable Legal Requirements.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Employee Plan is, and neither the Company nor any other Person that is considered a single employer with the Company under the Code or ERISA has ever maintained, sponsored, contributed to, or been required to contribute to, (i) a
            &#8220;defined benefit plan&#8221; as defined in Section 3(35) of ERISA or any plan that is or was subject to Title IV of ERISA or Code Section 412, including any &#8220;<a name="ignore14"></a>single employer&#8221; defined benefit plan or any &#8220;<a name="ignore15"></a>multiemployer





            plan&#8221;, each as defined in Section 4001 of ERISA, (ii) a &#8220;multiemployer plan&#8221;, as defined in Section 3(37) of ERISA, (iii) a &#8220;multiple employer plan&#8221; as described in Section 413(c) of the Code or Section 210 of ERISA, or (iv) a &#8220;multiple
            employer welfare arrangement&#8221; as defined in Section 3(40) of ERISA.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Each Employee Plan that is intended to be qualified under Section 401(a) of the Code has obtained a favorable determination letter from the IRS (or is the subject of a favorable opinion or advisory letter, if applicable) as to its
            qualified status under the Code upon which it can rely, each trust created thereunder has been determined by the IRS to be exempt from Tax under the provisions of Section 501(a) of the Code, and, to the knowledge of the Company, there are no
            circumstances or any events that have occurred that could reasonably be expected to affect adversely the qualified status or exemption or otherwise result in liability to the Acquired Corporations.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Employee Plan obligates any Acquired Corporation to provide any current or former director, officer or employee (or any beneficiary or dependent thereof) any life insurance, medical, welfare, or health benefits after his or her
            termination of employment or service with the Acquired Corporations, other than as required under Part 6 of Subtitle B of Title I of ERISA, Section 4980B of the Code or any similar applicable Legal Requirement, for which the recipient pays the
            full premiums.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">34</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Person is entitled to any gross-up, make-whole, indemnification, reimbursement, or other additional payment from the Acquired Corporations in respect of any Tax or interest or penalty related thereto under Section 409A of the Code or
            Section 4999 of the Code.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608351"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Except





          as explicitly set forth in <font style="font-family: 'Times New Roman';"><u>Section 2.8</u></font>, neither the execution and delivery of this Agreement nor the consummation of the Transactions (including in combination with other events or
          circumstances) could (i) result in any payment or benefit (whether of compensation, termination, or severance pay or otherwise) becoming due to any current or former employee, director, officer, independent contractor or other individual service
          provider of the Acquired Corporations, (ii) cause or accelerate the time of payment, funding or vesting, or increase the amount of, compensation or benefits due to any such employee, director, officer or independent contractor of the Acquired
          Corporations, (iii) limit or restrict the right of the Acquired Corporations, Parent or any of their respective Affiliates to merge, amend or terminate any Employee Plan or any related Contract, (iv) result in any forgiveness of indebtedness of
          any current or former employee, director, officer, independent contractor, or other individual service provider of the Acquired Corporations, or (v) result in amounts payable or benefits provided to any employee, director, officer, independent
          contractor or other individual service provider of the Acquired Corporations to fail to be deductible for federal income Tax purposes by virtue of Section 280G of the Code.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238405"></a><a name="z_Toc227238524"></a><a name="z_Toc228288343"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.18</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Environmental Matters</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196941426"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The





          Acquired Corporations are, and since January 1, 2020 have been, in compliance with all applicable Environmental Laws, which compliance includes obtaining, maintaining or complying with all Governmental Authorizations required under Environmental
          Laws for the operation of their business, except as would not be material to the Acquired Corporations taken as a whole.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As of the date of this Agreement, there is no Legal Proceeding relating to or arising under any Environmental Law that is pending or, to the knowledge of the Company, threatened against any Acquired Corporation or in respect of any Leased
            Real Property, except as would not be material to the Acquired Corporations taken as a whole.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Since January 1, 2020 through the date of this Agreement, except as would not be material to the Acquired Corporations taken as a whole, no Acquired Corporation has received any written notice, report or other information of or entered
            into any legally binding agreement, Order, settlement, judgment, injunction or decree involving uncompleted, outstanding or unresolved material violations, liabilities or requirements on the part of any Acquired Corporation relating to or
            arising under Environmental Laws.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">35</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">To the knowledge of the Company, there are, and since January 1, 2020 have been, no Hazardous Materials present or Releases on, at, under or from any property or facility currently or formerly owned, leased, operated or used by any
            Acquired Corporation, including the Leased Real Property, in a manner and concentration that would reasonably be expected to result in any material claim against or material liability of an Acquired Corporation under any Environmental Law.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">No Acquired Corporation has assumed, undertaken, or otherwise become subject to any material liability of another Person relating to Environmental Laws.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238406"></a><a name="z_Toc227238525"></a><a name="z_Toc228288344"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.19</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Insurance</font>. The Company has delivered or made available to Parent an accurate and complete copy of each material
        insurance policy relating to the business, assets and operations of the Acquired Corporations, which shall include the current policies of directors&#8217; and officers&#8217; insurance maintained by or for the benefit of the Acquired Corporations. The
        Acquired Corporations maintain insurance coverage in such amounts and covering such risks as are in accordance in all material respects with normal industry practice for companies of similar size and stage of development. To the knowledge of the
        Company, all such insurance policies are (i) in full force and effect, no notice of cancellation or material modification has been received (other than a notice in connection with ordinary renewals), (ii) all premiums due and payable in respect of
        such insurance policies have been paid, and (iii) there is no existing material default or event which, with the giving of notice or lapse of time or both, would constitute a material default, by any insured thereunder. As of the date of this
        Agreement, there is no claim pending under any of the Acquired Corporations&#8217; insurance policies as to which coverage has been questioned, denied or disputed by the underwriters of such policies, and, to the knowledge of the Company, there are no
        facts, circumstances or events that would reasonably be expected to give rise to any such claim, except as would not be, or would not reasonably be expected to be, material to the Acquired Corporations taken as a whole.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288345"></a><a name="z_Toc227238407"></a><a name="z_Toc227238526"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.20</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Legal Proceedings; Orders</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608350"></a><a name="z_Ref196941431"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">There are no Legal Proceedings pending and served (or, to the knowledge of the Company, pending and not served or threatened) against any Acquired Corporation or, to the knowledge of the Company, against any present
          or former officer, director or employee of an Acquired Corporation in such individual&#8217;s capacity as such.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">To the knowledge of the Company, there is no material Order, writ, injunction or judgment to which an Acquired Corporation is subject that remains outstanding.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As of the date of this Agreement, no material investigation by any Governmental Body with respect to an Acquired Corporation is pending or has been threatened.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">36</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.21</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;
          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Authority; Binding Nature of Agreement</font></font>. The Company and KalVista UK has the corporate power and authority to execute and deliver and to perform
        its obligations under this Agreement and to consummate the Transactions. The Board of Directors has (a) determined that this Agreement and the Transactions, including the Offer and the Merger, are fair to, and in the best interest of, the Company
        and its stockholders, (b) declared it advisable to enter into this Agreement, (c) approved the execution, delivery and performance by the Company of this Agreement and the consummation of the Transactions, including the Offer and the Merger, (d)
        resolved that the Merger shall be effected under Section 251(h) of the DGCL and (e) resolved to recommend that the stockholders of the Company tender their Shares to Purchaser pursuant to the Offer, in each case on the terms and subject to the
        conditions of this Agreement. The board of directors of KalVista UK has approved the execution, delivery and performance by KalVista UK of this Agreement. The resolutions in the prior two sentences, subject to <font style="font-family: 'Times New Roman';"><u>Section 6.1</u></font>, have not been subsequently withdrawn or modified in a manner adverse to Parent as of the date of this Agreement. This Agreement has been duly executed and delivered by the Company and KalVista UK, and assuming
        due authorization, execution and delivery by Parent and Purchaser, this Agreement constitutes the legal, valid and binding obligation of the Company and KalVista UK and is enforceable against the Company and KalVista UK in accordance with its
        terms, except as such enforcement may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors&#8217; rights, and by general equitable
        principles. If the Merger is consummated in accordance with Section 251(h) of the DGCL as contemplated hereby, no vote of the Company&#8217;s stockholders or any holder of Shares is necessary to authorize or adopt this Agreement or to consummate the
        Transactions.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref473295409"></a><a name="z_Ref473295448"></a><a name="z_Toc227238409"></a><a name="z_Toc227238528"></a><a name="z_Toc228288347"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.22</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Takeover Laws</font>. Assuming the accuracy of the
        representations and warranties of Parent and Purchaser set forth in <font style="font-family: 'Times New Roman';"><u>Section 4.8</u></font>, the Board of Directors has taken all actions necessary or appropriate, and will take after the date
        hereof, all actions that may be necessary or appropriate so that the restrictions applicable to business combinations contained in Section 203 of the DGCL and any Takeover Law are, and will be, to the extent such restrictions can be rendered
        inapplicable by action of the Board of Directors under Legal Requirements, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Offer, the Merger and the other Transactions. To the knowledge of
        the Company, assuming the accuracy of the representations of Parent and Purchaser in <font style="font-family: 'Times New Roman';"><u>Section 4.8</u></font>, no other Takeover Law applies to this Agreement or to the consummation of the Offer, the
        Merger and the other Transactions.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608442"></a><a name="z_Ref460608443"></a><a name="z_Ref460608444"></a><a name="z_Ref460608445"></a><a name="z_Ref460608446"></a><a name="z_Toc227238410"></a><a name="z_Toc227238529"></a><a name="z_Toc228288348"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.23</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Non-Contravention; Consents</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Hlk224562079"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Assuming





          compliance with the applicable provisions of the DGCL, the HSR Act, any applicable filing, notification or approval in any foreign jurisdiction required by Antitrust Laws and Foreign Investment Laws (if any) or Takeover Laws, and the rules and
          regulations of the SEC and Nasdaq, and assuming the accuracy of the representations and warranties of Parent and Purchaser herein, the execution and delivery of this Agreement by the Company do not and the consummation of the Transactions will
          not: (i) cause a violation of any of the provisions of the certificate of incorporation or bylaws (or other organizational or governing documents) of any Acquired Corporation; (ii) cause a violation by any Acquired Corporation of any Legal
          Requirement or Order applicable to an Acquired Corporation, or to which an Acquired Corporation is subject; (iii) require any consent or notice under, conflict with, result in breach of, or constitute a default under (or an event that with notice
          or lapse of time or both would become a default), or give rise to any right of purchase, increase in royalty or license fee, payment obligation, milestone acceleration, termination, amendment, cancellation, acceleration or other adverse change of
          any right or obligation or the loss of any benefit to which an Acquired Corporation is entitled under any provision of any Material Contract; or (iv) result in an Encumbrance (other than a Permitted Encumbrance) on any of the property or assets
          of any Acquired Corporation; except, in the case of <font style="font-family: 'Times New Roman';"><u>clauses (ii)</u></font>, <font style="font-family: 'Times New Roman';"><u>(iii)</u></font> and <font style="font-family: 'Times New Roman';"><u>(iv)</u></font>,
          as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">37</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Except for the filing of the certificate of merger with the Secretary of State of the State of Delaware or as may be required by the Exchange Act (including the filing with the SEC of the Schedule 14D-9 and such reports under the Exchange
            Act as may be required in connection with this Agreement and the Transactions), the DGCL, Takeover Laws, the HSR Act and any applicable filing, notification or approval in any foreign jurisdiction required by Antitrust Laws and Foreign
            Investment Laws (if any) and the applicable rules and regulations of the SEC and any national securities exchange, the Acquired Corporations are not required to give notice to, make any filing with, or obtain any Consent from any Governmental
            Body at any time prior to the Closing in connection with the execution and delivery of this Agreement by the Company, or the consummation by the Company of the Merger or the other Transactions, except those that the failure to make or obtain
            would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect and would not, or would not reasonably be expected to, materially impair, prevent or materially delay the Company&#8217;s ability to consummate the
            Transactions prior to the End Date on the terms set forth in this Agreement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608441"></a><a name="z_Toc227238411"></a><a name="z_Toc227238530"></a><a name="z_Toc228288349"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.24</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Opinion of Financial Advisor</font>. The Board of Directors has received the oral
        opinion of Centerview Partners LLC, financial advisor to the Company, to be subsequently confirmed by delivery of a written opinion to the Board of Directors, that, as of the date of such opinion, and based on and subject to the various assumptions
        made, procedures followed, matters considered, and qualifications and limitations set forth therein, the Offer Price or Merger Consideration per Share to be paid to the holders of Shares (other than Excluded Shares, Dissenting Shares or any Shares
        held by any affiliate of the Company or Parent) pursuant to this Agreement is fair, from a financial point of view, to such holders. The Company will make available to Parent solely for informational purposes and on a non-reliance basis, a signed
        copy of such written opinion, it being expressly understood and agreed that such opinion is for the benefit of the Board of Directors and may not be relied upon by Parent or Purchaser.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608440"></a><a name="z_Toc227238412"></a><a name="z_Toc227238531"></a><a name="z_Toc228288350"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">3.25</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Brokers and Other Advisors</font>. Except for Centerview Partners LLC, no broker,
        finder, investment banker, financial advisor or other Person performing similar functions is entitled to any brokerage, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission, or the reimbursement of expenses in connection therewith, in
        connection with the Transactions based upon arrangements made by or on behalf of the Company.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt; text-indent: 36pt;"><a name="z_Toc227238413"></a><a name="z_Toc227238532"></a><a name="z_Toc228288351"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt;">3.26</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">No TID U.S. Business</font></font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">.</font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">None of </font>the<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font>Acquired





          Corporations <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">are a &#8220;</font><a name="z_9kR3WTr26648Ef0lyEwPD2yv1G"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">TID U.S. Business&#8221;, as that term is
            defined at 31 C.F.R. &#167; 800.248.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Toc227238414"></a><a name="z_Toc227238533"></a><a name="z_Toc228288352"></a>SECTION 4</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Parent and Purchaser represent and warrant to the Company as follows:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">38</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;





          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Due Organization</font></font>. Each of Parent and Purchaser is a corporation or other Entity duly organized, validly existing and in good standing under the
        laws of its jurisdiction of organization and has all necessary power and authority: (a) to conduct its business in the manner in which its business is currently being conducted; and (b) to own and use its assets in the manner in which its assets
        are currently owned and used, except as would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238416"></a><a name="z_Toc227238535"></a><a name="z_Toc228288354"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Purchaser</font>. Purchaser was formed solely for the purpose of engaging in the Transactions and activities
        incidental thereto and has not engaged, and prior to the Effective Time will not engage, in any business activities or conducted any operations other than as contemplated by this Agreement in connection with the Transactions and those incident to
        Purchaser&#8217;s formation. Either Parent or a wholly owned Subsidiary of Parent owns beneficially and of record all of the outstanding capital stock of Purchaser, free and clear of all Encumbrances and transfer restrictions, except for Encumbrances or
        transfer restrictions of general applicability as may be provided under the Securities Act or applicable securities laws.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238417"></a><a name="z_Toc227238536"></a><a name="z_Toc228288355"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Authority; Binding Nature of Agreement</font>. Parent and Purchaser each have the corporate power and authority to
        execute and deliver and perform their respective obligations under this Agreement and to consummate the Transactions, subject, in the case of the Merger, to the adoption of this Agreement by Parent, as sole stockholder of Purchaser (which shall
        occur immediately following the execution of this Agreement). The board of directors of each of Parent and Purchaser have approved the execution, delivery and performance by Parent and Purchaser of this Agreement and the consummation of the
        Transactions, including the Offer and the Merger. This Agreement has been duly executed and delivered by Parent and Purchaser, and assuming due authorization, execution and delivery by the Company, KalVista UK or the Rights Agent (as the case may
        be), this Agreement constitutes the legal, valid and binding obligation of Parent and Purchaser and is enforceable against Parent and Purchaser in accordance with its terms, except as such enforcement may be subject to bankruptcy, insolvency,
        fraudulent transfer, reorganization, moratorium and other similar laws of general applicability relating to or affecting creditors&#8217; rights, and by general equitable principles.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238418"></a><a name="z_Toc227238537"></a><a name="z_Toc228288356"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Non-Contravention; Consents</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Assuming compliance with the applicable provisions of the DGCL, the HSR Act and any applicable filing, notification or approval in any foreign jurisdiction required by Antitrust Laws and Foreign Investment Laws (if any), and the applicable
            rules and regulations of the SEC and Nasdaq, and subject, in the case of the Merger, to the adoption of this Agreement by Parent, as sole stockholder of Purchaser (which shall occur immediately following the execution of this Agreement), the
            execution and delivery of this Agreement by Parent and Purchaser, and the consummation of the Transactions, will not: (i) cause a violation of any of the provisions of the certificate of incorporation or bylaws (or other organizational or
            governing documents) of Parent or Purchaser; (ii) cause a violation by Parent or Purchaser of any Legal Requirement or Order applicable to Parent or Purchaser, or to which Parent or Purchaser are subject; or (iii) require any consent or notice
            under, conflict with, result in breach of, or constitute a default under (or an event that with notice or lapse of time or both would become a default), or give rise to any right of purchase, termination, amendment, cancellation, acceleration
            or other adverse change of any right or obligation or the loss of any benefit to which Parent or Purchaser is entitled under any provision of any material Contract, except in the case of <font style="font-family: 'Times New Roman';"><u>clauses
              </u></font><a name="ignore16"></a><font style="font-family: 'Times New Roman';"><u>(ii)</u></font><a name="ignore17"></a> and <font style="font-family: 'Times New Roman';"><u>(iii)</u></font>, as would not reasonably be expected to have,
            individually or in the aggregate, a Parent Material Adverse Effect.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">39</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Except for the filing of the certificate of merger with the Secretary of State of the State of Delaware or as may be required by the Exchange Act (including the filing with the SEC of the Offer Documents), Takeover Laws, the DGCL, the HSR
            Act and any applicable filing, notification or approval in any foreign jurisdiction required by Antitrust Laws and Foreign Investment Laws (if any) and the applicable rules and regulations of the SEC and any national securities exchange,
            neither Parent nor Purchaser, nor any of Parent&#8217;s other Affiliates, is required to give notice to, make any filing with or obtain any Consent from any Governmental Body at any time prior to the Closing in connection with the execution and
            delivery of this Agreement by Parent or Purchaser, or the consummation by Parent or Purchaser of the Offer, the Merger or the other Transactions, except those that the failure to make or obtain would not, individually or in the aggregate,
            reasonably be expected to have a Parent Material Adverse Effect. No vote of Parent&#8217;s stockholders is necessary to approve this Agreement or any of the Transactions.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608439"></a><a name="z_Toc227238419"></a><a name="z_Toc227238538"></a><a name="z_Toc228288357"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Disclosure</font>. None of the Offer Documents will contain any untrue statement of a
        material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. None of the information with respect to
        Parent or Purchaser supplied or to be supplied by or on behalf of Parent or Purchaser or any of their Subsidiaries, specifically for inclusion or incorporation by reference in the Schedule 14D-9 will, (a) at the time such document is filed with the
        SEC, (b) at any time such document is amended or supplemented or (c) at the time such document is first published, sent or given to the Company&#8217;s stockholders, contain any untrue statement of a material fact or omit to state any material fact
        required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. For clarity, the representations and warranties in this <font style="font-family: 'Times New Roman';"><u>Section 4.5</u></font> will not apply to, and neither Parent nor Purchaser makes any representation with respect to, statements or omissions included or incorporated by reference in the Offer Documents or the Schedule 14D-9 based
        upon information supplied to Parent by the Company or any of its Representatives on behalf of the Company specifically for inclusion therein.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238420"></a><a name="z_Toc227238539"></a><a name="z_Toc228288358"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Absence of Litigation</font>. As of the date of this Agreement, there is no Legal Proceeding pending and served or, to
        the knowledge of Parent, pending and not served, against Parent or Purchaser, except as would not, and would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse Effect. To the knowledge of Parent or
        Purchaser, as of the date of this Agreement, neither Parent nor Purchaser is subject to any continuing Order of, consent decree, settlement agreement or similar written agreement with, or continuing investigation by, any Governmental Body, or any
        Order, writ, judgment, injunction, decree, determination or award of any Governmental Body, except as would not, and would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse Effect.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238421"></a><a name="z_Toc227238540"></a><a name="z_Toc228288359"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Funds</font>. At the Effective Time, Parent will have (and will make available to Purchaser in a timely manner)
        immediately available funds in cash in an amount sufficient to carry out all of Parent and Purchaser&#8217;s obligations under this Agreement and to consummate the Transactions by payment in cash of the aggregate Offer Price payable following the Offer
        Acceptance Time, the aggregate Merger Consideration payable following the Effective Time and the aggregate amounts payable to holders of Company Equity Awards following the Effective Time pursuant to <font style="font-family: 'Times New Roman';"><u>Section





            2.8</u></font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">40</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.8</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;





          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Ownership of Shares</font></font>. Except as contemplated by this Agreement, neither Parent nor any of Parent&#8217;s Affiliates directly or indirectly owns, and at
        all times for the past three (3) years, neither Parent nor any of Parent&#8217;s controlled Affiliates has owned, beneficially or otherwise, any Shares or any securities, contracts or obligations convertible into or exercisable or exchangeable for
        Shares. Neither Parent nor Purchaser is, nor for the past three (3) years has been, an &#8220;interested stockholder&#8221; of the Company under Section 203(c) of the DGCL.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288361"></a><a name="z_Toc227238423"></a><a name="z_Toc227238542"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Acknowledgement by Parent and Purchaser</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Neither Parent nor Purchaser is relying and neither Parent nor Purchaser has relied on any representations or warranties whatsoever regarding the Transactions or the subject matter of this Agreement, express or implied, except for the
            representations and warranties expressly set forth in <font style="font-family: 'Times New Roman';"><u>Section 3</u></font>. Such representations and warranties by the Acquired Corporations constitute the sole and exclusive representations and
            warranties of the Acquired Corporations in connection with the Transactions and each of Parent and Purchaser understands, acknowledges and agrees that all other representations and warranties of any kind or nature whether express, implied or
            statutory are specifically disclaimed by the Acquired Corporations.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In connection with the due diligence investigation of the Acquired Corporations by Parent and Purchaser and their respective Affiliates, stockholders or Representatives, Parent and Purchaser and their respective Affiliates, stockholders
            and Representatives have received and may continue to receive after the date hereof from the Company, the other Acquired Corporations and their respective Affiliates, stockholders and Representatives certain estimates, projections, forecasts
            and other forward-looking information, as well as certain business plan information, regarding the Acquired Corporations and their respective businesses and operations. Parent and Purchaser hereby acknowledge that there are uncertainties
            inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as well as in such business plans, and agree that Parent and Purchaser will have no claim against the Acquired Corporations, or any of
            their respective Affiliates, stockholders or Representatives, or any other Person with respect thereto except for any such representation or warranty expressly set forth in <font style="font-family: 'Times New Roman';"><u>Section 3</u></font>.
            Accordingly, Parent and Purchaser hereby acknowledge and agree that neither the Acquired Corporations nor any of their respective Affiliates, stockholders or Representatives, nor any other Person, has made or is making any express or implied
            representation or warranty with respect to such estimates, projections, forecasts, forward-looking statements or business plans except for any such representation or warranty expressly set forth in <font style="font-family: 'Times New Roman';"><u>Section





                3</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238424"></a><a name="z_Toc227238543"></a><a name="z_Toc228288362"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Brokers and Other Advisors</font>. Except for Persons, if any, whose fees and expenses shall be paid by Parent or
        Purchaser, no broker, finder, investment banker, financial advisor or other Person is entitled to any brokerage, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission, or the reimbursement of expenses in connection therewith, in
        connection with the Transactions based upon arrangements made by or on behalf of Parent, Purchaser, or any of their respective Subsidiaries.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">41</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">4.11</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;





          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Stockholder and Management Arrangements</font></font>. As of the date hereof, neither Parent nor Purchaser nor any of their respective Affiliates is a party to
        any Contract, or has authorized, made or entered into, or committed or agreed to enter into, any formal or informal arrangements or other understandings (whether or not binding) with any stockholder, director, officer, employee or other Affiliate
        of the Company (a) relating to (i) this Agreement, the Offer or the Merger, (ii) the Company or (iii) the Surviving Corporation, businesses or operations (including as to continuing employment) from and after the Effective Time; or (b) pursuant to
        which (i) any holder of Shares would be entitled to receive consideration of a different amount or nature than the Offer Price in respect of such holder&#8217;s Shares, (ii) any holder of Shares has agreed to approve this Agreement or vote against any
        Superior Offer, or (iii) any Person has agreed to provide, directly or indirectly, equity investment to Parent, Purchaser or the Company to finance any portion of the Offer or the Merger.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Toc227238426"></a><a name="z_Toc227238545"></a><a name="z_Toc228288364"></a>SECTION 5</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>CERTAIN COVENANTS OF THE COMPANY</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608438"></a><a name="z_Toc227238427"></a><a name="z_Toc227238546"></a><a name="z_Toc228288365"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">5.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Access and Investigation</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref227008010"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">During





          the period from the execution and delivery of this Agreement until the earlier of the Effective Time and the valid termination of this Agreement pursuant to <font style="font-family: 'Times New Roman';"><u>Section</u></font><u> 8</u> (the &#8220;<font style="font-family: 'Times New Roman';"><u>Pre-Closing Period</u></font>&#8221;), upon reasonable advance notice to the Company, the Company shall, and shall cause each Acquired Corporation and the respective Representatives of the Acquired
          Corporations to, provide <a name="z_9kR3WTr26648FcEnsp5tosVNw1yEKta5J9BC8OC"></a>Parent and Parent&#8217;s Representatives with reasonable access during normal business hours of the Company to the Company&#8217;s designated Representatives and assets and to
          all existing books, records, documents and information relating to the Acquired Corporations, and promptly provide<a name="z_9kMHG5YVt4886AHeGpur7vquXPy30GMvc7LBDEA"></a> Parent and Parent&#8217;s Representatives with all reasonably requested
          information regarding the business of the Acquired Corporations and such additional financial, operating and other data and information regarding the Acquired Corporations, as Parent may reasonably request, in each case for any reasonable
          business purpose in furtherance of the consummation of the Offer and the Merger or any integration or restructuring planning; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>,<font style="font-family: 'Times New Roman'; font-style: italic;"> however</font>, that any such access shall be conducted at Parent&#8217;s expense, at a reasonable time, under the supervision of appropriate personnel of the Acquired Corporations and in such a manner as not to
          unreasonably interfere with the normal operation of the business of the Acquired Corporations. Nothing herein shall require any of the Acquired Corporations to disclose any information to Parent if such disclosure would, in the Company&#8217;s
          reasonable discretion and after notice to Parent (i) jeopardize any attorney-client or other legal privilege (so long as the Acquired Corporations have reasonably cooperated with Parent to permit such inspection of or to disclose such information
          on a basis that does not waive such privilege with respect thereto), (ii) contravene any applicable Legal Requirement (so long as the Acquired Corporations have reasonably cooperated with Parent to permit disclosure to the extent permitted by
          Legal Requirements) or (iii) contravene any Contract to which an Acquired Corporation is a party or by which an Acquired Corporation is bound (so long as the Acquired Corporations have reasonably cooperated with Parent to permit disclosure to the
          extent permitted by such Contract). Notwithstanding the foregoing, nothing in this <font style="font-family: 'Times New Roman';"><u>Section 5.1</u></font> shall require an Acquired Corporation to disclose any information to Parent or Parent&#8217;s
          Representatives if such information relates to the applicable portions of the minutes of the meetings of the Board of Directors or any committee thereof (including any presentations or other materials prepared by or for the Board of Directors or
          such committee thereof) where the Board of Directors or committee thereof discussed (x) the Transactions, or any similar transaction involving an Acquired Corporation, (y) any Acquisition Proposal or (z) a Company Adverse Change Recommendation.
          With respect to the information disclosed pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 5.1</u></font>, Parent shall comply with, and shall instruct Parent&#8217;s Representatives to comply with, all of its obligations
          under the Confidentiality Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">42</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref227000894"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to applicable Legal Requirements, each of the Company and Parent shall promptly notify the other of (A) any notice or other communication received by such
          Party from any Governmental Body in connection with this Agreement, the Offer, the Merger or the other Transactions, or from any Person alleging that the consent of such Person is or may be required in connection with the Offer, the Merger or the
          other Transactions; or (B) any Legal Proceeding commenced or, to any Party&#8217;s knowledge, threatened in writing against, such Party or any of its Subsidiaries or otherwise relating to, involving or affecting such Party or any of its Subsidiaries,
          in each case in connection with, arising from or otherwise relating to the Offer, the Merger or any other Transaction.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">The Company shall
            give prompt notice to Parent of any change, circumstance, condition, development, effect, event, occurrence or state of facts that has had, individually or in the aggregate, a Material Adverse Effect, and Parent shall give prompt notice to the
            Company of any change, circumstance, condition, development, effect, event, occurrence or state of facts that has had, individually or in the aggregate, a Parent Material Adverse Effect.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">For the avoidance of doubt, the delivery of any notice pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 5.1(b)</u></font> shall not cure any breach of any representation or warranty requiring disclosure of such
            matter prior to the date of this Agreement or otherwise limit or affect the remedies available hereunder to any Party. The failure to deliver any such notice shall not cause any Offer Condition or any of the conditions set forth in <font style="font-family: 'Times New Roman';"><u>Section 6</u></font> to fail to be satisfied or give rise to any right to terminate under <font style="font-family: 'Times New Roman';"><u>Section 8</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iv)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Schedule of Company Registered IP Action Items. Without limiting any of the provisions of Section 5.1(a) or Section 5.1(b), during the Pre-Closing Period, the Company shall promptly provide, at Parent&#8217;s request, a schedule (in a form
            reasonably acceptable to Parent) setting forth all action items that, to the knowledge of an Acquired Corporation, are due in respect of any Exclusively Licensed IP for which the Company controls prosecution and maintenance thereof or Company
            Registered IP within the one hundred eighty (180)-day period following the date of such request, including any filings or payments due to Governmental Bodies as appropriate to prosecute, preserve, maintain and protect the Company Registered IP
            and such Exclusively Licensed IP.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref473286967"></a><a name="z_Toc227238428"></a><a name="z_Toc227238547"></a><a name="z_Ref460608431"></a><a name="z_Ref460608432"></a><a name="z_Ref460608434"></a><a name="z_Ref460608435"></a><a name="z_Ref460608437"></a><a name="z_Toc228288366"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">5.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Operation of the Acquired Corporations&#8217; Business</font>. During the Pre-Closing Period, except (x) as required or otherwise contemplated under this Agreement or as required by applicable
        Legal Requirements, (y) with the written consent of Parent (which consent shall not be unreasonably withheld, conditioned or delayed), or (z) as set forth in <font style="font-family: 'Times New Roman';"><u>Section 5.2</u></font> of the Company
        Disclosure Schedule:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">43</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the Company and KalVista UK shall, and the Company shall cause each Acquired Corporation to, conduct its business in the ordinary course consistent with past practice in all material respects; and</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608349"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the





          Company and KalVista UK shall not, and the Company shall cause each Acquired Corporation not to:</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref227241641"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(A)





          establish a record date for, declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock (including the Shares) or other equity or voting interests, or (B) repurchase, redeem or
          otherwise reacquire any of the Shares, or any rights, warrants or options to acquire any of the Shares or its equity interests, other than: (1) repurchases of Shares outstanding as of the date hereof pursuant to the Company&#8217;s right (under written
          commitments in effect as of the date hereof) to purchase Shares held by a director, officer, employee or independent contractor of the Acquired Corporations only upon termination of such Person&#8217;s employment or engagement by the Company; (2)
          repurchases or forfeitures of Company Equity Awards (or Shares issued upon the exercise, vesting or forfeiture thereof) outstanding on the date hereof in accordance with their terms as in effect on the date hereof; (3) settlements in cash (in
          whole or in part) or conversion of any of the Convertible Senior Notes in accordance with their terms as of the date hereof; (4) in connection with the exercise, cancellation or conversion of Company Warrants in accordance with their terms as of
          the date hereof; (5) in connection with withholding to satisfy the exercise price and/or Tax obligations with respect to Company Equity Awards outstanding on the date hereof to the extent required by their terms as in effect on the date hereof or
          (6) among Acquired Corporations;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref227435905"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">split, combine, subdivide or reclassify any shares of its capital stock (including the Shares) or other equity interests;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref196921819"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">sell, issue, grant, deliver, pledge, transfer, encumber, dispose of or authorize the sale, issuance, grant, delivery, pledge, transfer or encumbrance of (A) any capital stock, equity interest or other security, (B) any option, call, warrant,
          restricted securities, restricted stock unit, stock appreciation rights, incentive award measured based on the Shares or similar equity or equity-based awards with respect to any Acquired Corporation or right to acquire any capital stock, voting
          securities, equity interest or other security, or (C) any instrument convertible into or exchangeable for or settled in any capital stock, voting securities, equity interest or other security (except (x) that the Company may issue Shares as
          required to be issued upon the exercise or vesting (as the case may be) of the Company Equity Awards or Company Warrants, in each case as outstanding on the date hereof in accordance with their terms in effect on the date hereof, or issuable to
          participants in the Company ESPP in accordance with the terms thereof in effect on the date hereof, or upon conversion of the Convertible Senior Notes, in each case, that are outstanding as of the date hereof (or in the case of the ESPP, made
          pursuant to elections in effect on the date hereof); (y) that the Company may issue Company Warrants to the extent required in connection with any Indebtedness permitted to be established or incurred under <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)(xiv)</u></font>; or (z) with respect to sales, grants, pledges, transfers or encumbrances (or authorizations with respect to any of the foregoing)) constituting Encumbrances created or incurred in connection with any
          Indebtedness permitted to be established or incurred under <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)(xiv)</u></font>;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">44</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iv)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">except as required under any Employee Plan that has been disclosed on <font style="font-family: 'Times New Roman';"><u>Section 3.17(a)</u></font> of the Company Disclosure Schedule, (A) increase any benefits or increase the compensation
            payable or paid, whether conditionally or otherwise, to any current or former employee, director, officer or independent contractor of the Acquired Corporations other than in connection with increases in base salaries and target bonus
            opportunities in connection with promotions as permitted under <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)(v)</u></font>, <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that such
            increases are in the ordinary course of business and consistent with past practice, (B) establish, adopt, terminate or amend any Employee Plan (or any plan, program, arrangement or agreement that would be an Employee Plan if it were in
            existence on the date hereof), other than the renewals of broad-based Employee Plans in the ordinary course of business consistent with past practice if the cost related to such renewal is not material or with respect to the entry into offer
            letters or promotion letters on the Company&#8217;s standard form that do not provide for severance or other termination-related entitlements in connection with any hire, promotion, engagement, or termination not otherwise prohibited by <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)(v)</u></font>, (C) grant any bonus, deferred compensation, severance or termination pay or benefit or grant any equity or equity-based awards to any employee, director, officer, or
            independent contractor of the Acquired Corporations, or (D) take any action, or grant any right, to accelerate the vesting under any Employee Plans (or any plan, program, arrangement or agreement that would be an Employee Plan if it were in
            existence on the date hereof);</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref227436557"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">hire,





          promote, engage or terminate (other than a termination for cause) the employment or engagement of any employee or independent contractor who earns or will earn (or prior to such termination, did earn) annual base compensation in excess of
          $200,000;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(vi)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">engage in any broad-based written or oral discussions or communications with any employee, director, officer, or independent contractor of the Acquired Corporations regarding post-Closing compensation and benefits;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref227435934"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">take




          any action that would constitute a &#8220;mass layoff&#8221; or &#8220;plant closing&#8221; within the meaning of, or would otherwise trigger notice requirements or liability under, the WARN Act;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(viii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">terminate, allow to lapse or expire, suspend, modify or otherwise take any step to limit the effectiveness or validity of, or fail to maintain as valid and in full force and effect, any applicable material Governmental Authorization owned
            or controlled by any Acquired Corporation;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref228027426"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(ix)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">amend




          or permit the adoption of any amendment to its certificate of incorporation or bylaws or other charter or organizational or governing documents;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref227435948"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(x)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">form





          any Subsidiary, acquire any equity or voting interest in any other Entity or enter into any joint venture, or clinical or commercial collaboration agreement or any other material collaboration, license, development, partnership, limited liability
          company, strategic alliance, material research, commercialization or similar material arrangement or trigger or exercise any right of first negotiation or right of first refusal under any collaboration, license or development agreement or similar
          arrangement;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">45</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xi)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">make or authorize any capital expenditure in excess of $50,000 in the aggregate;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref227435969"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xii)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">acquire,




          lease, license, sublicense, pledge, sell or otherwise dispose of, divest or spin-off, abandon, waive, covenant not to assert, relinquish or permit to lapse, transfer or assign, guarantee, exchange or swap, mortgage or otherwise encumber
          (including pursuant to a sale-leaseback transaction or securitization) or subject to any material Encumbrance (other than Permitted Encumbrances) any material tangible asset or property (except (A) in the ordinary course of business consistent
          with past practice, (B) pursuant to dispositions of obsolete, surplus or worn out assets that are no longer useful in the conduct of the business of the Acquired Corporations, (C) capital expenditures permitted by <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)(xi)</u></font>, (D) transactions among Acquired Corporations, (E) with respect to pledges, sales or other dispositions constituting Encumbrances created or incurred in connection with any Indebtedness
          permitted to be established or incurred under <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)(xiv)</u></font> or (F) pursuant to Contracts, to which an Acquired Corporation is a party, made available to Parent and in effect prior
          to the date of this Agreement);</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xiii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">acquire, lease, license, sublicense, pledge, encumber, sell or otherwise dispose of, or abandon or permit to lapse, or transfer or assign any item of Company IP, nor disclose any Trade Secrets to a third Person other than pursuant to a
            written confidentiality agreement (except (A) in the ordinary course of business consistent with past practice&#160; (including entering into Standard IP Contracts or Permitted Encumbrances)), (B) abandoning or permitting to lapse any Company
            Registered IP at the end of its statutory term or otherwise in the ordinary course of business consistent with past practice, or (C) transactions among Acquired Corporations);</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref131532117"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xiv)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">lend





          money or make capital contributions or advances to or make investments in, any Person, or incur, assume or guarantee or otherwise become contractually liable for any material Indebtedness for borrowed money (except for (A) advances to directors,
          employees, consultants and other third parties involved in the sales, marketing and distribution of Company products for travel and other business related expenses in the ordinary course of business consistent with past practice and in compliance
          with the Company&#8217;s policies related thereto; (B) advances of expenses as required under the Company&#8217;s certificate of incorporation or bylaws or any Contract made available to Parent; (C) surety bonds, letters of credit or similar instruments
          issued in the ordinary course of business consistent with past practice and (D) Indebtedness in an aggregate principal amount not to exceed $100,000);</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref131532871"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xv)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(A)





          amend or modify or breach in any material respect, or voluntarily terminate, any Material Contract (but excluding the amendment or modification of any statement of work, purchase order or ancillary agreement or documentation issued under an
          existing Material Contract, not in excess of $100,000 individually), (B) enter into any Contract which would have been a Material Contract if such Contract was outstanding as of the execution and delivery of this Agreement (but excluding the
          entry into any statement of work, purchase order or ancillary agreement or documentation issued under an existing Material Contract, not in excess of $100,000 individually), in each case of clauses (A) and (B), except in the ordinary course of
          business consistent with past practice or as otherwise permitted by <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)</u></font>, or (C) amend, modify, breach in any respect, or terminate, that certain Material Contract identified
          on <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)(xv)(C)</u></font> of the Company Disclosure Schedule;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">46</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xvi)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><a name="z_Ref227241618"></a>(A) change any income or other material method of Tax accounting or any Tax accounting period; (B) make (except in the ordinary course of business), change or revoke any income or other material Tax election;
            (C) file an amended income or other material Tax Return; (D) enter into a closing agreement with any Governmental Body regarding any income or other material Taxes; (E) settle, compromise or consent to any income or other material Tax claim or
            assessment or surrender a right to a material Tax refund; (F) waive or extend the statute of limitations with respect to any Tax or Tax Return, other than any automatically granted extension obtained to file Tax Returns or in connection with
            any pending Tax claim or proceeding; or (G) take any action that will cause a change in the (x) U.S. federal (and applicable state or local) income Tax classification or (y) Tax residency, in each case, of any Acquired Corporation from its
            classification or residency, as applicable, as of the date hereof;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref227436014"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xvii)</font>&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">commence





          any Legal Proceeding or settle, release or waive or compromise any Legal Proceeding or other claim (or threatened Legal Proceeding or other claim) against any Acquired Corporation, other than: (A) any settlement that involves a Tax claim or
          assessment which is exclusively governed by <font style="font-family: 'Times New Roman';"><u>clause (xvi)</u></font> above; (B) any settlement or compromise with any Governmental Body where (1) the amount paid does not exceed $50,000 in the
          aggregate, (2) such settlement or compromise does not impose any non-monetary restrictions or obligations that are material to the Acquired Corporations, taken as a whole, and (3) such settlement does not involve any finding or admission of any
          violation of Legal Requirements or admission of any wrongdoing by any Acquired Corporation; (C) any settlement or compromise that relates to Intellectual Property Rights where (1) the amount paid does not exceed $50,000 in the aggregate, (2) such
          settlement or compromise does not impose any non-monetary restrictions or obligations that are material to the Acquired Corporations, taken as a whole, and (3) such settlement does not involve any finding or admission of any violation of Legal
          Requirements or admission of any wrongdoing by any Acquired Corporation; (D) any other settlement or compromise that (1) results solely in monetary obligations involving only the payment of monies by the Acquired Corporations of not more than
          $100,000 in the aggregate (excluding monetary obligations that are funded by an indemnity obligation to, or an insurance policy of, any Acquired Corporation) or (2) results in no monetary or other material non-monetary obligation of any Acquired
          Corporation; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that the settlement, release, waiver or compromise of any Legal Proceeding or claim brought by the stockholders of the Company against the Company
          and/or its directors relating to the Transactions or a breach of this Agreement or any other agreements contemplated hereby shall be subject to <font style="font-family: 'Times New Roman';"><u>Section 2.7</u></font> or <font style="font-family: 'Times New Roman';"><u>Section 6.5</u></font>, as applicable;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref227436021"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xviii)</font>&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">enter





          into any collective bargaining agreement or other Contract with any Union;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref227436032"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xix)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">adopt





          or implement any stockholder rights plan or similar arrangement;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">47</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xx)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">adopt a plan or agreement of complete or partial liquidation or dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of any of the Acquired Corporations; or</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref227436057"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xxi)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">authorize





          any of, or agree or commit to take, any of the actions described in the foregoing <font style="font-family: 'Times New Roman';"><u>clauses (i)</u></font> through <font style="font-family: 'Times New Roman';"><u>(xx)</u></font> of this <font style="font-family: 'Times New Roman';"><u>Section 5.2(b)</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Notwithstanding the foregoing, nothing contained herein shall give to Parent or Purchaser, directly or indirectly, rights to control or direct the operations of the
        Acquired Corporations prior to the Offer Acceptance Time. Prior to the Effective Time, each of Parent and the Company shall exercise, consistent with the terms and conditions hereof, complete control and supervision of its and its, if applicable,
        Subsidiaries&#8217; respective operations.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288367"></a><a name="z_Ref460608419"></a><a name="z_Ref460608420"></a><a name="z_Ref460608421"></a><a name="z_Ref460608422"></a><a name="z_Ref460608423"></a><a name="z_Ref460608424"></a><a name="z_Ref460608425"></a><a name="z_Ref460608426"></a><a name="z_Ref460608427"></a><a name="z_Ref460608428"></a><a name="z_Ref460608429"></a><a name="z_Ref460608430"></a><a name="z_Toc227238429"></a><a name="z_Toc227238548"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">5.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">No





          Solicitation</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473293052"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">For





          the purposes of this Agreement, &#8220;<font style="font-family: 'Times New Roman';"><u>Acceptable Confidentiality Agreement</u></font>&#8221; means any customary confidentiality agreement that (i) contains provisions that are not materially less favorable
          to the Company than those contained in the Confidentiality Agreement and (ii) does not prohibit the Company from providing any information to Parent in accordance with this <font style="font-family: 'Times New Roman';"><u>Section 5.3</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Except as permitted by this <u>Section 5.3</u>, during the Pre-Closing Period, the Company shall (and shall cause each Acquired Corporation to) not, and shall use reasonable best
              efforts to cause their respective Representatives not to, directly or indirectly (i) continue any solicitation, knowing encouragement, discussions or negotiations with any Persons that may be ongoing with respect to an Acquisition Proposal;
              (ii) (A) solicit, initiate or knowingly facilitate or encourage (including by way of furnishing non-public information) any inquiries regarding, or the making of any proposal or offer that constitutes, or could reasonably be expected to lead
              to, an Acquisition Proposal, (B) engage in, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any other Person any non-public information in connection with, or for the purpose of soliciting or
              knowingly encouraging or facilitating, an Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal or (C) approve, adopt, endorse or recommend or enter into any letter of intent,
              acquisition agreement, agreement in principle or similar agreement with respect to an Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal</font>; (iii) waive or release any Person
            from, forebear in the enforcement of, or amend any standstill agreement or any standstill provisions of any other Contract; or (iv) resolve or agree to do any of the foregoing, unless in the case of <font style="font-family: 'Times New Roman';"><u>clause (iii)</u></font>, <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the Board of Directors determines in good faith, after consultation with the Company&#8217;s outside legal counsel, that the failure to do so
              would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders under applicable Legal Requirements</font>. As promptly as reasonably practicable following the date hereof (and in any event within one
            (1) business day following the date hereof), the Company shall request the prompt return or destruction (to the extent provided for by the applicable confidentiality agreement) of all non-public information previously furnished to any Person
            (other than <a name="z_9kMIH5YVt4886AHeGpur7vquXPy30GMvc7LBDEA"></a>Parent and Parent&#8217;s Representatives) that has, within the one (1)-year period prior to the date of this Agreement, made or indicated an intention to make an Acquisition
            Proposal.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">48</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Notwithstanding anything in this Agreement to the contrary, if at any time after the execution and delivery of this Agreement and prior to the Offer Acceptance Time any Acquired Corporation or any of their Representatives receives a <font style="font-family: 'Times New Roman'; font-style: italic;">bona fide</font> written Acquisition Proposal from any Person or group of Persons, which Acquisition Proposal was made or renewed after the execution and delivery of this Agreement,
            and did not, directly or indirectly, result from any material breach of this <font style="font-family: 'Times New Roman';"><u>Section 5.3</u></font>, and the Board of Directors determines in good faith, after consultation with its financial
            advisors and outside legal counsel, that such Acquisition Proposal constitutes or could reasonably be expected to lead to a Superior Offer, then the Company and its Representatives may (i) furnish, pursuant to an Acceptable Confidentiality
            Agreement, information (including non-public information) with respect to the Acquired Corporations to the Person or group of Persons who has made such Acquisition Proposal and the Representatives of such Person or group of Persons; <font style="font-family: 'Times New Roman'; font-style: italic;">provided </font>that the Company shall as promptly as practicable (and in any event within twenty-four (24) hours) provide to Parent any non-public information concerning the
            Acquired Corporations that is provided to any Person to the extent access to such information was not previously provided to Parent or its Representatives and (ii) engage in or otherwise participate in discussions or negotiations with the
            Person or group of Persons making such Acquisition Proposal and the Representatives of such Person or group of Persons; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that in the case of <font style="font-family: 'Times New Roman';"><u>clauses (i)</u></font> and <font style="font-family: 'Times New Roman';"><u>(ii)</u></font>, that at or prior to the first
            time that the Company furnishes any information to or participates in any discussions or negotiations with any Person after the date of this Agreement, the Company shall provide written notice to Parent of such determination in good faith of
            the Board of Directors as provided for above.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473289291"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">During





          the Pre-Closing Period, the Company shall (i) promptly (and in any event within twenty-four (24) hours) notify Parent in writing if any inquiries, proposals or offers with respect to, or that would reasonably be expected to lead to, an
          Acquisition Proposal are received by any Acquired Corporation and provide to Parent a copy of any written Acquisition Proposal (including any proposed term sheet, letter of intent, acquisition agreement or similar agreement with respect thereto,
          to the extent such documents are provided to the Company in connection with such Acquisition Proposal) and a summary of any material unwritten terms and conditions thereof (and indicate the identity of such Person), and (ii) keep Parent
          reasonably informed of any material developments, discussions or negotiations regarding any Acquisition Proposal (including any material changes to the terms thereof) on a prompt basis (and in any event within twenty-four (24) hours of any
          request by Parent for an update as to the status of any such material development, discussion or negotiation).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608348"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Nothing





          in this <font style="font-family: 'Times New Roman';"><u>Section 5.3</u></font> or elsewhere in this Agreement shall prohibit the Company from (i) taking and disclosing to the stockholders of the Company a position contemplated by Rule 14e-2(a),
          Rule 14d-9 or Item 1012(a) of Regulation M-A promulgated under the Exchange Act, including any &#8220;stop, look and listen&#8221; communication pursuant to Rule 14d-9(f) promulgated under the Exchange Act, or (ii) making any disclosure to the stockholders
          of the Company that is required by applicable Legal Requirements; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that the
          Board of Directors shall not effect a Company Adverse Change Recommendation except in accordance with <font style="font-family: 'Times New Roman';"><u>Section 6.1(b)</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">49</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-size: 10pt;"><a name="z_Toc227238430"></a><a name="z_Toc227238549"></a></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SECTION 6</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref227001286"></a><font style="font-family: 'Times New Roman';"><u>ADDITIONAL COVENANTS OF THE PARTIES</u></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288369"></a><a name="z_Ref460608417"></a><a name="z_Ref460608418"></a><a name="z_Toc227238431"></a><a name="z_Toc227238550"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Company Board Recommendation</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608347"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Subject





          to <font style="font-family: 'Times New Roman';"><u>Section 6.1(b)</u></font>, the Company hereby consents to the inclusion of a description of the Company Board Recommendation in the Offer Documents. During the Pre-Closing Period, subject to <font style="font-family: 'Times New Roman';"><u>Section 6.1(b)</u></font>, neither the Board of Directors nor any committee thereof shall (i)(A) withdraw or withhold (or modify or qualify in a manner adverse to Parent or Purchaser), or publicly
          propose to withdraw or withhold (or modify or qualify in a manner adverse to Parent or Purchaser), the Company Board Recommendation, (B) adopt, approve, recommend or declare advisable, or publicly propose to approve, recommend or declare
          advisable, any Acquisition Proposal, (C) after public announcement of an Acquisition Proposal (other than a tender offer or exchange offer), fail to publicly affirm the Company Board Recommendation within three (3) business days after a written
          request by Parent to do so (or, if earlier, by the close of business on the business day immediately preceding the scheduled date of the Expiration Date), (D) following the commencement of a tender offer or exchange offer relating to the Shares
          by a Person unaffiliated with Parent, fail to publicly affirm the Company Board Recommendation and recommend that the Company&#8217;s stockholders reject such tender offer or exchange offer within ten (10) business days after the commencement of such
          tender offer or exchange offer pursuant to Rule 14d-9(f) promulgated under the Exchange Act (or, if earlier, by the close of business on the business day immediately preceding the scheduled date of the Expiration Date) or (E) fail to include the
          Company Board Recommendation in the Schedule 14D-9 when filed with the SEC or disseminated to the Company&#8217;s stockholders (any action described in this <font style="font-family: 'Times New Roman';"><u>clause (i)</u></font> being referred to as a
          &#8220;<font style="font-family: 'Times New Roman';"><u>Company Adverse Change Recommendation</u></font>&#8221;) or (ii) approve, recommend or declare advisable, or propose to approve, recommend or declare advisable, or cause or allow the Company to execute
          or enter into any Contract, letter of intent, memorandum of understanding, agreement in principle or term sheet with respect to any Acquisition Proposal, or Contract that would require, or would reasonably be expected to cause, the Company to
          abandon, terminate, delay or fail to consummate, or that would otherwise materially impede, interfere with or be inconsistent with, the Transactions (other than an Acceptable Confidentiality Agreement).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608346"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Notwithstanding





          anything to the contrary contained in this Agreement, at any time prior to the Offer Acceptance Time, and subject to compliance with the other provisions of this <font style="font-family: 'Times New Roman';"><u>Section 6.1</u></font>:</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">50</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">if any Acquired Corporation has received a <font style="font-family: 'Times New Roman'; font-style: italic;">bona fide </font>written Acquisition Proposal, which was made after the date of this Agreement, from any Person that has not
            been withdrawn and after consultation with outside legal counsel, the Board of Directors shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer, (x) the Board of Directors may make a Company Adverse Change
            Recommendation, or (y) <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that the Company and its Subsidiaries are not in breach of <font style="font-family: 'Times New Roman';"><u>Section 5.3</u></font> and
            subject to the other provisions of <font style="font-family: 'Times New Roman';"><u>Section 8.1(e)</u></font>, the Company may terminate this Agreement pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8.1(e)</u></font> to
            enter into a Specified Agreement with respect to such Superior Offer, in each case under (x) or (y), only if: (A) the Board of Directors determines in good faith, after consultation with the Company&#8217;s outside legal counsel, that the failure to
            do so would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders under applicable Legal Requirements; (B) the Company shall have given Parent prior written notice of its intention to consider making
            a Company Adverse Change Recommendation or terminating this Agreement pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8.1(e)</u></font> at least four (4) business days prior to making any such Company Adverse Change
            Recommendation or termination (a &#8220;<font style="font-family: 'Times New Roman';"><u>Determination Notice</u></font>&#8221;) (which notice, and the delivery thereof, shall not constitute a Company Adverse Change Recommendation or termination) and, if
            desired by Parent, during such four (4)-business day period shall have negotiated, and caused its Representatives to negotiate, in good faith with respect to any revisions to the terms of this Agreement or another proposal, to the extent
            proposed by Parent, so that such Acquisition Proposal would cease to constitute a Superior Offer; and (C) (1) the Company shall have provided to Parent information with respect to such Acquisition Proposal in accordance with <font style="font-family: 'Times New Roman';"><u>Section 5.3(d)</u></font>, as well as a copy of any acquisition agreement with respect to such Acquisition Proposal and a copy of any financing commitments relating thereto (or, if not provided in
            writing to the Company, a written summary of the material terms thereof), (2) the Company shall have given Parent the four (4)-business day period after the Determination Notice to propose revisions to the terms of this Agreement or make
            another proposal so that such Acquisition Proposal would cease to constitute a Superior Offer, and (3) after giving effect to the proposals made by Parent during such period, if any, after consultation with the Company&#8217;s outside legal counsel,
            the Board of Directors shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer and that the failure to make the Company Adverse Change Recommendation or terminate this Agreement pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8.1(e)</u></font> would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders under applicable Legal Requirements. Issuance of any <a name="ignore21"></a>&#8220;stop, look and listen&#8221; communication by or on behalf of the Company pursuant to Rule 14d-9(f) promulgated under the Exchange Act, taking and disclosing a position or otherwise making any disclosure as is required under
            Rule 14e-2(a), Rule 14d-9 or Item 1012(a) of Regulation M-A promulgated under the Exchange Act or otherwise complying with applicable Legal Requirements shall not be considered a Company Adverse Change Recommendation and shall not require the
            giving of a Determination Notice or compliance with the procedures set forth in this <font style="font-family: 'Times New Roman';"><u>Section 6.1</u></font>. The provisions of this <font style="font-family: 'Times New Roman';"><u>Section
                6.1(b)(i)</u></font> shall also apply to any change to any of the financial terms (including the form, amount and timing of payment of consideration) or other material amendment to any Acquisition Proposal and shall require a new
            Determination Notice, except that the references to four (4) business days shall be deemed to be two (2) business days; and<a name="z_Ref460608322"></a></font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref226644592"></a><a name="z_Ref473478171"></a><a name="z_Ref227006293"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">other than in connection with an Acquisition Proposal, the Board of Directors may make a Company Adverse Change Recommendation only in respect of an Intervening Event only if: (A) the
          Board of Directors determines in good faith, after consultation with the Company&#8217;s outside legal counsel, that the failure to do so would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders under
          applicable Legal Requirements; (B) the Company shall have given Parent a Determination Notice at least four (4) business days prior to making any such Company Adverse Change Recommendation and, if desired by Parent, during such four (4)-business
          day period shall have negotiated, and caused its Representatives to negotiate, in good faith with respect to any revisions to the terms of this Agreement or another proposal to the extent proposed by Parent so that a Company Adverse Change
          Recommendation would no longer be necessary; and (C) (1) the Company shall have specified in reasonable detail the facts and circumstances that render a Company Adverse Change Recommendation necessary, (2) the Company shall have given Parent the
          four (4)-business day period after the Determination Notice to propose revisions to the terms of this Agreement or make another proposal so that a Company Adverse Change Recommendation would no longer be necessary, and (3) after giving effect to
          the proposals made by Parent during such period, if any, after consultation with the Company&#8217;s outside legal counsel, the Board of Directors shall have determined, in good faith, that the failure to make the Company Adverse Change Recommendation
          would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders under applicable Legal Requirements. The provisions of this <font style="font-family: 'Times New Roman';"><u>Section 6.1(b)(ii)</u></font>
          shall also apply to any material change to the facts and circumstances relating to such Intervening Event specified by the Company pursuant to <font style="font-family: 'Times New Roman';"><u>clause (C)(1)</u></font> above and require a new
          Determination Notice (<font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>,<font style="font-family: 'Times New Roman'; font-style: italic;">&#160;</font>that for the purposes of such subsequent Determination Notice, all references to &#8220;four (4) business days&#8221; shall be deemed to be &#8220;two (2) business days&#8221;).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">51</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288370"></a><a name="z_Ref460608414"></a><a name="z_Ref460608415"></a><a name="z_Ref460608416"></a><a name="z_Ref227007249"></a><a name="z_Toc227238432"></a><a name="z_Toc227238551"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Filings,





          Consents and Approvals</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608344"></a><a name="z_Ref226642967"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Parties agree to use their reasonable best efforts to take promptly any and all steps necessary to avoid or eliminate each and every impediment under the Antitrust Laws and Foreign Investment Laws, that may be
          asserted by any Governmental Body or any other party, so as to enable the Closing to occur as promptly as practicable, but in no case later than the End Date, including providing as promptly as reasonably practicable all information required by
          any Governmental Body pursuant to its evaluation of the Transactions under the HSR Act or other applicable Antitrust Laws and Foreign Investment Laws. Notwithstanding the foregoing, Parent and its Affiliates shall not have an obligation to
          propose, negotiate, commit to and consent to any divestiture, sale, disposition, hold separate Order or other structural or conduct relief, or other operational undertakings, in order to obtain clearance from any Governmental Body.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608343"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Subject





          to the terms and conditions of this Agreement, each of the Parties shall (and shall cause their respective Affiliates, if applicable, to): (i) promptly, but in no event later than ten (10) business days after the date hereof, make an appropriate
          filing of all notification and report forms as required by the HSR Act with respect to the Transactions and (ii) promptly, but in no event later than fifteen (15) business days after the date hereof, prepare and make, any other filings,
          notifications or other Consents that are required to be made with, or obtained from, any other Governmental Bodies under applicable Antitrust Laws and Foreign Investment Laws in connection with the Transactions. The Company shall cooperate with,
          and promptly provide, Parent with all the information and documents reasonably required by Parent for the purpose of making such filings.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">52</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196941416"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The





          Parties shall jointly control the overall strategy with respect to the Transactions under Antitrust Laws and Foreign Investment Laws, including the right to determine the strategy and timing for any such filings, submissions, communications and
          meetings and each Party shall consider in good faith the views of the other Party, and keep the other Party informed of the status of such matters. Without limiting the generality of anything contained in this <font style="font-family: 'Times New Roman';"><u>Section 6.2</u></font>, during the Pre-Closing Period, each Party shall (i) give the other Parties prompt notice of the making or commencement of any request, inquiry, investigation, action or Legal Proceeding brought by a
          Governmental Body or brought by a third party before any Governmental Body, in each case, with respect to the Transactions under the Antitrust Laws and Foreign Investment Laws, (ii) keep the other Parties informed as to the status of any such
          request, inquiry, investigation, action or Legal Proceeding, (iii) promptly inform the other Parties of, and wherever practicable give the other Parties reasonable advance notice of, and the opportunity to participate in, any communication to or
          from the FTC, DOJ or any other Governmental Body in connection with any such request, inquiry, investigation, action or Legal Proceeding, (iv) promptly furnish to the other Parties, subject to an appropriate confidentiality agreement to limit
          disclosure to counsel and outside consultants, copies of documents provided to or received from any Governmental Body in connection with any such request, inquiry, investigation, action or Legal Proceeding (other than &#8220;<a name="z_9kR3WTr26648HiZnk3rcw3z5jVwt27sSY4BM79P"></a>Transaction-Related Documents&#8221; and &#8220;<a name="z_9kR3WTr26648IfPhk3rnrWSx8BHJ"></a>Plans and Reports&#8221; as those terms are used in the rules and regulations under the HSR Act, that contain
          valuation information (which can be redacted)), (v) subject to an appropriate confidentiality agreement to limit disclosure to counsel and outside consultants, and to the extent reasonably practicable, consult and cooperate with the other Parties
          and consider in good faith the views of the other Parties in connection with any analysis, appearance, presentation, memorandum, brief, argument, opinion or proposal made or submitted in connection with any such request, inquiry, investigation,
          action or Legal Proceeding, and (vi) except as may be prohibited by any Governmental Body or by any Legal Requirement, in connection with any such request, inquiry, investigation, action or Legal Proceeding in respect of the Transactions, give
          the other party reasonable advance notice of, and permit authorized Representatives of the other Party to be present at each meeting or conference relating to such request, inquiry, investigation, action or Legal Proceeding and to have access to
          and be consulted in connection with any argument, opinion or proposal made or submitted to any Governmental Body in connection with such request, inquiry, investigation, action or Legal Proceeding. Notwithstanding anything to the contrary in this
          <font style="font-family: 'Times New Roman';"><u>Section 6.2</u></font>, the Parties may redact materials provided to one another (A) to remove competitively sensitive information or information concerning valuation; (B) as necessary to comply
          with Legal Requirements and Contracts; and (C) as necessary to address reasonable attorney-client privilege or other privilege or confidentiality concerns.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">During the Pre-Closing Period, the Company undertakes that it shall not (and shall cause its Affiliates not to) enter into any transactions (whether by way of asset purchase, equity purchase, merger, or otherwise) which would reasonably be
            expected to materially delay, or materially reduce the likelihood of obtaining, approval of any Governmental Body of the Transactions, pursuant to any Antitrust Laws.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608406"></a><a name="z_Ref460608407"></a><a name="z_Ref460608408"></a><a name="z_Ref460608409"></a><a name="z_Ref460608410"></a><a name="z_Toc227238433"></a><a name="z_Toc227238552"></a><a name="z_Toc228288371"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Employee Benefits</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196927675"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">For





          a period of one (1) year following the Closing Date, Parent shall provide, or cause to be provided, to each employee of an Acquired Corporation who is employed by an Acquired Corporation as of immediately prior to the Closing Date and who
          continues to be employed by the Surviving Corporation (or any Affiliate thereof, including, for the avoidance of doubt, Parent and Parent&#8217;s Affiliates) during such one (1)-year period (each, a &#8220;<font style="font-family: 'Times New Roman';"><u>Continuing





              Employee</u></font>&#8221;) with (i) a base salary or hourly wage rate (as applicable) and target annual or short-term cash incentive opportunities that, in the aggregate, are at least equal to the base salary or hourly wage rate (as applicable)
          and target annual or short-term cash incentive opportunities provided to such Continuing Employee immediately prior to the Closing Date and (ii) broad-based employee benefits (excluding any change-in-control or transaction-based payments,
          long-term incentives, nonqualified deferred compensation, severance, retention, equity or equity-based compensation, defined benefit plans, and post-retirement or retiree medical or retiree welfare benefits (the &#8220;<font style="font-family: 'Times New Roman';"><u>Excluded Benefits</u></font>&#8221;)) that are no less favorable in the aggregate to, at the discretion of Parent, the employee benefits (other than the Excluded Benefits) provided (A) by an Acquired Corporation to such Continuing
          Employee immediately prior to the Closing Date or (B) by Parent or its Affiliates (other than, following the Closing, the Surviving Corporation and its Subsidiaries) to similarly situated employees of Parent or its Affiliates.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">53</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref227012058"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">For





          the one (1)-year period following the Closing Date, Parent shall, or shall cause its applicable Affiliate (including, following the Closing, the Surviving Corporation and its Subsidiaries) to, provide each Continuing Employee with severance
          benefits that are no less favorable than, at the discretion of Parent, (i) the severance benefits made available to such Continuing Employee immediately prior to the Closing Date and set forth on <font style="font-family: 'Times New Roman';"><u>Section





              6.3(b)</u></font> of the Company Disclosure Schedule or (ii) the severance benefits provided to similarly situated employees of Parent or any of its Affiliates.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref227236540"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Parent





          shall, or shall cause the Surviving Corporation or its Subsidiaries to, give each Continuing Employee full credit for such Continuing Employee&#8217;s service with the Company and its Subsidiaries (and any Affiliates or predecessors thereto) for
          vesting, future paid time off accruals and eligibility purposes (but not for benefit accrual purposes) under the broad-based benefit plans maintained by Parent or any of its Affiliates (including the Surviving Corporation and its Subsidiaries,
          the &#8220;<font style="font-family: 'Times New Roman';"><u>Parent Employee Plans</u></font>&#8221;) in which the Continuing Employee participates following Closing to the same extent recognized by the Company or its Subsidiaries immediately prior to the
          Closing Date; <font style="font-family: 'Times New Roman'; font-style: italic;">provided, however</font>, that such service shall not be recognized to the extent that such recognition would result in a duplication of benefits with respect to the
          same period of service.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196941423"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Following





          the Closing Date, with respect to any Parent Employee Plans providing for health or welfare benefits in which Continuing Employees are eligible to participate, Parent or an Affiliate of Parent shall, until the earlier of (x) the end of the
          calendar year in which the Closing Date occurs or (y) the end of the applicable benefit plan year in which Closing occurs, use commercially reasonable efforts to: (i) waive any preexisting condition limitations otherwise applicable to Continuing
          Employees and their eligible dependents under any plan of Parent or an Affiliate that provides health and welfare benefits in which Continuing Employees are eligible to participate following the Closing Date to the same extent as such preexisting
          condition limitations are waived for similarly situated employees of Parent, (ii) honor and credit any deductible, co-payment and out-of-pocket expenses incurred by the Continuing Employees and their eligible dependents under the health and
          welfare plans in which they participated immediately prior to transitioning into a plan of Parent or an Affiliate during the portion of the plan year prior to such transition in satisfying any deductibles, co-payments or out-of-pocket maximums
          under health plans of Parent or an Affiliate and (iii) waive any waiting period limitation or evidence of insurability requirement that would otherwise be applicable to a Continuing Employee and his or her eligible dependents on or after the
          Closing Date, in each case to the extent such Continuing Employee or eligible dependent had satisfied any similar limitation or requirement under an analogous Employee Plan prior to the Closing Date and to the same extent as such terms and
          conditions apply to similarly situated employees of Parent.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">54</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Notwithstanding anything to the contrary set forth in this Agreement, this <font style="font-family: 'Times New Roman';"><u>Section 6.3</u></font> will not be deemed to: (i) create any rights to continued employment or service or
            guarantee employment for any period of time with Parent, the Company or any of their respective Affiliates, or preclude the ability of Parent, Company or any of their respective Affiliates to terminate the employment or service of any employee
            or any other Person; (ii) create, terminate, modify, or amend any Employee Plan or any other benefit or compensation plan, program, agreement or arrangement, or limit the ability of Parent, the Company or any of their respective Affiliates to
            amend, modify, or terminate any benefit or compensation plan, program, policy, contract, agreement or arrangement; (iii) alter or limit the ability of Parent or the Company or any of their respective Affiliates to amend, modify or terminate any
            benefit plan, program, agreement or arrangement at any time assumed, established, sponsored or maintained by any of them; or (iv) create any third-party beneficiary rights in any employee or any other Person (or beneficiary or dependent
            thereof).</font></font></div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> <br>
          </font></font></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288372"></a><a name="z_Ref460608401"></a><a name="z_Ref460608402"></a><a name="z_Ref460608403"></a><a name="z_Ref460608404"></a><a name="z_Ref460608405"></a><a name="z_Toc227238434"></a><a name="z_Toc227238553"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Indemnification of Officers and Directors</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref343117161"></a><a name="z_Ref196941417"></a><a name="z_Ref227254275"></a><a name="z_Ref460608338"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">For a period of six (6) years from the Effective Time, Parent agrees that all rights to indemnification, advancement of expenses and
            exculpation from liabilities for acts or omissions occurring at or prior to the Effective Time (whether asserted or claimed prior to, at or after the Effective Time) now existing in favor of the current or former directors or officers of any
            Acquired Corporation and any indemnification or other similar agreements of any Acquired Corporation, in each case as in effect on the date of this Agreement, shall continue in full force and effect in accordance with their terms, and the
            Surviving Corporation shall (and shall cause each Acquired Corporation to) perform their obligations thereunder. </font><a name="z_Hlk131691501"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Without limiting the
            foregoing, during the period commencing at the Effective Time and ending on the sixth (6</font><sup style="color: #000000; vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">) anniversary of the Effective Time, Parent shall, and shall cause the Surviving Corporation and its Subsidiaries to, and the Surviving Corporation agrees that it will, indemnify and hold harmless each individual who is as
            of the date of this Agreement, or who becomes prior to the Effective Time, a director or officer of any Acquired Corporation or who is as of the date of this Agreement, or who thereafter commences prior to the Effective Time, serving at the
            request of any Acquired Corporation as a director or officer of another Person (the &#8220;<u>Indemnified Persons&#8221;</u>), pursuant to and to the extent provided in the certificate of incorporation and bylaws (or other organizational documents) of each
            of the Acquired Corporations in effect on the date of this Agreement or any indemnification agreement between such Indemnified Person and any of the Acquired Corporations in effect on the date of this Agreement and set forth on the Company
            Disclosure Schedule, against all claims, losses, liabilities, damages, judgments, inquiries, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit or
            proceeding, whether civil, criminal, administrative or investigative (including with respect to matters existing or occurring at or prior to the Effective Time, including this Agreement and the Transactions and actions contemplated hereby),
            arising out of or pertaining to the fact that the Indemnified Person is or was a director or officer of any Acquired Corporation or is or was serving at the request of any Acquired Corporation as a director or officer of another Person, whether
            asserted or claimed prior to, at or after the Effective Time, to the fullest extent permitted under applicable Legal Requirements; </font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">provided</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, </font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">however</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">,
            that neither Parent nor the Surviving Corporation nor any of their respective Subsidiaries shall be obligated to indemnify or hold harmless any Indemnified Person in connection with any claim, action, suit or proceeding arising out of or
            resulting from fraud, intentional misconduct or knowing violation of law by such Indemnified Person; </font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">provided</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, </font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">further</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, that the foregoing exceptions
            shall not limit or affect the obligation of Parent or the Surviving Corporation to advance expenses pursuant to clause (x) of this <u>Section 6.4(a)</u>. In the event of any such claim, action, suit or proceeding, (x) Parent shall, and shall
            cause the Surviving Corporation and its Subsidiaries to, pay, in advance of the final disposition of such claim, action, suit or proceeding, any expenses incurred in defense thereof by the Indemnified Person upon receipt of an undertaking by
            such Indemnified Person to repay such amount if it shall ultimately be determined that such Indemnified Person is not entitled to be indemnified pursuant to the preceding sentence and (y) Parent shall, and shall cause the Surviving Corporation
            and its Subsidiaries to, reasonably cooperate in the defense of any such matter.</font>&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Parent and the Surviving Corporation shall have the right (but not the obligation) to
            assume the defense of any claim, action, suit, or proceeding for which indemnification is sought under this <u>Section 6.4(a)</u>, with counsel reasonably satisfactory to the Indemnified Person, except to the extent otherwise provided in an
            indemnification agreement between such Indemnified Person and any of the Acquired Corporations in effect on the date of this Agreement and set forth on the Company Disclosure Schedule. If Parent assumes such defense, the Indemnified Person
            shall not be entitled to retain separate counsel at the expense of Parent or the Surviving Corporation, unless (a) Parent agrees in writing to pay such fees, (b) the Indemnified Person has been advised by counsel that there is an actual
            conflict of interest between the Indemnified Person and Parent in the conduct of the defense, or (c) Parent fails to diligently pursue the defense after assuming it.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">55</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">For a period of six (6) years from and after the Effective Time, Parent and the Surviving Corporation shall either cause to be maintained in effect the current policies of directors&#8217; and officers&#8217; insurance maintained by or for the benefit
            of the Acquired Corporations or provide substitute policies for the Acquired Corporations and their current and former directors and officers who are currently covered by the directors&#8217; and officers&#8217; insurance coverage currently maintained by
            or for the benefit of the Acquired Corporations, in either case, of not less than the existing coverage and having other terms not less favorable to the insured Persons than the directors&#8217; and officers&#8217; insurance coverage currently maintained
            by or for the benefit of the Acquired Corporations with respect to claims arising from facts or events that occurred at or before the Effective Time (with insurance carriers having at least an <a name="ignore54"></a>&#8220;A&#8221; rating by A.M. Best
            with respect to directors&#8217; and officers&#8217; insurance), except that in no event shall Parent or the Surviving Corporation be required to pay with respect to such insurance policies more than 300% of the aggregate annual premium most recently paid
            by the Acquired Corporations prior to the date of this Agreement (the &#8220;<font style="font-family: 'Times New Roman';"><u>Maximum Amount&#8221;</u></font>), and if the Surviving Corporation is unable to obtain the insurance required by this <font style="font-family: 'Times New Roman';"><u>Section 6.4(b)</u></font> it shall obtain as much comparable insurance as possible for the years within such six (6)-year period for a premium equal to the Maximum Amount. In lieu of such insurance,
            prior to the Effective Time the Company may, at its option, purchase a <a name="ignore55"></a>&#8220;tail&#8221; directors&#8217; and officers&#8217; insurance policy for the Acquired Corporations and their current and former directors and officers who are currently
            covered by the directors&#8217; and officers&#8217; insurance coverage currently maintained by or for the benefit of the Acquired Corporations, such tail to provide coverage in an amount not less than the existing coverage and to have other terms not less
            favorable to the insured Persons than the directors&#8217; and officers&#8217; insurance coverage currently maintained by or for the benefit of the Acquired Corporations with respect to claims arising from facts or events that occurred at or before the
            Effective Time; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that in no event shall the cost of any such tail policy exceed the Maximum Amount. Parent and the Surviving Corporation shall maintain such
            policies in full force and effect, and continue to honor the obligations thereunder.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">56</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref404067196"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In





          the event that any Acquired Corporation or any of its successors or assigns (i) consolidates with or merges into any other Person and is not the continuing or surviving corporation or Entity of such consolidation or merger or (ii) transfers or
          conveys all or substantially all of its properties and assets to any Person, then, and in each such case, the Acquired Corporation, as applicable, shall cause proper provision to be made so that the successors and assigns of such Acquired
          Corporation assume the obligations set forth in this <font style="font-family: 'Times New Roman';"><u>Section 6.4</u></font>.<a name="z_Ref345410716"></a></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The provisions of this <font style="font-family: 'Times New Roman';"><u>Section 6.4</u></font> (i) shall survive the Offer Acceptance Time and the Effective Time, (ii) are intended to be for the benefit of, and will be enforceable by,
            each indemnified or insured party (including the Indemnified Persons), his or her heirs, successors, assigns and representatives, and (iii) are in addition to, and not in substitution for, any other rights to indemnification, advancement of
            expenses, exculpation or contribution that any such Person may have by contract or otherwise. Unless required by applicable Legal Requirement, this <font style="font-family: 'Times New Roman';"><u>Section 6.4</u></font> may not be amended,
            altered or repealed after the Offer Acceptance Time in such a manner as to adversely affect the rights of any Indemnified Person or any of their successors, assigns or heirs without the prior written consent of the affected Indemnified Person.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref473287305"></a><a name="z_Toc227238435"></a><a name="z_Toc227238554"></a><a name="z_Toc228288373"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Stockholder Litigation</font>. The Company shall notify Parent in writing within
        twenty-four (24) hours after becoming aware of any litigation commenced or threatened in writing against the Company and/or its directors or officers relating to the Transactions. The Company shall give Parent the (a) opportunity to participate in
        the defense of any such litigation, (b) right to review and comment on all material filings or responses to be made by the Company in connection with any litigation against the Company and/or its directors or officers relating to the Transactions
        (and shall give due consideration to Parent&#8217;s comments and other advice in respect to such litigation), and (c) the right to consult on any settlement with respect to such litigation, and the Company shall in good faith take such comments into
        account. No such settlement shall be agreed to without Parent&#8217;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed); <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that in no event shall Parent be required to consent to any such settlement that does not provide for the unconditional release of Parent, its Affiliates and
        Representatives and all Persons entitled to indemnification by Parent or the Company, in each case from any liability in connection with such litigation; <font style="font-family: 'Times New Roman'; font-style: italic;">provided further</font>,
        that the Company shall otherwise control the defense and the disclosure of information in connection therewith shall be subject to the provisions of <font style="font-family: 'Times New Roman';"><u>Section 5.1</u></font>, including regarding
        attorney-client privilege or other applicable legal privilege.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref473287274"></a><a name="z_Ref473295040"></a><a name="z_Toc227238436"></a><a name="z_Toc227238555"></a><a name="z_Toc228288374"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Additional Agreements</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Subject to the terms, limitations and conditions of this Agreement, including <font style="font-family: 'Times New Roman';"><u>Section 6.2(a)</u></font>, Parent and the Company shall use reasonable best efforts to take, or cause to be
            taken, all actions necessary to consummate the Offer and the Merger and make effective the other Transactions. Without limiting the generality of the foregoing, subject to the terms, limitations and conditions of this Agreement, each Party to
            this Agreement shall use reasonable best efforts to (a) make all filings (if any) and give all notices (if any) required to be made and given by such Party pursuant to any Material Contract in connection with the Offer and the Merger and the
            other Transactions, (b) seek each Consent (if any) required to be obtained pursuant to any Material Contract by such Party in connection with the Transactions to the extent requested in writing by Parent and (c) seek to lift any restraint,
            injunction or other legal bar to the Offer or the Merger brought by any third Person against such Party.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">57</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Prior to the Closing, the Acquired Corporations shall take the actions set forth on <font style="font-family: 'Times New Roman';"><u>Section 6.6(b)</u></font> of the Company Disclosure<font style="font-family: 'Times New Roman'; font-style: italic;">&#160;</font>Schedule.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238437"></a><a name="z_Toc227238556"></a><a name="z_Toc228288375"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Disclosure</font>. The initial press release relating to this Agreement shall be a joint press release issued by the
        Company and Parent and thereafter Parent and the Company shall consult with each other before issuing any further press release(s) or otherwise making any public statement (to the extent not previously issued or made in accordance with this
        Agreement) with respect to the Offer, the Merger, this Agreement or any of the other Transactions and shall not issue any such press release or public statement without the other Party&#8217;s written consent. Notwithstanding the foregoing: (a) each
        Party may, without such consultation or consent, make any public statement in response to questions from the press, analysts, investors or those attending industry conferences, make internal announcements to employees and make disclosures in
        Company SEC Documents, so long as such statements are consistent with previous press releases, public disclosures or public statements made jointly by the Parties (or individually, if approved by the other Party); (b) a Party may, without the prior
        consent of the other Party but subject to giving advance notice to the other Party and consulting with the other Party with respect to the content thereof, issue any such press release or make any such public announcement or statement as may be
        required by Legal Requirement; and (c) the Company need not consult with Parent in connection with such portion of any press release, public statement or filing to be issued or made pursuant to <font style="font-family: 'Times New Roman';"><u>Section





            5.3(e)</u></font> or with respect to any Acquisition Proposal or Company Adverse Change Recommendation.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref196941438"></a><a name="z_Toc227238438"></a><a name="z_Toc227238557"></a><a name="z_Toc228288376"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Takeover Laws</font>. If any Takeover Law may become, or may purport to be, applicable
        to the Transactions, each of Parent, Purchaser and the Company and the members of their respective boards of directors shall use their respective reasonable best efforts, subject in the case of Parent and Purchaser to the limitations set forth in <font style="font-family: 'Times New Roman';"><u>Section 6.2</u></font>, to grant such approvals and take such actions as are necessary so that the Transactions may be consummated as promptly as practicable on the terms and conditions contemplated
        hereby and otherwise act to lawfully eliminate the effect of any Takeover Law on any of the Transactions.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238439"></a><a name="z_Toc227238558"></a><a name="z_Toc228288377"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Section 16 Matters</font>. The Company, and the Board of Directors, shall, to the extent necessary, take appropriate
        action, prior to or as of the Offer Acceptance Time, to approve, for purposes of Section 16(b) of the Exchange Act, the disposition and cancellation or deemed disposition and cancellation of Shares and Company Equity Awards in the Merger by any
        officer or director of the Company who is subject to Section 16 of the Exchange Act intended to cause such dispositions and/or cancellations to be exempt under Rule 16b-3 promulgated under the Exchange Act.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">58</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.10</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;





          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Rule 14d-10 Matters</font></font>. Prior to the Offer Acceptance Time and to the extent permitted by applicable Legal Requirements, the compensation committee
        of the Board of Directors will approve, as an &#8220;<a name="ignore27"></a>employment compensation, severance or other employee benefit arrangement&#8221; within the meaning of Rule 14d-10(d)(2) under the Exchange Act, each agreement, arrangement or
        understanding between Purchaser, the Company or their respective Affiliates and any of the officers, directors or employees of the Acquired Corporations that are effective as of the date of this Agreement or are entered into after the date of this
        Agreement and prior to the Offer Acceptance Time pursuant to which compensation is paid to such officer, director or employee and will take all other action reasonably necessary to satisfy the requirements of the non-exclusive safe harbor set forth
        in Rule 14d-10(d)(2) under the Exchange Act.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref227007344"></a><a name="z_Ref227007408"></a><a name="z_Ref227007460"></a><a name="z_Toc227238441"></a><a name="z_Toc227238560"></a><a name="z_Toc228288379"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Stock Exchange Delisting;
          Deregistration</font>. Prior to the Closing Date, the Company shall cooperate with Parent and use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or
        advisable on its part under applicable laws and rules and policies of Nasdaq to enable the delisting by the Surviving Corporation of the Shares from Nasdaq and the deregistration of the Shares under the Exchange Act as promptly as practicable after
        the Effective Time.<font style="font-family: 'Times New Roman';">&#160;</font>If the Surviving Corporation is reasonably likely to be required to file any reports in accordance with the Exchange Act during the period between the Closing and the date a
        Form 15 is filed (the &#8220;<font style="font-family: 'Times New Roman';"><u>Delisting Period</u></font>&#8221;), the Company will deliver to Parent at least five (5) business days prior to the Closing a substantially final draft of any such reports
        reasonably likely to be required to be filed during the Delisting Period (&#8220;<font style="font-family: 'Times New Roman';"><u>Post-Closing SEC Reports</u></font>&#8221;). The Post-Closing SEC Reports provided by the Company in accordance with this <font style="font-family: 'Times New Roman';"><u>Section 6.11</u></font> will (i) not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made
        therein, in the light of the circumstances under which they were made, not misleading and (ii) comply in all material respects with the applicable Legal Requirements.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.12</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;
          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Notices to Holders of Company Warrants</font></font>. During the Pre-Closing Period, the Company shall deliver any notices required in connection with the
        Transactions under the terms of any outstanding Company Warrants to the holders thereof, and the Company shall provide Parent with a reasonable opportunity to review and comment on such notices and will give reasonable and good faith consideration
        to any comments provided by Parent to such notices.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288381"></a><a name="z_Toc227238443"></a><a name="z_Toc227238562"></a><a name="z_Ref227617905"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Treatment of Convertible Senior Notes</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Prior to the Effective Time, the Company shall use reasonable best efforts to take all actions as may be required in accordance with, and subject to the terms of, the applicable provisions of the Convertible Senior Notes Indenture,
            including the giving of the notices required by the Convertible Senior Notes Indenture in connection with the Transactions.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref227617732"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The





          Company shall use its reasonable best efforts to (i) execute and deliver any supplemental indentures required in connection with the Transactions and the consummation thereof to be executed and delivered to the Trustee (as defined in the
          Convertible Senior Notes Indenture) at or prior to the Effective Time under the Convertible Senior Notes Indenture and (ii) cause to be executed and delivered to the Trustee an officer&#8217;s certificate and an opinion of counsel (as such terms are
          defined in the Convertible Senior Notes Indenture) and any other related documentation required by the Convertible Senior Notes Indenture in connection with such supplemental indenture; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that opinions of counsel required by the Convertible Senior Notes Indenture, as may be necessary to comply with all of the terms and conditions of the Convertible Senior Notes Indenture in connection with the
          Transactions shall be delivered by Parent and its counsel to the extent required to be delivered on or after the Effective Time.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">59</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As promptly as practicable following the date hereof and otherwise as reasonably requested by Parent, the Company shall provide Parent with the position listing of the Convertible Senior Notes, including the number of record holders.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Parent shall be given a reasonable opportunity to review any notice, announcement, certificate or legal opinion before such document is provided to the Trustee under the Convertible Senior Notes Indenture prior to the Effective Time, and
            the Company shall in good faith consider any comments made by Parent.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Company shall not make any settlement election under or make any change to the terms of the Convertible Senior Notes Indenture or take any action that would result in a change to the <a name="z_9kMHG5YVt3CD6BFOHz7zwB306kS16"></a><a name="z_9kMHG5YVt3BC6BGPHz7zwB306kS16"></a>Conversion Rate (as defined in the Convertible Senior Notes Indenture), in each case, without the prior written consent of Parent.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Notwithstanding anything to the contrary in the foregoing, none of the Acquired Corporations shall be required to agree to any term or take any action in connection with its obligations under this <font style="font-family: 'Times New Roman';"><u>Section 6.13</u></font> that is not conditioned upon consummation of the Transactions.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288382"></a><a name="z_Ref226649987"></a><a name="z_Toc227238444"></a><a name="z_Toc227238563"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">6.14</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Financing Assistance</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref227236274"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Subject





          to applicable Legal Requirements, during the Pre-Closing Period, the Company shall, and shall cause each Acquired Corporation to, and shall use reasonable best efforts to cause its and their respective Representatives to, use its and their
          reasonable best efforts to provide such cooperation as may be reasonably requested by Parent in connection with arranging, obtaining or syndicating third-party debt financing (if any) by Parent or any of its wholly owned Subsidiaries, the
          proceeds of which are intended to be used to consummate the Transactions (the &#8220;<font style="font-family: 'Times New Roman';"><u>Debt Financing</u></font>&#8221;); <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that
          neither the Company nor any Acquired Corporation nor any of their respective Representatives shall be required to: (A) prepare or provide any financial statements or other financial information other than financial statements or other financial
          information that are filed or required to be filed with the SEC (before giving effect to any grace periods, exemptive Orders or other similar relief that would change the applicable due date) or to the extent such financial information is readily
          available to the Company; (B) provide any guarantees or grant any security interests on any of their equity interests or assets or otherwise become subject to any Encumbrance prior to the Effective Time; (C) take any action that would reasonably
          be expected to (i) give rise to a breach of any provision of their organizational documents or any representation, warranty, or covenant in this Agreement or the failure of any condition to Closing set forth in <font style="font-family: 'Times New Roman';"><u>Annex I</u></font> to be satisfied or (ii) conflict with, violate or result in a breach of or give rise to any right of termination or cancellation under any Material Contract; (D) incur any expense or liability that is not
          promptly reimbursed by Parent upon written request by the Company; or (E) adopt resolutions or consents, or deliver any opinion of legal counsel, relating to the Debt Financing prior to the Effective Time.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">60</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">All confidential information provided by the Company, any Acquired Corporation, or their respective Representatives pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 6.14</u></font> shall be kept confidential in
            accordance with the Confidentiality Agreement, except that Parent shall be permitted to disclose such information as applicable to any number of Financing Parties as would be reasonable and customary in connection with the Debt Financing; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, that such Financing Parties shall have agreed in writing that all confidential information shared with Financing Parties shall be kept confidential and otherwise
            treated in accordance with the Confidentiality Agreement. Parent shall indemnify and hold harmless the Company, the Acquired Corporations, and their respective Representatives from and against any and all losses, claims, damages, liabilities,
            and reasonable and documented out-of-pocket costs and expenses (including reasonable and documented attorneys&#8217; fees, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or
            payable in connection with or in respect of any thereof)) suffered or incurred in connection with any action taken by the Company, the Acquired Corporations, or their respective Representatives pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 6.14</u>&#160;</font>(other than the use of any information provided by Company, any of Acquired Corporations or any of its or their respective Representatives in writing for use in connection with the Debt Financing)
            whether or not the Transactions are consummated or this Agreement is terminated, except in the event such losses, claims, damages, liabilities, reasonable out-of-pocket costs, reasonable out-of-pocket attorneys&#8217; fees, judgments, fines,
            penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of any thereof) arise out of or result from the willful misconduct of the Company or the Acquired
            Corporations in fulfilling their obligations pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 6.14</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref_ContractCompanion_9kb9Ur145"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Notwithstanding anything to the contrary in this Agreement, the condition set forth in <font style="font-family: 'Times New Roman';"><u>Annex I</u></font>, <font style="font-family: 'Times New Roman';"><u>clause (c)</u></font>,
          as it applies to the obligations of the Company under this <font style="font-family: 'Times New Roman';"><u>Section 6.14</u></font>, will be deemed to be satisfied unless the Debt Financing is not obtained and the Company&#8217;s willful and material
          breach of its obligations under this <font style="font-family: 'Times New Roman';"><u>Section 6.14</u></font> was the primary cause of the failure of the Debt Financing to be obtained.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Toc227055534"></a><a name="z_Toc227238445"></a><a name="z_Toc227238564"></a><a name="z_Toc228288383"></a>SECTION 7</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref460608478"></a><font style="font-family: 'Times New Roman';"><u>CONDITIONS PRECEDENT TO THE MERGER</u></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The obligations of the Parties to effect the Merger are subject to the satisfaction or, to the extent permitted by applicable Legal Requirement, waiver
        as of the Closing of each of the following conditions:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608398"></a><a name="z_Ref460608399"></a><a name="z_Toc227238446"></a><a name="z_Toc227238565"></a><a name="z_Toc228288384"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">7.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">No Restraints</font>. There shall not have been issued by
        any Governmental Body of competent jurisdiction in a jurisdiction where either Parent and its Affiliates or the Acquired Corporations operate their respective businesses or own any material assets (a &#8220;<font style="font-family: 'Times New Roman';"><u>Specified





            Governmental Body</u></font>&#8221;) and remain in effect any temporary restraining order, preliminary or permanent injunction or other Order preventing the consummation of the Merger, nor shall any Legal Requirement have been promulgated, enacted,
        issued or deemed applicable to the Merger by any Specified Governmental Body which prohibits or makes illegal the consummation of the Merger.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">61</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238447"></a><a name="z_Toc227238566"></a><a name="z_Toc228288385"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">7.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Consummation of Offer</font>. Purchaser (or Parent on Purchaser&#8217;s behalf) shall have accepted for payment all of the
        Shares validly tendered pursuant to the Offer and not validly withdrawn.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Toc227238448"></a><a name="z_Toc227238567"></a><a name="z_Toc228288386"></a>SECTION 8</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref460608477"></a><font style="font-family: 'Times New Roman';"><u>TERMINATION</u></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608394"></a><a name="z_Ref460608395"></a><a name="z_Ref460608396"></a><a name="z_Ref460608397"></a><a name="z_Toc227238449"></a><a name="z_Toc227238568"></a><a name="z_Toc228288387"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">8.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Termination</font>.
        This Agreement may be terminated prior to the Effective Time:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">by mutual written consent of Parent and the Company at any time prior to the Offer Acceptance Time;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608337"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">by





          either Parent or the Company, at any time prior to the Offer Acceptance Time, if the Closing shall not have occurred on or prior to midnight Eastern Time, on October 29, 2026 (such date and time, the &#8220;<font style="font-family: 'Times New Roman';"><u>End





              Date</u></font>&#8221;); <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that <a name="z_cp_text_1_1314"></a>in the case of this
          <font style="font-family: 'Times New Roman';"><u>Section 8.1(b)</u></font>, (x) if on the End Date all <a name="z_cp_text_4_1315"></a>of the conditions set forth in <font style="font-family: 'Times New Roman';"><u>Annex I</u></font>, other than
          <font style="font-family: 'Times New Roman';"><u>clause (e)</u></font> or <font style="font-family: 'Times New Roman';"><u>(g)</u></font> (solely in respect of the HSR Act, other Antitrust laws and Foreign Investment Laws) set forth in <font style="font-family: 'Times New Roman';"><u>Annex I</u></font> shall have been satisfied or waived by Parent or Purchaser, to the extent waivable by Parent or Purchaser (other than conditions that by their nature are to be satisfied at the Offer
          Acceptance Time, each of which is then capable of being satisfied), then the End Date shall automatically be extended by a period of 90 days (and all references to the End Date herein and in <font style="font-family: 'Times New Roman';"><u>Annex
              I</u></font> shall be as so extended); and (y) the right to terminate this Agreement pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 8.1(b)</u></font> shall not be available to any Party whose material breach of
          this Agreement has caused or resulted in the Offer not being consummated by such date;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608336"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">by





          either Parent or the Company if a Specified Governmental Body of competent jurisdiction shall have issued an Order or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the
          acceptance for payment of Shares pursuant to the Offer or the Merger or making the consummation of the Offer or the Merger illegal, which Order or other action shall be final and nonappealable; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that the right to terminate this Agreement pursuant to this <font style="font-family: 'Times New Roman';"><u>Section
              8.1(c)</u></font> shall not be available to any Party whose material breach of this Agreement has caused or resulted in the issuance of such final and nonappealable Order or other action or to any Party that has failed to use its reasonable
          best efforts as required by <font style="font-family: 'Times New Roman';"><u>Sections 6.2</u></font> and <font style="font-family: 'Times New Roman';"><u>6.6</u></font> to remove such Order or other action;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608335"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">by





          Parent at any time prior to the Offer Acceptance Time, if: (i) the Board of Directors shall have failed to include the Company Board Recommendation in the Schedule 14D-9 when mailed, or shall have effected a Company Adverse Change Recommendation;
          or (ii) in the case of a tender offer or exchange offer subject to Regulation 14D under the Exchange Act, other than the Offer, the Board of Directors fails to recommend, in a <a name="z_9kR3WTr26649GfVvqij1uv406"></a>Solicitation/<a name="z_9kMHG5YVt48867DfMep0zsuuiz84Apq56B568O"></a>Recommendation Statement on Schedule 14D-9, rejection of such tender offer or exchange offer within ten (10) business days of the commencement of such tender offer or exchange offer;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">62</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">by the Company, at any time prior to the Offer Acceptance Time, in order to accept a Superior Offer and substantially concurrently enter into a binding written definitive
              acquisition agreement providing for the consummation of a transaction which the Board of Directors shall have determined, in good faith, constitutes a Superior Offer (a &#8220;<u>Specified Agreement</u>&#8221;);</font><font style="font-family: 'Times New Roman'; font-style: italic;">&#160;</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">provided</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, </font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">however</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">,</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">&#160;</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">that (i) the Company shall not have violated <u>Section 5.3</u>, (ii) the Company and the Board of Directors shall have complied with <u>Section 6.1(b)</u> and (iii) the Company
              shall have paid, or caused to be paid, the Termination Fee immediately before or simultaneously with and as a condition to such termination;</font></font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608332"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">by





          Parent at any time prior to the Offer Acceptance Time, if a breach of any representation or warranty contained in this Agreement or failure to perform any covenant or obligation in this Agreement on the part of the Company shall have occurred
          such that <a name="ignore28"></a>a condition set forth in <font style="font-family: 'Times New Roman';"><u>clause (b)</u></font> or <font style="font-family: 'Times New Roman';"><u>(c)</u></font> of <font style="font-family: 'Times New Roman';"><u>Annex I</u></font> would not be satisfied and cannot be cured by the Company by the End Date, or if capable of being cured in such time period, shall not have been cured within thirty (30) days of the date Parent gives the Company
          written notice of such breach or failure to perform; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that Parent shall not have
          the right to terminate this Agreement pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 8.1(f)</u></font> if either Parent or Purchaser is then in material breach of any representation, warranty, covenant or obligation
          hereunder which breach would permit the Company to terminate this Agreement pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8.1(g)</u></font>;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608331"></a><a name="z_Ref16782444"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">by the Company at any time prior to the Offer Acceptance Time, if a breach of any representation or warranty contained in this Agreement or failure to perform any covenant or obligation in this Agreement on the part
          of Parent or Purchaser shall have occurred, in each case, if such breach or failure would reasonably be expected to prevent Parent or Purchaser from consummating the Transactions and such breach or failure cannot be cured by Parent or Purchaser,
          as applicable, by the End Date, or, if capable of being cured in such time period, shall not have been cured within thirty (30) days of the date the Company gives Parent written notice of such breach or failure to perform; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that the Company shall not have the right to terminate this Agreement pursuant to
          this <font style="font-family: 'Times New Roman';"><u>Section 8.1(g)</u></font> if the Company is then in material breach of any representation, warranty, covenant or obligation hereunder which breach would give rise to a failure of a condition
          set forth in <font style="font-family: 'Times New Roman';"><u>clause (b)</u></font> or <font style="font-family: 'Times New Roman';"><u>(c)</u></font> of <font style="font-family: 'Times New Roman';"><u>Annex I</u></font> (if such condition
          were tested as of the date of such breach instead of as of the Offer Acceptance Time); or</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">by the Company (i) if following the expiration of the Offer, Purchaser shall have failed to accept for payment all Shares validly tendered (and not validly withdrawn) pursuant to the Offer in accordance with <font style="font-family: 'Times New Roman';"><u>Section 1.1(h)</u></font> or (ii) if following the Offer Acceptance Time, Purchaser shall have failed to purchase all Shares validly tendered (and not validly withdrawn) pursuant to the Offer in accordance with <font style="font-family: 'Times New Roman';"><u>Section 1.1(h)</u></font>.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">63</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">8.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;





          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Effect of Termination</font></font>. In the event of the termination of this Agreement as provided in <font style="font-family: 'Times New Roman';"><u>Section
            8.1</u></font>, written notice thereof shall be given to the other Party or Parties, specifying the provision hereof pursuant to which such termination is made, and this Agreement shall be of no further force or effect and there shall be no
        liability on the part of Parent, Purchaser or the Company or any of their respective former, current or future officers, directors, partners, stockholders, managers, members or Affiliates following any such termination; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that (a) the final two sentences of <font style="font-family: 'Times New Roman';"><u>Section 1.1(d)</u></font>,
        the final sentence of <font style="font-family: 'Times New Roman';"><u>Section 1.2(b)</u></font>, the final sentence of <font style="font-family: 'Times New Roman';"><u>Section 5.1(a)</u></font>, this <font style="font-family: 'Times New Roman';"><u>Section 8.2</u></font>, <font style="font-family: 'Times New Roman';"><u>Section 8.3</u></font>, <font style="font-family: 'Times New Roman';"><u>Section 9</u></font> (other than <font style="font-family: 'Times New Roman';"><u>Section





            9.5(b)</u></font>) and, solely to the extent applicable to the foregoing provisions, any definitions in <font style="font-family: 'Times New Roman';"><u>Exhibit A</u></font> or elsewhere in this Agreement shall survive the termination of this
        Agreement and shall remain in full force and effect, (b) the Confidentiality Agreement shall survive the termination of this Agreement and shall remain in full force and effect in accordance with its terms and (c) except as otherwise provided in <font style="font-family: 'Times New Roman';"><u>Section 8.3</u></font>, no such termination shall <a name="z_Hlk192325972"></a>relieve any Party of any liability or damages (which, in the case of liabilities or damages payable by Parent and Purchaser
        may include, to the fullest extent permitted by Section 261(a)(1) of the DGCL, amounts representing, or based on the loss of, any premium or other economic entitlement the Company&#8217;s stockholders would be entitled to receive under this Agreement if
        the Closing were to occur in accordance with the terms of this Agreement, which shall be deemed in such event to be damages of the Company), resulting from any Fraud or willful and material breach of this Agreement prior to such termination.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref228234196"></a><a name="z_Ref228234221"></a><a name="z_Toc228288389"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">8.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Expenses; Termination Fees</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Except as set forth in this <font style="font-family: 'Times New Roman';"><u>Section 8.3</u></font>, all fees and expenses incurred in connection with this Agreement and the Transactions shall be paid by the Party incurring such expenses,
            whether or not the Offer and Merger are consummated.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608330"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In





          the event that:</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref460608321"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">this Agreement is terminated by the Company pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8.1(e)</u></font>;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref460608320"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">this Agreement is terminated by Parent pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8.1(d)</u></font>; or</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 108pt; font-size: 10pt;"><a name="z_Ref460608319"></a><a name="z_Ref196941418"></a><a name="z_Ref473292022"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">each of the following <font style="font-family: 'Times New Roman';"><u>clauses (A)</u></font>, <font style="font-family: 'Times New Roman';"><u>(B)</u></font> and <font style="font-family: 'Times New Roman';"><u>(C)</u></font> are satisfied: (A) this Agreement is terminated by Parent or the Company pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8.1(b)</u></font> (but in the case of a
          termination by the Company, only if at such time Parent would not be prohibited from terminating this Agreement pursuant to proviso <font style="font-family: 'Times New Roman';"><u>(y)</u></font> to <font style="font-family: 'Times New Roman';"><u>Section





              8.1(b)</u></font>) or by Parent pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8.1(f)</u></font>, (B) any Person shall have publicly disclosed a <font style="font-family: 'Times New Roman'; font-style: italic;">bona
            fide</font> Acquisition Proposal, or such Acquisition Proposal has otherwise been communicated to the Board of Directors or the Company&#8217;s stockholders, after the date hereof and prior to such termination and such Acquisition Proposal has not
          been publicly withdrawn prior to such termination and (C) within twelve (12) months of such termination, the Company shall have entered into a definitive agreement with respect to, or consummated, an Acquisition Proposal with such Person; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that for purposes of <font style="font-family: 'Times New Roman';"><u>clauses (B)</u></font> and <font style="font-family: 'Times New Roman';"><u>(C)</u></font> the
          references to &#8220;20%&#8221; in the definition of &#8220;Acquisition Proposal&#8221; shall be deemed to be references to &#8220;50%&#8221;;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">64</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">then, in any such event under <font style="font-family: 'Times New Roman';"><u>clause (i)</u></font>, <font style="font-family: 'Times New Roman';"><u>(ii)</u></font> or <font style="font-family: 'Times New Roman';"><u>(iii)</u></font> of this <font style="font-family: 'Times New Roman';"><u>Section 8.3(b)</u></font>, the Company shall pay to Parent or its designee the
        Termination Fee by wire transfer of same day funds (x) in the case of <font style="font-family: 'Times New Roman';"><u>Section 8.3(b)(i)</u></font>, on the date that the Specified Agreement is executed (or if the Specified Agreement is executed on
        a day that is not a business day, the next business day), (y) in the case of <font style="font-family: 'Times New Roman';"><u>Section 8.3(b)(ii)</u></font>, within three (3) business days after such termination or (z) in the case of <font style="font-family: 'Times New Roman';"><u>Section 8.3(b)(iii)</u></font>, on the date that the Acquisition Proposal referred to in <font style="font-family: 'Times New Roman';"><u>clause (C)</u></font> of <font style="font-family: 'Times New Roman';"><u>Section 8.3(b)(iii)</u></font> is consummated (or if the consummation occurs on a day that is not a business day, the next business day); it being understood that in no event shall the Company be required to pay the Termination Fee on
        more than one occasion. As used herein, &#8220;<font style="font-family: 'Times New Roman';"><u>Termination Fee</u></font>&#8221; shall mean a cash amount equal to $66,400,000. Payment of the Termination Fee pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 8.3(b)</u></font> shall be deemed to be liquidated damages for any and all losses or damages suffered or incurred by Parent, Purchaser, any of their respective Affiliates or any other Person in connection with this
        Agreement (and the termination hereof), the Transactions (and the abandonment thereof) or any matter forming the basis for such termination, and none of Parent, Purchaser or any of their respective Affiliates shall be entitled to bring or maintain
        any claim, action or proceeding against the Company or any of its Affiliates arising out of or in connection with this Agreement, any of the Transactions or any matters forming the basis for such termination.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473292760"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In





          the event of any termination described in <font style="font-family: 'Times New Roman';"><u>Section 8.3(b)</u></font>, (i) payment from the Company to Parent of the Termination Fee pursuant to <font style="font-family: 'Times New Roman';"><u>Section





              8.3(b)</u></font> shall be the sole and exclusive remedy of Parent, Purchaser or any of their respective Affiliates against the Acquired Corporations and any of their respective former, current or future officers, directors, partners,
          stockholders, managers, members or Affiliates (collectively, &#8220;<font style="font-family: 'Times New Roman';"><u>Company Related Parties</u></font>&#8221;) for any loss suffered as a result of the failure of the Offer or the Merger to be consummated or
          for a breach or failure to perform hereunder or otherwise, and (ii) upon payment of such amount(s), none of the Company Related Parties shall have any further liability or obligation relating to or arising out of this Agreement or the
          Transactions; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, that neither Parent, Purchaser nor the Company shall be released from any liabilities or damages arising out of any Fraud by such Party or a willful
          and material breach of this Agreement by such Party.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473292199"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The





          Parties acknowledge that the agreements contained in this <font style="font-family: 'Times New Roman';"><u>Section 8.3</u></font> are an integral part of the Transactions and that, without these agreements, the Parties would not enter into this
          Agreement; accordingly, if the Company fails to timely pay any amount due pursuant to <font style="font-family: 'Times New Roman';"><u>Section 8.3(b)</u></font>, and, in order to obtain the payment, Parent commences a Legal Proceeding which
          results in a judgment against the Company, the Company shall pay Parent its reasonable and documented costs and expenses (including reasonable and documented attorneys&#8217; fees) in connection with such suit, together with interest on such amount at
          the prime rate as published in the Wall Street Journal in effect on the date such payment was required to be made through the date such payment was actually received.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Toc227238452"></a><a name="z_Toc227238571"></a><a name="z_Toc228288390"></a>SECTION 9</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Ref460608476"></a><font style="font-family: 'Times New Roman';"><u>MISCELLANEOUS PROVISIONS</u></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238453"></a><a name="z_Toc227238572"></a><a name="z_Toc228288391"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Amendment</font>. Prior to the Effective Time, this Agreement may be amended with the approval of the respective
        boards of directors of the Company, Parent and Purchaser at any time. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Parties.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">65</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;





          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Waiver</font></font>. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of
        any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude
        any other or further exercise thereof or of any other power, right, privilege or remedy. No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the
        waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver or failure to insist on strict compliance with an obligation, covenant,
        agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. At any time prior to the Effective Time, Parent and Purchaser, on the one hand, and the Company, on the other hand, may, to the
        extent permissible under applicable Legal Requirements, (a) extend the time for the performance of any of the obligations or other acts of the other, (b) waive any breach of the representations and warranties of the other contained herein or in any
        document delivered pursuant hereto or (c) waive compliance by the other with any of the agreements or covenants contained herein. Any such extension or waiver shall be valid only if is expressly set forth in a written instrument duly executed and
        delivered on behalf of the Party or Parties to be bound thereby, but such extension or waiver or failure to insist on strict compliance with an obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect
        to, any subsequent or other failure.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238455"></a><a name="z_Toc227238574"></a><a name="z_Toc228288393"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">No Survival of Representations and Warranties</font>. None of the representations and warranties contained in this
        Agreement, the Company Disclosure Schedule or in any certificate or schedule or other document delivered by any Person pursuant to this Agreement shall survive the Effective Time.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238456"></a><a name="z_Toc227238575"></a><a name="z_Toc228288394"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Entire Agreement; Counterparts</font>. This Agreement (including its Exhibits, Annexes and the Company Disclosure
        Schedule) and the Confidentiality Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties and their respective Affiliates, with respect to the
        subject matter hereof and thereof. This Agreement may be executed in one or more counterparts, including by <a name="z_9kR3WTr26649HRGmtAzou"></a>Docusign, facsimile or by email with .pdf attachments, all of which shall be considered one and the
        same agreement, and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Parties.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc228288395"></a><a name="z_Ref473292715"></a><a name="z_Toc227238457"></a><a name="z_Toc227238576"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608327"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">This





          Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof. In any action or proceeding arising
          out of or relating to this Agreement or any of the Transactions: (i) each of the Parties irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of: (A) the Chancery Court of the State of Delaware and any
          state appellate court therefrom, (B) if (but only if) the court in <font style="font-family: 'Times New Roman';"><u>clause (A)</u></font> lacks subject matter jurisdiction, the Superior Court of the State of Delaware sitting in New Castle County
          and any state appellate court therefrom or (C) if (but only if) the courts in <font style="font-family: 'Times New Roman';"><u>clause (A)</u></font> and <font style="font-family: 'Times New Roman';"><u>(B)</u></font> lack subject matter
          jurisdiction, the United States District Court in the State of Delaware and any appellate court therefrom (collectively, the courts described in <font style="font-family: 'Times New Roman';"><u>clauses (A)</u></font> through <font style="font-family: 'Times New Roman';"><u>(C)</u></font>, the &#8220;<font style="font-family: 'Times New Roman';"><u>Delaware Courts</u></font>&#8221;); and (ii) each of the Parties irrevocably consents to service of process by first class certified
          mail, return receipt requested, postage prepaid, to the address at which such Party is to receive notice in accordance with <font style="font-family: 'Times New Roman';"><u>Section 9.9</u></font>. Each of the <a name="El2bt6O"></a>Parties
          irrevocably and unconditionally (1) agrees not to commence any such action or proceeding except in the Delaware Courts, (2) agrees that any claim in respect of any such action or proceeding may be heard and determined in the Delaware Courts, (3)
          waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the jurisdiction or laying of venue of any such action or proceeding in the Delaware Courts and (4) waives, to the fullest
          extent permitted by <a name="El2tt6O"></a>law, the defense of an inconvenient forum to the maintenance of such action or proceeding in the Delaware Courts. The Parties agree that a final judgment in any such action or proceeding shall be
          conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable Legal Requirements; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>,<font style="font-family: 'Times New Roman'; font-style: italic;"> however</font>, that nothing in the foregoing shall restrict any Party&#8217;s rights to seek any post-judgment relief regarding, or any appeal from, such final trial court judgment.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">66</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref460608326"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The





          Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that the Parties do not perform their obligations under the provisions of this Agreement in accordance
          with its specified terms or otherwise breach such provisions. The Parties acknowledge and agree that (i) the Parties shall be entitled to an injunction or injunctions, specific performance, or other equitable relief, to prevent breaches of this
          Agreement and to enforce specifically the terms and provisions hereof in the courts described in <font style="font-family: 'Times New Roman';"><u>Section 9.5(a)</u></font> without proof of damages or otherwise, this being in addition to any
          other remedy to which they are entitled under this Agreement, and (ii) the right of specific performance is an integral part of the Transactions and without that right, neither the Company nor Parent would have entered into this Agreement. Each
          of the Parties agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that the other Parties have an adequate remedy at law or that an award of specific performance is not an
          appropriate remedy for any reason at law or equity. The Parties acknowledge and agree that any Party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement
          in accordance with this <font style="font-family: 'Times New Roman';"><u>Section 9.5(b)</u></font> shall not be required to provide any bond or other security in connection with any such Order or injunction.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref473292518"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">EACH





          OF THE PARTIES IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING BETWEEN THE PARTIES (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE), INCLUDING ANY COUNTERCLAIM, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
          TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT THEREOF. EACH PARTY (I) MAKES THIS WAIVER VOLUNTARILY AND (II) ACKNOWLEDGES THAT SUCH PARTY HAS BEEN INDUCED TO
          ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS CONTAINED IN THIS <font style="font-family: 'Times New Roman';"><u>SECTION 9.5</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608386"></a><a name="z_Toc227238458"></a><a name="z_Toc227238577"></a><a name="z_Toc228288396"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Assignability</font>. This Agreement shall be binding upon, and shall be enforceable by
        and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>,<font style="font-family: 'Times New Roman'; font-style: italic;"> however</font>, that neither this Agreement nor any of the rights hereunder may be assigned by a Party without the prior written consent of the other Parties, and any attempted assignment of this Agreement or any of such rights without
        such consent shall be void and of no effect.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">67</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238459"></a><a name="z_Toc227238578"></a><a name="z_Toc228288397"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">No Third Party Beneficiaries</font>. Nothing in this Agreement, express or implied, is intended to or shall confer
        upon any Person (other than the Parties) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement; except for: (a) if the Offer Acceptance Time occurs, (i) the right of the Company&#8217;s stockholders to receive the
        Offer Price or Merger Consideration, as applicable, pursuant to <font style="font-family: 'Times New Roman';"><u>Section 1</u></font> or <font style="font-family: 'Times New Roman';"><u>Section 2</u></font> following the Offer Acceptance Time or
        the Effective Time, as applicable, in accordance with the terms of this Agreement, and (ii) the right of the holders of Company Equity Awards to receive the Merger Consideration pursuant to <font style="font-family: 'Times New Roman';"><u>Section
            2.8</u></font> following the Effective Time in accordance with the terms of this Agreement; (b) the provisions set forth in <font style="font-family: 'Times New Roman';"><u>Section 6.4</u></font> of this Agreement; and (c) the limitations on
        liability of the Company Related Parties set forth in <font style="font-family: 'Times New Roman';"><u>Section 8.3(c)</u></font>. The Parties hereby agree that the Company shall have the right, on its own behalf and, in accordance with and to the
        fullest extent permitted by Section 261(a)(2)&#8239;of the DGCL, as representative on behalf of the Company&#8217;s stockholders and the holders of Company Equity Awards to pursue specific performance as set forth in <font style="font-family: 'Times New Roman';"><u>Section 9.5(b)</u></font> or damages to the fullest extent permitted by Section 261(a)(1) of the DGCL. For the avoidance of doubt, (i) only the Company (and not the Company&#8217;s stockholders or the holders of Company Equity Awards) may
        bring an action pursuing liability for such damages and (ii) the Company may retain, without distribution to the Company&#8217;s stockholders or the holders of Company Equity Awards, any damages received.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238460"></a><a name="z_Toc227238579"></a><a name="z_Toc228288398"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Transfer Taxes</font>. Except as otherwise provided in <font style="font-family: 'Times New Roman';"><u>Sections
            1.1(i)</u></font> and <font style="font-family: 'Times New Roman';"><u>2.6(b)</u></font>, all transfer, documentary, sales, use, stamp, registration and other similar Taxes and fees, including any penalties and interest, with respect to the
        Transactions shall be borne by the Company and expressly shall not be a liability of holders of Shares.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Ref460608385"></a><a name="z_Toc227238461"></a><a name="z_Toc227238580"></a><a name="z_Toc228288399"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Notices</font>. All notices and other communications required or permitted to be given
        to any Party hereunder shall be in writing and shall be deemed properly delivered on (a) the date and time of delivery if delivered personally, (b) the date and time of transmittal if delivered by email (<font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, except in the case of written request delivered pursuant to <font style="font-family: 'Times New Roman';"><u>clause (iii)</u></font> of <font style="font-family: 'Times New Roman';"><u>Section 1.1(c)</u></font>,
        no &#8220;bounce back&#8221; or similar message of non-delivery is received with respect thereto), (c) the first business day following the date of dispatch if delivered utilizing a next-day service by a recognized next-day courier or (d) upon confirmed
        receipt if delivered by registered or certified mail, return receipt requested, postage prepaid. All notices or other communications hereunder shall be delivered to the addresses or email addresses set forth below, or pursuant to such other
        instructions as the Party to receive such notice or communication shall have specified in a written notice given to the other Parties:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">if to Parent or Purchaser (or following the Effective Time, the Surviving Corporation):</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Chiesi Farmaceutici S.p.A.</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Via Palermo 26/A</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Parma, 43122</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Italy</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Attention: [***]<br>
      </div>
      <div style="text-align: left; margin-left: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Email:</font><font style="font-size: 10pt;"> &#160; </font>[***]</div>
      <div style="text-align: left; margin-left: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
          </font></font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">68</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">with a copy (which shall not constitute notice) to:</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Ropes &amp; Gray LLP</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">800 Boylston Street</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Boston, Massachusetts 02199</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Attention: Zachary Blume</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Email: &#160;&#160;</font><font style="font-size: 10pt;"> <font style="font-family: 'Times New Roman';">zachary.blume@ropesgray.com</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">if to the Company or KalVista UK (prior to the Effective Time):</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">KalVista Pharmaceuticals, Inc.</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">200 Crossing Blvd</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Framingham, MA 01702</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Attention: [***]</div>
      <div style="text-align: left; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Email:&#160;&#160; [***]</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">with copies (which shall not constitute notice) to:</div>
      <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><font style="font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Kirkland &amp; Ellis LLP</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">200 Clarendon Street</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Boston, Massachusetts 02116</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Attention: Graham Robinson; Chad&#233; Severin</div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">E-mail:</font><font style="font-size: 10pt;">&#160; <font style="font-family: 'Times New Roman';">graham.robinson@kirkland.com</font></font></div>
      <div style="text-align: left; text-indent: 36pt; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">chade.severin@kirkland.com</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Fenwick &amp; West LLP</div>
      <div style="text-align: justify; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">401 Union St</div>
      <div style="text-align: justify; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Seattle, WA 98101</div>
      <div style="text-align: justify; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">Attention: Effie Toshav; Ethan Skerry</div>
      <div style="text-align: justify; margin-left: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Email:</font><font style="font-size: 10pt;">&#160;&#160; <font style="font-family: 'Times New Roman';">etoshav@fenwick.com</font></font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">eskerry@fenwick.com</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><a name="z_Toc227238462"></a><a name="z_Toc227238581"></a><a name="z_Toc228288400"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.10</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Severability</font>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any
        jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a
        final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision,
        to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement
        shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term
        or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">69</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.11</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;
          <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Obligation of Parent</font></font>. Parent shall ensure that Purchaser (and, following the Effective Time, the Surviving Corporation) duly performs, satisfies
        and discharges on a timely basis each of the covenants, obligations and liabilities applicable to Purchaser or the Surviving Corporation, as applicable, under this Agreement, and Parent shall be jointly and severally liable with Purchaser or the
        Surviving Corporation, as applicable, for the due and timely performance and satisfaction of each of said covenants, obligations and liabilities.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 0pt; margin-left: 36pt;"><a name="z_Toc228288402"></a><a name="z_Toc227238464"></a><a name="z_Toc227238583"></a><font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">9.12</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0);">Construction</font>.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the
            masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">All references to days or months shall be deemed references to calendar days or months unless otherwise specified herein.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As used in this Agreement, the word &#8220;<a name="ignore37"></a>including&#8221; and words of similar import shall mean including without limiting the generality of any description preceding such term, unless otherwise specified.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">As used in this Agreement, the words &#8220;hereof&#8221;, &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to
              any particular provision of this Agreement. The words &#8220;date hereof&#8221; when used in this Agreement shall refer to the date of this Agreement. The terms &#8220;or&#8221;, &#8220;any&#8221; and &#8220;either&#8221; are not exclusive. The word &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221;
              shall mean the degree to which a subject or other thing extends, and such phrase shall not simply mean &#8220;if&#8221;.</font><font style="font-family: 'Times New Roman';">&#160;</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The
              word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;. With respect to any grant of rights to, in or under any intellectual property, the word &#8220;license&#8221; or &#8220;licenses&#8221; shall be deemed to include &#8220;sublicense&#8221; or
              &#8220;sublicenses&#8221;, as applicable.</font></font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Except as otherwise indicated, all references in this Agreement to &#8220;<a name="ignore39"></a>Sections&#8221;, &#8220;<a name="ignore40"></a>Exhibits&#8221; or &#8220;<a name="ignore41"></a>Annexes&#8221; are intended to refer to Sections of this Agreement and Exhibits or
            Annexes to this Agreement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this
            Agreement.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The term &#8220;dollars&#8221; and character &#8220;$&#8221; shall mean United States dollars.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Whenever this Agreement refers to a number of days, such number shall refer to calendar days unless business days are specified. Except in the case of <font style="font-family: 'Times New Roman';"><u>Section 9.12(l)</u></font>, if any
            action is to be taken or given on or by a particular calendar day, and such calendar day is not a business day, then such action may be deferred until the next business day.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">70</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(j)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">All accounting terms used and not defined herein shall have the respective meanings given to them under GAAP.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(k)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Any reference to (i) any Contract (including this Agreement) is to the Contract as amended, modified, supplemented, restated, or replaced from time to time (in the case of any Contract, to the extent permitted by the terms thereof and, if
            applicable, the terms of this Agreement); (ii) any Governmental Body includes any successor to that Governmental Body; and (iii) any applicable Legal Requirement refers to such applicable Legal Requirement as amended, modified, supplemented, or
            replaced from time to time (and, in the case of statutes, include any rule and regulation promulgated under such statute) and references to any section of any applicable Legal Requirement includes any successor to such section (<font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that, for purposes of any representation and warranty in this Agreement that is made as of a specific date, references to any Legal Requirement or Contract shall be
            deemed to refer to such Legal Requirement or Contract, as amended, and to any rule or regulation promulgated thereunder, in each case, as of such date).</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref196941436"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Documents





          or other information or materials will be deemed to have been &#8220;made available&#8221;, &#8220;furnished&#8221;, &#8220;provided&#8221;, or &#8220;delivered&#8221; by the Company if such documents, information or materials have been physically or electronically delivered to Parent at least
          one (1) calendar day prior to the execution and delivery of this Agreement, including by being posted to the virtual data room managed by the Company and hosted by Datasite, or filed with or furnished to the SEC and available on EDGAR prior to
          the execution and delivery of this Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(m)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">References herein to any statute includes all rules and regulations promulgated thereunder.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(n)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Any statute defined or referred to herein means such statute as from time to time amended, modified or supplemented, including by succession of comparable successor statutes.</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">[Signature page follows]</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">71</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">IN WITNESS WHEREOF</font><font style="font-size: 10pt;">, the Parties
          have caused this Agreement to be executed as of the date first above written.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z74579d7ec10540ee92c4c6e429749e79" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-variant: small-caps; font-weight: bold;">Chiesi Farmaceutici S.p.A.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Giacomo Chiesi </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Name: Giacomo Chiesi</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Title: Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-variant: small-caps; font-weight: bold;">Skyline Merger Sub, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">/s/ John Hess</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Name: John Hess</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Title: President and Secretary</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-variant: small-caps; font-weight: bold;">KalVista Pharmaceuticals, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Benjamin L. Palleiko</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Name: Benjamin L. Palleiko</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Title: Chief Executive Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-variant: small-caps; font-weight: bold;">KalVista Pharmaceuticals Limited</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Benjamin L. Palleiko </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Name: Benjamin L. Palleiko</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Title: Director</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">[Signature Page to Agreement and Plan of Merger]</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%A-%%-->
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXHIBIT A</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CERTAIN DEFINITIONS</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">For purposes of the Agreement (including this <font style="font-family: 'Times New Roman';"><u>Exhibit A</u></font> and <font style="font-family: 'Times New Roman';"><u>Annex I</u></font>):</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Acceptable Confidentiality Agreement</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Acceptable Confidentiality Agreement</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 5.3(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Acquired Corporations</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Acquired Corporations</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.1(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Acquisition Proposal</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Acquisition Proposal</u></font>&#8221; shall mean any proposal or offer from any Person (other than Parent and its Affiliates) or &#8220;<a name="ignore43"></a>group&#8221;, within the meaning of Section 13(d) of the
          Exchange Act, including any amendment or modification to any existing proposal or offer, relating to, in a single transaction or series of related transactions, any (a) acquisition or exclusive license of assets of the Acquired Corporations equal
          to 20% or more of the Acquired Corporations&#8217; consolidated assets or to which 20% or more of the Company&#8217;s revenues or earnings on a consolidated basis are attributable, (b) issuance or acquisition of 20% or more of the outstanding Company Common
          Stock, (c) recapitalization, tender offer or exchange offer that if consummated would result in any Person or group beneficially owning 20% or more of the outstanding Company Common Stock or (d) merger, consolidation, amalgamation, share
          exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving the Company that if consummated would result in any Person or group beneficially owning 20% or more of the outstanding Company Common
          Stock, in each case (a) through (d) other than the Transactions.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Affiliate</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Affiliate</u></font>&#8221; shall mean, as to any Person, any other Person that, directly or indirectly, controls, or is controlled by, or is under common control with, such Person. For this purpose, &#8220;<a name="ignore44"></a>control&#8221; (including, with its correlative meanings, &#8220;<a name="ignore45"></a>controlled by&#8221; and &#8220;<a name="ignore46"></a>under common control with&#8221;) shall mean the possession, directly or indirectly, of the power to direct or
          cause the direction of management or policies of a Person, whether through the ownership of securities or partnership or other ownership interests, by Contract or otherwise.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Agreement</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Agreement</u></font>&#8221; is defined in the preamble to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Anti-Corruption Laws</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Anti-Corruption Laws</u></font>&#8221; shall mean the Foreign Corrupt Practices Act of 1977, the UK Bribery Act of 2010, and any applicable Legal Requirements of similar effect, and the related regulations
          and published interpretations thereunder.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Antitrust and Foreign Investment Approvals</font><font style="font-size: 10pt;">.<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>&#8220;<font style="font-family: 'Times New Roman';"><u>Antitrust and Foreign Investment Approvals</u></font>&#8221;<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>shall mean clearance, approval (including deemed clearance and approval, including as a result of waiting periods having lapsed, expired, or been terminated) or confirmation of non-notifiability (or
          equivalent confirmation that no filing or approval is required) by the <a name="z_9kR3WTr26649JRK3nfv2ltD1u2suE"></a>Bundeskartellamt under applicable Antitrust Laws in Germany and the<a name="z_9kR3WTr2664ACXVrtykhsE2"></a> Presidenza del <a name="z_9kR3WTr2664ADLFx2ynruy"></a>Consiglio dei <a name="z_9kR3WTr2664AEWJrsyAA0"></a>Ministri under applicable Foreign Investment Laws in Italy.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-1</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Antitrust Laws</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Antitrust Laws</u></font>&#8221; shall mean the Sherman Act, the Clayton Act, the HSR Act, the Federal Trade Commission Act, all applicable foreign antitrust laws and all other applicable Legal Requirements
          issued by a Governmental Body that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening of competition<a name="z_Hlk224563077"></a>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Artificial Intelligence Tools</font><font style="font-size: 10pt;">.<font style="font-family: 'Times New Roman'; font-weight: bold;"> &#8220;</font><font style="font-family: 'Times New Roman';"><u>Artificial Intelligence Tools</u></font><font style="font-family: 'Times New Roman'; font-weight: bold;">&#8221; </font>shall mean a
          software system that employs trained machine learning models, large language models, or similar generative architectures to produce novel outputs based on prompts or other inputs.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Board of Directors</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Board of Directors</u></font>&#8221; is defined in the <a name="z_9kR3WTr2664AFTK273qxxx406"></a>Introduction to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Book-Entry Shares</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Book-Entry Shares</u></font>&#8221; shall mean non-certificated Shares represented by book-entry.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">business day</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>business day</u></font>&#8221; shall mean a day except a Saturday, a Sunday or other day on which banks in the City of New York, NY are authorized or required by Legal Requirements to be closed.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Capitalization Date</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Capitalization Date</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.3(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Certificated Shares</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Certificated Shares</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 2.6(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Certificates</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Certificates</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 2.6(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Change of Control Payment</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Change of Control Payment</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.9(a)(vii)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Closing</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Closing</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 2.3(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Closing Date</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Closing Date</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 2.3(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">CMS</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>CMS</u></font>&#8221; shall mean the <a name="z_9kR3WTr2664AGO5n3vu9yv8hPnssl16cXv00t04"></a>Centers for Medicare &amp; Medicaid Services or any successor agency thereto.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Code</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Code</u></font>&#8221; shall mean the Internal Revenue Code of 1986.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company</u></font>&#8221; is defined in the preamble to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Adverse Change Recommendation</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Adverse Change Recommendation</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 6.1(a)(i)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Board Recommendation</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Board Recommendation</u></font>&#8221; is defined in the <a name="z_9kMHG5YVt4886CHVM495szzz628"></a>Introduction to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Common Stock</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Common Stock</u></font>&#8221; shall mean the common stock, $0.001 par value per share, of the Company.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Disclosure Documents</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Disclosure Documents</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.4(g)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Disclosure Schedule</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Disclosure Schedule</u></font>&#8221; shall mean the disclosure schedule that has been prepared by the Company in accordance with the requirements of the Agreement and that has been delivered by the
          Company to Parent on the date of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_Ref174894167"></a><font style="font-family: 'Times New Roman'; font-weight: bold;">Company Equity Award</font><font style="font-family: 'Times New Roman';">. &#8220;<u>Company Equity Award</u></font>&#8221; shall mean each Company Option and Company RSU.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Equity Plans</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Equity Plans</u></font>&#8221; shall mean the Company 2015 <a name="z_9kR3WTr2664AHVKldp5141WYqt"></a>Incentive Plan, the Company 2017 <a name="z_9kR3WTr2664AISJ6zzGgQrjvB7A7cewz"></a>Equity
          Incentive Plan, and the Company 2021 <a name="z_9kR3WTr2664AJTJ6zzGgQs00lwxzFsfx0"></a>Equity Inducement Plan and any sub-plan to the foregoing, as each may be amended and restated from time to time.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company ESPP</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company ESPP</u></font>&#8221; shall mean the Company 2017 <a name="z_9kR3WTr2664AKUFxxxB2jYiBvsglK3ut5Aik25"></a>Employee Stock Purchase Plan.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company IP</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company IP</u></font>&#8221; shall mean all Intellectual Property Rights that are owned or purported to be owned by any of the Acquired Corporations.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company IT Assets</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company IT Assets</u></font>&#8221; shall mean computers, computer software, firmware, middleware, servers, workstations, routers, hubs, switches, data communications lines and all other information
          technology equipment, and all associated documentation owned by the Company or the Acquired Corporations, or licensed or leased to the Company or the Acquired Corporations pursuant to written agreements (excluding any public networks).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Options</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Options</u></font>&#8221; shall mean all options to purchase Shares granted under any Company Equity Plan. A purchase right under the Company ESPP is not considered to be a Company Option for
          purposes of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Preferred Stock</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Preferred Stock</u></font>&#8221; shall mean the preferred stock, $0.001 par value per share, of the Company.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Registered IP</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Registered IP</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.8(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Related Parties</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Related Parties</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 8.3(c)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Returns</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Returns</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.15(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company RSUs</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company RSUs</u></font>&#8221; shall mean all restricted stock units granted under any Company Equity Plan.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company SEC Documents</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company SEC Documents</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.4(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Company Warrants</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Company Warrants</u></font>&#8221; shall mean all warrants set forth in Schedule A of the Company Disclosure Schedule.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Confidentiality Agreement</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Confidentiality Agreement</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.2(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Consent</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Consent</u></font>&#8221; shall mean any approval, consent, ratification, permission, waiver or authorization.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Continuing Employee</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Continuing Employee</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 6.3(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Contract</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Contract</u></font>&#8221; shall mean any contract, agreement, deed, mortgage, lease, sublease, license, sublicense or other legally enforceable commitment, promise, undertaking, obligation, arrangement,
          instrument or understanding, whether written or oral, to which or by which such Person is a party or otherwise subject to be bound.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Convertible Senior Notes</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Convertible Senior Notes</u></font>&#8221; shall mean the Company&#8217;s 3.250% Convertible Senior Notes due 2031 issued under the Convertible Senior Notes Indenture.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Convertible Senior Notes Indenture</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Convertible Senior Notes Indenture</u></font>&#8221; shall mean the <a name="z_9kR3WTr2664BCPKmep5DCx"></a>Indenture, dated as of September 29, 2025, between the Company and <a name="z_9kR3WTr2664BDcBt2lwdfDFFaQ79yxM"></a>U.S. Bank Trust Company, <a name="z_9kR3WTr2664BEWCpyu0nmNPEBwrq2B7D"></a>National Association, as trustee, as amended or supplemented as of the date of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Copyrights</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Copyrights</u></font>&#8221; is defined in the definition of Intellectual Property Rights.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">DEA</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>DEA</u></font>&#8221; means the United States Drug Enforcement Administration or any successor agency thereto.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Debt Financing</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Debt Financing</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 6.14(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Delaware Courts</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Delaware Courts</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 9.5(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Delisting Period</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Delisting Period</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 6.11</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Depository Agent</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Depository Agent</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 2.6(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Determination Notice</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Determination Notice</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 6.1(b)(i)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">DGCL</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>DGCL</u></font>&#8221; shall mean the Delaware General Corporation Law.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Dissenting Shares</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Dissenting Shares</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 2.7</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">DOJ</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>DOJ</u></font>&#8221; shall mean the U.S. Department of Justice.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">EDGAR</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>EDGAR</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.9(b)</u></font> of the Agreement.</font></div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Effective Time</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Effective Time</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 2.3(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Employee Plan</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Employee Plan</u></font>&#8221; shall mean any &#8220;employee benefit plan&#8221; within the meaning of Section 3(3) of ERISA, and any other plan, program, policy, practice, contract, agreement or arrangement providing
          for compensation or benefits, whether or not subject to ERISA, whether or not reduced to writing, and whether covering a single individual or group of individuals, including, but not limited to, any (a) bonus, deferred compensation, incentive
          compensation, stock purchase, stock option, other equity or equity-based award, severance pay, termination pay, death and disability benefits, hospitalization, medical, life insurance, flexible benefits, profit-sharing, pension or retirement
          plan, policy, program, agreement or arrangement, and (b) employment, offer letter, individual consulting, severance agreement, and each other employee benefit plan, or arrangement, in each case that is (i) sponsored, maintained, contributed to or
          required to be contributed to by an Acquired Corporation for the benefit of any current or former employee, director, officer, or independent contractor of an Acquired Corporation, (ii) with respect to which an Acquired Corporation has or would
          reasonably be expected to have any current or contingent liability or to which an Acquired Corporation is a party, in each case, excluding any plan or arrangement that is maintained by a Governmental Body.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Encumbrance</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Encumbrance</u></font>&#8221; shall mean any lien, pledge, hypothecation, mortgage, security interest, encumbrance, right of first refusal, preemptive right or similar restriction of any nature.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">End Date</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>End Date</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 8.1(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Entity</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Entity</u></font>&#8221; shall mean any corporation (including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company
          (including any company limited by shares, limited liability company or joint stock company), Union, firm, society or other enterprise, association, organization or entity.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Environmental Law</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Environmental Law</u></font>&#8221; shall mean any federal, state, local or foreign Legal Requirement relating to pollution or protection of human health, worker health or the environment (including ambient
          air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges, Releases or threatened Releases of Hazardous Materials, or otherwise relating to the manufacture, processing,
          distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">ERISA</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>ERISA</u></font>&#8221; shall mean the Employee Retirement Income Security Act of 1974.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Exchange Act</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Exchange Act</u></font>&#8221; shall mean the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Excluded Benefits</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Excluded Benefits</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 6.3(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Excluded Shares</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Excluded Shares</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.1(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Exclusively Licensed IP</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Exclusively Licensed IP</u></font>&#8221; means all Intellectual Property Rights exclusively licensed to an Acquired Corporation.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Expiration Date</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Expiration Date</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.1(c)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Extension Deadline</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Extension Deadline</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.1(c)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">FDA</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>FDA</u></font>&#8221; shall mean the United States Food and Drug Administration.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Federal Health Care Program</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Federal Health Care Program</u></font>&#8221; shall mean any federal health care program as defined in 42 U.S.C. &#167; 1320a-7b(f), including the Medicare, Medicaid, 340B, VA, and TRICARE programs.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Financing Parties</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Financing Parties</u></font>&#8221; shall mean the entities that have committed or plan to commit to provide or otherwise enter into agreements in connection with the Debt Financing in connection with the
          consummation of the Transactions, and their respective Affiliates and their and their respective Affiliates&#8217; officers, directors, employees, agents and representatives and their respective successors and assigns; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that neither Parent, Purchaser nor any Affiliate of Parent or Purchaser shall be a Financing Party.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Foreign Investment Laws.</font><font style="font-size: 10pt;"> &#8220;<font style="font-family: 'Times New Roman';"><u>Foreign Investment Laws&#8221;</u></font> shall mean all applicable federal, state, and foreign statutes, rules, regulations, Orders, decrees and other Legal Requirements that are intended to prohibit,
          restrict or regulate foreign direct investment or investment that could affect national security interests, including the Italian Decree Law No. 21/2012.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Fraud</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Fraud</u></font>&#8221; means intentional common law fraud under the Laws of the State of Delaware with respect to the representations and warranties set forth in the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">FTC</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>FTC</u></font>&#8221; shall mean the U.S. Federal Trade Commission.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">GAAP</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>GAAP</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.4(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">GDPR</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>GDPR</u></font>&#8221; shall mean European Union General Data Protection Regulation (EU) 2016/679.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Global Trade Laws</font><font style="font-size: 10pt;">.<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>&#8220;<font style="font-family: 'Times New Roman';"><u>Global Trade Laws</u></font>&#8221; shall mean (a) the trade, sanctions, export control, import, and anti-boycott laws and
          regulations imposed, administered, or enforced by the U.S. government, including the Export Administration Regulations, the International Traffic in Arms Regulations, the customs and import laws administered by U.S. Customs and Border Protection,
          the Foreign Trade Regulations, and the economic and trade sanctions administered by the OFAC or the U.S. Department of State; and (b) other applicable trade, sanctions, export control, import, and anti-boycott laws and regulations.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Good Clinical Practices</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Good Clinical Practices</u></font>&#8221; shall mean the then-current standards for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials contained in
          21 C.F.R. Parts 11, 50, 54, 56 and 312, the <a name="z_9kR3WTr2664BFSK2ut3nu3z5srUSHH0w6"></a>International Council for <a name="z_9kR3WTr2664BGS6n0y0v81w517CgdCwt27A7"></a>Harmonization&#8217;s Guideline for Good Clinical Practice, and any similar
          state, local or foreign Legal Requirements, as applicable.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Good Laboratory Practices</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Good Laboratory Practices</u></font>&#8221; shall mean the then-current standards for conducting non-clinical laboratory studies contained in 21 C.F.R. Part 58, the United States Animal Welfare Act, the <a name="z_9kR3WTr2664BHUK2ut3nu3z5srUSHH0w648LpTA"></a>International Council for Harmonisation&#8217;s Guideline on Nonclinical Safety Studies for the <a name="z_9kR3WTr2664BIPFxnvvv8vPZBsuXQ367xq0uvH1"></a>Conduct of Human Clinical Trials for
          Pharmaceuticals and the <a name="z_9kR3WTr2664BJWK2ut3nu3z5srUSHH0w648LpTA"></a>International Council for Harmonisation&#8217;s Guideline on Safety Pharmacology Studies for Human Pharmaceuticals, and any similar state, local or foreign Legal
          Requirements, as applicable.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Good Manufacturing Practices</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Good Manufacturing Practices</u></font>&#8221; shall mean the then-current standards for the methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or
          holding of a drug contained in 21 C.F.R. Parts 210 and 211 and any similar state, local or foreign Legal Requirements, as applicable.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Governmental Authorization</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Governmental Authorization</u></font>&#8221; shall mean any: permit, license, certificate, approval, consent, grant, franchise, permission, approval, clearance, registration, qualification, waiver, exemption
          or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant to any Legal Requirement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Governmental Body</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Governmental Body</u></font>&#8221; shall mean any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state,
          administrative, local, municipal, foreign, international, multinational, supranational or other government; or (c) governmental or quasi-governmental authority of any nature including any governmental division, department, agency, commission,
          instrumentality, official, ministry, fund, foundation, center, organization, unit or body and any court or other tribunal, or any arbitrator or arbitral body.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Hazardous Materials</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Hazardous Materials</u></font>&#8221; shall mean any waste, material, or substance that is listed, regulated or defined under any Environmental Law and includes any pollutant, chemical substance, hazardous
          substance, hazardous waste, special waste, solid waste, asbestos, mold, radioactive material, polychlorinated biphenyls, petroleum or petroleum-derived substance or waste.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Healthcare Regulatory Filings</font><font style="font-size: 10pt;">.
          &#8220;<font style="font-family: 'Times New Roman';"><u>Healthcare Regulatory Filings</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.12(c)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Healthcare Regulatory Laws</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Healthcare Regulatory Laws</u></font>&#8221; shall mean all Legal Requirements of any Governmental Body pertaining to healthcare regulatory matters applicable to the Acquired Corporations and their
          respective operations, products, and assets, including, in each case as applicable to the business of the Acquired Corporations and as each may be amended from time to time: (i) all federal, state, and local fraud and abuse and patient inducement
          laws relating to the solicitation or acceptance of improper incentives involving Persons operating in the healthcare industry, including the <a name="z_9kR3WTr2664BLV8detqlTHhp96QE05emI8C73ea"></a>Federal Health Care Program Anti-Kickback
          Statute, 42 U.S.C. &#167; 1320a-7b(b); the False Claims Act, 31 U.S.C. &#167;&#167; 3729-3733; the Program Fraud Civil Remedies Act, 31 U.S.C. &#167;&#167; 3801-3812; the Anti-Kickback Act of 1986, 41 U.S.C. &#167;&#167; 51-58; the <a name="z_9kR3WTr2664CDJ9z0rWU2t0xwLuV0xwGE0BtWE"></a>Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; 1320a-7a and 1320a-7b; the <a name="z_9kR3WTr2664CEN8detqlTHhp96QE05emI8C73io"></a>Federal Health Care Program Exclusion Laws, 42 U.S.C. &#167; 1320a-7;
          the <a name="z_9kR3WTr2664CFNEprsunu3yxVSruulnyFEAugy9"></a>Eliminating Kickbacks in Recovery Act of 2018, 18 U.S.C. &#167; 220; the Federal Health Care Fraud Law, 18 U.S.C. &#167; 1347; the <a name="z_9kR3WTr2664CGYSpoaIyBsuAG"></a>Open Payments
          provisions of the <a name="z_9kR3WTr2664CHL4gq3tdcosKBx2MF5"></a>Affordable Care Act, 42 U.S.C. &#167; 1320a-7h; and the regulations promulgated pursuant to such statutes and all other applicable Legal Requirements regarding financial relationships
          with referral sources, the submission of false claims, billing and coding, patient brokering, co-pay assistance programs, free drug and other patient support programs, and patient or program charges; (ii) Medicare (Title XVIII of the Social
          Security Act) and Medicaid (Title XIX of the Social Security Act) and any other federal and state Legal Requirements imposed in connection with any health care program for which reimbursement is provided by a Governmental Body; (iii) the <a name="z_9kR3WTr2664CIbEpykq6jc8B2m295Byz3RO0AND"></a>Patient Protection and Affordability Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, 42 U.S.C. &#167; 18001 et seq.; (iv) all Legal Requirements governing
          government pricing or price reporting programs and regulations promulgated thereunder, and any other similar Legal Requirement, including the collection, reporting, and processing of any drug pricing or product attribute data or any applicable
          rebate, discount, chargeback, adjustment, or restatement, under applicable rules and regulations relating to the <a name="z_9kR3WTr2664CJZFdiibimIRF5dWnk38fnJ9D84"></a>Medicaid Drug Rebate Program, 42 U.S.C. &#167; 1396r&#8211;8, and any state supplemental
          rebate program; <a name="z_9kR3WTr2664CKaFdiibrw"></a>Medicare Part B average sales price reporting, 42 U.S.C. &#167; 1395w&#8211;3a; the federal TRICARE statute, 10 U.S.C. &#167; 1071 et seq.; the Veterans Health Care Act of 1992, 38 U.S.C. &#167; 8126, or any
          Legal Requirements relating to any state pharmaceutical assistance program; the 340B <a name="z_9kR3WTr2664CLSJ7xTZzlmyxagC261x"></a>Drug Pricing Program, Section 340B of the Federal Public Health Service Act, 42 U.S.C. &#167; 256B; and any successor
          government programs; (v) HIPAA and comparable state Legal Requirements regulating the privacy and security of personal information; (vi) any criminal Legal Requirements relating to healthcare, including, but not limited to, those specified in 18
          U.S.C. &#167; 24 and 18 U.S.C. &#167; 286; (vii) the Medicare as <a name="z_9kR3WTr2664CMiLcnzpdsHqN382"></a>Secondary Payer provisions of the Social Security Act, 42 U.S.C. &#167; 1395y(b); (viii) the <a name="z_9kR3WTr2664DEWL1DyjkjpfN3GxzFvrJID4B8WP"></a>Physician






          Payment Sunshine Act (42 U.S.C. &#167; 1320a&#8211;7h) and the implementing regulations set forth at 42 C.F.R. &#167;&#167; 403.900-403.914, as well as all applicable state Legal Requirements governing marketing, labeling, regulating, or requiring reporting of
          interactions between pharmaceutical manufacturers and health care professionals and other members of the healthcare industry; (ix) the <a name="z_9kR3WTr2664DFLJ7xWLm22sZUzADJB65"></a>Drug Sample Reporting provisions of the <a name="z_9kMHG5YVt4886EJN6is5vfequMDz4OH7"></a>Affordable Care Act, 42 U.S.C. &#167; 1320a-7i; (x) the Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167; 301 et seq.; (xi) the Federal Controlled Substances Act, 21 U.S.C. &#167; 801 et seq.; (xii) Title 21,
          Code of Federal Regulations; (xiii) the Public Health Service Act, 42 U.S.C. &#167; 201 et seq., including the Clinical Laboratory Improvement Amendments of 1988, 42 U.S.C. &#167; 263a; (xiv) the PhRMA Code and other applicable, generally accepted trade
          association codes of conduct; (xv) federal and state consumer protection laws; (xvi) all applicable fee splitting and reimbursement Legal Requirements applicable to products of the Acquired Corporations; (xvii) all Legal Requirements, including
          state laws regarding the manufacture, wholesale, distribution, marketing, labeling, promotion, sale, advertising, dispensing, or communication regarding, pharmaceutical products, including state licensing laws or regulations promulgated by state
          professional boards, as well as state transparency laws; (xviii) Legal Requirements governing pharmacovigilance activities and adverse event reporting, (xix) comparable state, federal, or foreign Legal Requirements governing the design,
          development, research, testing, manufacturing, processing, storing, importing or exporting, labeling, packaging, quality, approval, promotion, advertising, distributing, supplying, commercializing, offering for sale, sale, use or marketing of
          products of the Acquired Corporations, including Good Clinical Practices, Good Laboratory Practices, and Good Manufacturing Practices; and (xx) any rules, regulations, and legally binding directives, policy statements, or guidance promulgated or
          issued pursuant to such laws, as each of the foregoing may be amended from time to time.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">HIPAA</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>HIPAA</u></font>&#8221; shall mean, collectively, the Health Insurance Portability and Accountability Act of 1996, Public Law 104-191, as amended by the Health Information Technology for Economic and
          Clinical Health Act, and all implementing regulations promulgated thereunder, as each may be amended from time to time.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">HRSA</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>HRSA</u></font>&#8221; shall mean the Health Resources and Services Administration or any successor agency thereto.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">HSR Act</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>HSR Act</u></font>&#8221; shall mean the Hart-Scott-Rodino Antitrust Improvements Act of 1976.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">In-bound IP Contract</font><font style="font-size: 10pt;">.<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>&#8220;<font style="font-family: 'Times New Roman';"><u>In-bound IP Contract</u></font>&#8221;<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.8(g)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Indebtedness</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Indebtedness</u></font>&#8221; shall mean, without duplication, (i) any indebtedness for borrowed money (including the issuance of any debt security) to any Person, including that portion of obligations with
          respect to any capital leases that is classified as a liability on a balance sheet in conformity with GAAP, (ii) any obligations evidenced by notes, bonds, debentures or similar Contracts for indebtedness for borrowed money owing to any Person,
          (iii) any reimbursement obligations in respect of all drawn amounts under letters of credit and bankers&#8217; acceptances (other than obligations in respect of letters of credit and bankers&#8217; acceptances used as security for leases), bank guarantees,
          surety bonds and similar instruments, in each case to the extent drawn upon, including the principal, interest and fees owing thereon, (iv) all indebtedness created or arising under any conditional sale or other title retention agreement with
          respect to property acquired or deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business), (v) net obligations of any interest rate, swap, currency swap, forward currency or interest
          rate Contracts or other interest rate or currency hedging arrangements or (vi) any guaranty of any such obligations described in <font style="font-family: 'Times New Roman';"><u>clauses </u></font><a name="ignore48"></a><font style="font-family: 'Times New Roman';"><u>(i)</u></font> through <a name="ignore49"></a><font style="font-family: 'Times New Roman';"><u>(v)</u></font> of any Person other than an Acquired Corporation (other than, in any case, accounts
          payable to trade creditors and accrued expenses, in each case, arising in the ordinary course of business consistent with past practice), except that Indebtedness shall not include obligations between or among any of the Acquired Corporations.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Indemnified Persons</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Indemnified Persons</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 6.4(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Initial Expiration Date</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Initial Expiration Date</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.1(c)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Intellectual Property Rights</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Intellectual Property Rights</u></font>&#8221; shall mean all rights, title and interests in and to all intellectual property and industrial property rights of every kind, nature and description throughout
          the world, including all U.S. and foreign (a) patents, patent applications, invention disclosures, and all related continuations, continuations-in-part, divisionals, reissues, re-examinations, substitutions, and extensions thereof (&#8220;<font style="font-family: 'Times New Roman';"><u>Patents</u></font>&#8221;), (b) trademarks, service marks, names, corporate names, trade names, Internet domain names, logos, slogans, trade dress, design rights, and other similar designations of source or
          origin, together with the goodwill symbolized by any of the foregoing and applications and registrations for the foregoing (&#8220;<font style="font-family: 'Times New Roman';"><u>Trademarks</u></font>&#8221;), (c) copyrights and copyrightable subject matter
          (&#8220;<font style="font-family: 'Times New Roman';"><u>Copyrights</u></font>&#8221;), (d) trade secrets, database rights and other confidential and proprietary ideas, know-how, inventions, proprietary processes, formulae, models, and methodologies (&#8220;<font style="font-family: 'Times New Roman';"><u>Trade Secrets</u></font>&#8221;), and (e) any registrations, applications or rights arising under applicable law or Contract related to any of the foregoing.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Intervening Event</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Intervening Event</u></font>&#8221; shall mean any material event, fact, development, or occurrence that affects the business, assets or operations of the Company that is unknown to, and not reasonably
          foreseeable by, the Board of Directors as of the date of the Agreement, the material consequences of which were not known to, and not reasonably foreseeable by, the Board of Directors as of the date of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">IP Contracts</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>IP Contracts</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.8(g)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">IRS</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>IRS</u></font>&#8221; shall mean the U.S. Internal Revenue Service.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">KalVista UK</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>KalVista UK</u></font>&#8221; is defined in the preamble to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">knowledge</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>knowledge</u></font>&#8221; with respect to an Entity shall mean with respect to any matter in question the actual knowledge, after reasonable inquiry, of such Entity&#8217;s executive officers.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Leased Real Property</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Leased Real Property</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.7(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Legal Proceeding</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Legal Proceeding</u></font>&#8221; shall mean any action, suit, charge, complaint, <font style="font-family: 'Times New Roman'; font-style: italic;">qui tam </font>complaint, formal written demand, civil
          investigative demand, petition, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), audit, examination, hearing or investigation commenced, brought, conducted or heard by or
          before any Governmental Body or any arbitrator or arbitration panel, whether civil, criminal, administrative, or otherwise, in law or equity.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Legal Requirement</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Legal Requirement</u></font>&#8221; shall mean any federal, state, local, municipal, foreign, international, multinational, supranational or other law, statute, constitution, resolution, ordinance, common
          law, code, edict, decree, rule, regulation, ruling, treaty, Order, Governmental Authorization, interpretation, binding guidance, or other requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the
          authority of any Governmental Body (or under the authority of Nasdaq or another stock exchange) or any similar provision having the force and effect of law.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Material Adverse Effect</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Material Adverse Effect</u></font>&#8221; shall mean any event, occurrence, circumstance, change or effect which, individually or when taken together with all other events, occurrences, circumstances,
          changes or effects which have occurred in the applicable determination period for a Material Adverse Effect, has had or would reasonably be expected to have a material adverse effect on (a) the ability of the Company to consummate the Offer and
          the Merger on or before the End Date or (b) the business, assets, financial condition or results of operations of the Acquired Corporations, taken as a whole; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>,<font style="font-family: 'Times New Roman'; font-style: italic;"> however</font>, that none of the following shall be deemed to constitute or be taken into account in determining whether there is, or would reasonably be expected to be, a Material
          Adverse Effect for purposes of <font style="font-family: 'Times New Roman';"><u>clause (b)</u></font> above: (i) any change in the market price or trading volume of the Company&#8217;s stock or change in the Company&#8217;s credit ratings; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that the underlying causes of any such change may be considered in determining whether a Material Adverse Effect has occurred to the extent not otherwise excluded by
          another exception herein; (ii) any event, occurrence, circumstance, change or effect resulting from the announcement, pendency or performance of the Transactions (other than for purposes of any representation or warranty contained in <font style="font-family: 'Times New Roman';"><u>Section 3.23</u></font> and the condition set forth in <font style="font-family: 'Times New Roman';"><u>clause (b)(iv)</u></font> of <font style="font-family: 'Times New Roman';"><u>Annex I</u></font>
          solely as such condition relates to <font style="font-family: 'Times New Roman';"><u>Section 3.23</u></font>); (iii) any event, occurrence, circumstance, change or effect generally affecting the industries in which the Acquired Corporations
          operate or in the economy generally or other general business, financial or market conditions; (iv) any event, occurrence, circumstance, change or effect arising directly or indirectly from or otherwise relating to fluctuations in the value of
          any currency or interest rates; (v) any event, occurrence, circumstance, change or effect arising directly or indirectly from or otherwise relating to any act of terrorism, war, national or international calamity, natural disaster, acts of god,
          epidemic, pandemic, trade wars or any other similar event; (vi) the failure of the Company to meet internal or analysts&#8217; expectations or projections; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that the
          underlying causes of such failure<a name="z_Hlk199182839"></a> may be considered in determining whether a Material Adverse Effect has occurred to the extent not otherwise excluded by another exception herein; (vii) any adverse effect arising
          directly from or otherwise directly relating to any action taken by an Acquired Corporation at the written direction of Parent or any action specifically required to be taken by an Acquired Corporation under the Agreement, or the failure of an
          Acquired Corporation to take any action that such Acquired Corporation is specifically prohibited by the terms of the Agreement from taking to the extent Parent fails to give its consent thereto after a written request therefor pursuant to <font style="font-family: 'Times New Roman';"><u>Section 5.2</u></font>; (viii) any event, occurrence, circumstance, change or effect resulting or arising from the identity of, or any facts or circumstances relating to, Parent, Purchaser or any of
          their respective Affiliates; (ix) any event, occurrence, circumstance, change or effect arising directly or indirectly from or otherwise relating to any change in, or any compliance with or action taken for the purpose of complying with any
          change in, any Legal Requirement or GAAP (or interpretations of any Legal Requirement or GAAP); (x) any Legal Proceeding described in <font style="font-family: 'Times New Roman';"><u>Section 2.7</u></font> or <font style="font-family: 'Times New Roman';"><u>Section 6.5</u></font>; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(xi) </font>any event, occurrence, circumstance, change or effect resulting or arising from Parent&#8217;s or Purchaser&#8217;s breach of the
          Agreement;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> or (xii) the availability of or cost of equity, debt or other financing to Parent or Purchaser</font>; <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that any event, occurrence, circumstance, change or effect referred to in the foregoing <font style="font-family: 'Times New Roman';"><u>clauses</u></font>&#160;<font style="font-family: 'Times New Roman';"><u>(iii)</u></font>,
          <font style="font-family: 'Times New Roman';"><u>(iv)</u></font>, <font style="font-family: 'Times New Roman';"><u>(v)</u></font> and <font style="font-family: 'Times New Roman';"><u>(ix)</u></font> may be taken into account in determining
          whether there is, or would be reasonably expected to be, a Material Adverse Effect solely to the extent such event, occurrence, circumstance, change or effect disproportionately affects the Acquired Corporations relative to other participants in
          the industries in which the Acquired Corporations operate.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Material Contract</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Material Contract</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.9(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Maximum Amount</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Maximum Amount</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 6.4(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Merger</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Merger</u></font>&#8221; is defined in the <a name="z_9kMIH5YVt4886CHVM495szzz628"></a>Introduction to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Merger Consideration</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Merger Consideration</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 2.5(a)(iii)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Minimum Condition</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Minimum Condition</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Annex I</u></font><font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>to the
          Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Nasdaq</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Nasdaq</u></font>&#8221; shall mean The Nasdaq Global Select Market.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Non-U.S. Plan</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Non-U.S. Plan</u></font>&#8221; means an Employee Plan that is sponsored or maintained primarily for the benefit of current or former employees, directors, officers, or independent contractors of an Acquired
          Corporation outside of the United States.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">OFAC</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>OFAC</u></font>&#8221; shall mean the U.S. Treasury Department&#8217;s Office of Foreign Assets Control.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Offer</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Offer</u></font>&#8221; is defined in the <a name="z_9kMJI5YVt4886CHVM495szzz628"></a>Introduction to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Offer Acceptance Time</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Offer Acceptance Time</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.1(h)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Offer Commencement Date</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Offer Commencement Date</u></font>&#8221; shall mean the date on which Purchaser commences the Offer, within the meaning of Rule 14d-2 under the Exchange Act.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Offer Conditions</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Offer Conditions</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.1(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Offer Documents</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Offer Documents</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.1(e)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Offer Price</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Offer Price</u></font>&#8221; is defined in the <a name="z_9kMKJ5YVt4886CHVM495szzz628"></a>Introduction to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Offer to Purchase</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Offer to Purchase</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.1(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Order</font><font style="font-size: 10pt;">.<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>&#8220;<font style="font-family: 'Times New Roman';"><u>Order</u></font>&#8221; shall mean any order, writ, judgment, injunction, decree, stipulation, ruling, decision, verdict, determination or award made,
          issued or entered by or with any Governmental Body.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Out-bound IP Contract</font><font style="font-size: 10pt;">.<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>&#8220;<font style="font-family: 'Times New Roman';"><u>Out-bound IP Contract</u></font>&#8221;<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.8(g)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Parent</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Parent</u></font>&#8221;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">&#160;</font>is defined in the preamble to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Parent Employee Plans</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Parent Employee Plans</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 6.3(c)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Parent Material Adverse Effect</font><font style="font-size: 10pt;">.
          &#8220;<font style="font-family: 'Times New Roman';"><u>Parent Material Adverse Effect</u></font>&#8221; shall mean any effect, change, event or occurrence that would or would reasonably be expected to, individually or in the aggregate, materially impair,
          prevent or materially delay Parent&#8217;s or Purchaser&#8217;s ability to consummate the Transactions in a timely manner on the terms set forth herein.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Parties</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Parties</u></font>&#8221; shall mean Parent, Purchaser, and the Company.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Patents</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Patents</u></font>&#8221; is defined in the definition for Intellectual Property Rights.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Paying Agent</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Paying Agent</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 2.6(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Payment Fund</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Payment Fund</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 2.6(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Permitted Encumbrance</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Permitted Encumbrance</u></font>&#8221; shall mean (a) any Encumbrance for Taxes (i) that are not due and payable or (ii) the validity of which is being contested in good faith by appropriate proceedings,
          (b) any Encumbrance representing the rights of customers, suppliers and subcontractors in the ordinary course of business consistent with past practice under the terms of any Contracts to which the relevant Party is a party or under general
          principles of commercial or government contract law (including mechanics&#8217;, materialmen&#8217;s, carriers&#8217;, workmen&#8217;s, warehouseman&#8217;s, repairmen&#8217;s, landlords&#8217; and similar liens granted or which arise in the ordinary course of business consistent with
          past practice), (c) any interest or title of a lessor under leases (other than capital leases) entered into by an Acquired Corporation in the ordinary course of business, and any Encumbrance related thereto, (d) in the case of any Contract,
          Encumbrances that are restrictions against the transfer or assignment thereof that are included in the terms of such Contract, (e) non-exclusive licenses of Intellectual Property Rights entered into in the ordinary course of business consistent
          with past practices, and (f) in the case of real property, Encumbrances that are easements, rights-of-way, encroachments, restrictions, conditions and other similar Encumbrances incurred or suffered in the ordinary course of business consistent
          with past practice and which, individually or in the aggregate, do not and would not materially impair the use (or contemplated use), utility or value of the applicable real property or otherwise materially impair the present or contemplated
          business operations at such location, or zoning, entitlement, building and other land use regulations imposed by Governmental Bodies having jurisdiction over such real property or that are otherwise set forth on a title report.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Person</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Person</u></font>&#8221; shall mean any individual, Entity or Governmental Body.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Personal Data</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Personal Data</u></font>&#8221; shall mean (a) any information, that alone or in combination with other information, identifies, relates to, describes, or is associated with an identified or identifiable
          natural person or that is reasonably capable of being used to identify a natural person, including a person&#8217;s name, address, phone number, fax number, e-mail address, social security number or other government-issued identifier and (b) any data
          or information defined as &#8220;personal data&#8221;, &#8220;personal information&#8221;, &#8220;personally identifiable information&#8221;, &#8220;nonpublic personal information&#8221;, &#8220;personal health information&#8221;, &#8220;individually identifiable health information&#8221; or similar terms under any
          applicable Legal Requirement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">PhRMA Code</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>PhRMA Code</u></font>&#8221; shall mean the <a name="z_9kR3WTr2664DGYLdo1lch0G5piskY67q47y"></a>Pharmaceutical Research and <a name="z_9kR3WTr2664DHWBj4xecwFEz0FD1OQ17CyrSb90"></a>Manufacturers of America
          Code on <a name="z_9kR3WTr2664DITK2utqcw3z5A"></a>Interactions with <a name="z_9kR3WTr2664DJTAai2zjdtyXfB0r5KB8E10J"></a>Healthcare Professionals and <a name="z_9kR3WTr2664DKcVvsnjx1rz"></a>Principles on <a name="z_9kR3WTr2664DLQFxnvvv8vKLy12slvpqCw0J"></a>Conduct of Clinical Trials.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Post-Closing SEC Reports</font><font style="font-size: 10pt;">. &#8220;<u>Post-Closing


            SEC Reports</u>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 6.11</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Pre-Closing Period</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Pre-Closing Period</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 5.1(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Privacy and Data Security Requirements</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Privacy and Data Security Requirements</u></font>&#8221; shall mean: (a) any Legal Requirements regulating the collecting, accessing, using, disclosing, electronically transmitting, securing,
          sharing, processing, linking, transferring or storing of Personal Data, including the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.), as amended by the Health Information Technology for Economic and
          Clinical Health Act, state privacy laws (such as the California Consumer Privacy Act of 2018, as amended by the Consumer Privacy Rights Act of 2020, and the Virginia Consumer Data Protection Act) together with any implementing regulations, the
          GDPR, any other Legal Requirements implementing the GDPR into national law and Japan&#8217;s Act on the Protection of Personal Information; (b) obligations under all Contracts to which any Acquired Corporation is a party or is otherwise bound that
          relate to the collection or processing of Personal Data; (c) all of the Acquired Corporations&#8217; written internal or publicly posted policies and representations (including if posted on any Acquired Corporations&#8217; websites, products or services)
          regarding the collection, use, disclosure, transfer, storage, maintenance, retention, deletion, disposal, modification, linkage, or protection or processing of Personal Data; and (d) applicable pre-market and post-market guidance issued by the
          FDA regarding the integrity, security, privacy and reliability of electronic systems and data used in FDA-regulated activities, in each case to the extent applicable to the business of the Acquired Corporations.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Process, Processed or Processing</font><font style="font-size: 10pt;">.
          &#8220;<a name="z_9kMHG5YVt48868CbX3pgxC"></a><font style="font-family: 'Times New Roman';"><u>Process</u></font>&#8221;, &#8220;<font style="font-family: 'Times New Roman';"><u>Processed</u></font>&#8221; or &#8220;<font style="font-family: 'Times New Roman';"><u>Processing</u></font>&#8221;
          shall mean, with respect to Personal Data, an operation or set of operations, whether or not by automated means, such as collection, storage, maintenance, receipt, recording, organization, safeguarding, security, structuring, storage, adaptation,
          enhancement, enrichment or alteration, ingestion, compilation, combination, retrieval, consultation, analysis, use, disclosure by transmission, sharing, transfer, dissemination or otherwise making available, alignment or combination, restriction,
          de-identification, erasure or destruction.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Purchaser</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Purchaser</u></font>&#8221; is defined in the preamble to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Registered IP</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Registered IP</u></font>&#8221; shall mean all Patents, Trademarks and Copyrights that are registered or issued under the authority of any Governmental Body, all applications for any of the foregoing, domain
          names, and social media handles.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Regulatory Permit</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Regulatory Permit</u></font>&#8221; shall mean all investigational new drug applications, clinical trial authorizations, new drug applications, supplemental new drug applications, marketing authorization
          applications, abbreviated new drug applications, establishment registrations, as defined in 21 C.F.R. &#167; 207, and product listings, as defined in 21 C.F.R. &#167; 207, manufacturer, distributor, or wholesale licenses or permits, and all supplements or
          amendments thereto, and all comparable Governmental Authorizations.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Release</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Release</u></font>&#8221; shall mean any presence, emission, spill, seepage, leak, escape, leaching, discharge, injection, pumping, pouring, emptying, dumping, disposal, migration, or release of Hazardous
          Materials from any source into or upon the environment, including the air, soil, improvements, surface water, groundwater, the sewer, septic system, storm drain, publicly owned treatment works, or waste treatment, storage, or disposal systems.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Representatives</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Representatives</u></font>&#8221; shall mean officers, directors, employees, attorneys, accountants, investment bankers, consultants, agents, financial advisors, other advisors and other representatives.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Restricted Party</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Restricted Party</u></font>&#8221; shall mean any Person (a) included on one or more of the Restricted Party Lists; (b) located, organized, or ordinarily resident in a country, territory, or region that is
          the subject of sanctions administered by OFAC that broadly prohibit business or dealings with such country, territory, or region; (c) owned or controlled by, or acting on behalf of, any of the foregoing; or (d) with whom U.S. Persons are
          otherwise prohibited from transacting under Global Trade Laws.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Restricted Party Lists</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Restricted Party Lists</u></font>&#8221; shall `mean the list of sanctioned parties maintained by the United Nations; the <a name="z_9kR3WTr2664EIcWpdihlxBeF16v1w38tdV8HDJ6"></a>Specially Designated
          Nationals and Blocked Persons List, the <a name="z_9kR3WTr2664EJQI1skntgOqt0739Ege7qvAPufJ"></a>Foreign Sanctions Evaders List, the <a name="z_9kR3WTr2664EKeLcs54rmfPru184AFlRu5LH453"></a>Sectoral Sanctions Identifications List, and other lists
          administered by OFAC; the <a name="z_9kR3WTr2664ELhBv8pumiUQzEC8DmXBN"></a>U.S. Denied Persons List, the <a name="z_9kR3WTr2664EMiBwI401IlQ4G"></a>U.S. Entity List, the <a name="z_9kR3WTr2664ENjBCY6yv0pqqmUU8K"></a>U.S. Unverified List, and
          the <a name="z_9kR3WTr2664EOkB4Lrs1utIgQweo55nZDP"></a>U.S. Military End-User List, all administered by the U.S. Department of Commerce; the consolidated list of Persons, <a name="z_9kR3WTr266566NM1576sosKPB789v6vs8y2wCUQ"></a>Groups and
          Entities Subject to EU Financial Sanctions, as implemented by the <a name="z_9kR3WTr266567MxwHyx02UQ90sv1oar8ODGX4pI"></a>EU Common Foreign &amp; Security Policy; the <a name="z_9kR3WTr266568Qs5btdsDDIeP7CE83wp6BweeIU"></a>HM Treasury
          Consolidated List of Financial Sanctions Targets in the UK; and similar lists of restricted parties maintained by other relevant governmental authorities.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Sarbanes-Oxley Act</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Sarbanes-Oxley Act</u></font>&#8221; means the Sarbanes-Oxley Act of 2002.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Schedule 14D-9</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Schedule 14D-9</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.2(a)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">SEC</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>SEC</u></font>&#8221; shall mean the United States Securities and Exchange Commission.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Securities Act</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Securities Act</u></font>&#8221; shall mean the Securities Act of 1933.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Security Incident</font><font style="font-size: 10pt;">.<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>&#8220;<u>Security Incident</u>&#8221; shall mean any (a) unauthorized or unlawful Processing, loss, theft, or misuse of Personal Data, (b) a compromise of the security, integrity, or
          confidentiality of any Personal Data controlled by an Acquired Corporation or any IT system, or (c) phishing, ransomware, denial of service (<a name="z_9kR3WTr266569NGc"></a>DoS) or other cyberattack that has resulted in a monetary loss or
          business disruption to an Acquired Corporation.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Shares</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Shares</u></font>&#8221; is defined in the <a name="z_9kMLK5YVt4886CHVM495szzz628"></a>Introduction to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Specified Agreement</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Specified Agreement</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 8.1(e)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Specified Governmental Body</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Specified Governmental Body</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 7.1</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Standard IP Contracts</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Standard IP Contracts</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 3.8(g)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Stockholder List Date</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Stockholder List Date</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 1.2(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-15</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Subsidiary</font><font style="font-size: 10pt;">. An Entity shall be
          deemed to be a &#8220;<a name="z_9kR3WTr24456AdbrqykljtI"></a><font style="font-family: 'Times New Roman';"><u>Subsidiary</u></font>&#8221; of another Person if such Person directly or indirectly owns, beneficially or of record, (a) an amount of voting
          securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such Entity&#8217;s board of directors or other governing body, or (b) at least 50% of the outstanding equity or
          financial interests of such Entity.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Superior Offer</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Superior Offer</u></font>&#8221; shall mean a <font style="font-family: 'Times New Roman'; font-style: italic;">bona fide</font> written Acquisition Proposal that the Board of Directors determines, in its
          good faith judgment, after consultation with the Company&#8217;s outside legal counsel and financial advisors, is reasonably likely to be consummated in accordance with its terms, taking into account all legal, regulatory and financing aspects
          (including certainty of closing) of the proposal and the Person making the proposal and other aspects of the Acquisition Proposal that the Board of Directors deems relevant, and if consummated, would result in a transaction more favorable to the
          Company&#8217;s stockholders (solely in their capacity as such) from a financial point of view than the Transactions (including after giving effect to proposals, if any, made by Parent pursuant to <font style="font-family: 'Times New Roman';"><u>Section





              6.1(b)(i)</u></font>); <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font> that for purposes of the definition of <a name="ignore59"></a>&#8220;Superior Offer&#8221;, the references to <a name="ignore60"></a>&#8220;20%&#8221; in the
          definition of Acquisition Proposal shall be deemed to be references to <a name="ignore61"></a>&#8220;50%&#8221;.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Surviving Corporation</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Surviving Corporation</u></font>&#8221; is defined in the <a name="z_9kMML5YVt4886CHVM495szzz628"></a>Introduction to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Takeover Laws</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Takeover Laws</u></font>&#8221; shall mean any &#8220;<a name="ignore62"></a>moratorium&#8221;, &#8220;<a name="ignore63"></a>control share acquisition&#8221;, &#8220;<a name="ignore64"></a>fair price&#8221;, &#8220;<a name="ignore65"></a>supermajority&#8221;,






          &#8220;<a name="ignore66"></a>affiliate transactions&#8221;, or &#8220;<a name="ignore67"></a>business combination statute or regulation&#8221; or other similar state anti-takeover laws and regulations (including, for the avoidance of doubt, Section 203 of the DGCL).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Tax</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Tax</u></font>&#8221; shall mean any and all U.S. federal, state or local or non-U.S. taxes, charges, levies in the nature of, or similar to, tax, including any net income, alternative or add-on minimum, customs duties, levies
          or assessments, escheat and unclaimed property obligations, gross income, gross receipts, sales, use, ad valorem, value added, transfer, franchise, profits, license, registration, recording, documentary, gains, withholding, payroll, employment,
          national insurance contribution liabilities, severance, stamp, occupation, premium, property, environmental, privilege or windfall profit, estimated or other tax, together with any interest, penalty, or addition thereto.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Tax Return</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Tax Return</u></font>&#8221; shall mean any return (including any information return), report, statement, declaration, estimate, schedule, form, election, claims for refund, requests for extension,
          certificate or other document or information filed or required to be filed with any Governmental Body in connection with the determination, assessment, collection or payment of any Tax and any attachments thereto or amendments thereof.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Termination Condition</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Termination Condition</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Annex I</u></font> to the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Termination Fee</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Termination Fee</u></font>&#8221; is defined in <font style="font-family: 'Times New Roman';"><u>Section 8.3(b)</u></font> of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-16</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Trade Secrets</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Trade Secrets</u></font>&#8221; is defined in the definition of Intellectual Property Rights.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Trademarks</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Trademarks</u></font>&#8221; is defined in the definition of Intellectual Property Rights.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Transactions</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Transactions</u></font>&#8221; shall mean (a) the execution and delivery of the Agreement and (b) all of the transactions contemplated by the Agreement, including the Offer and the Merger.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Union</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>Union</u></font>&#8221; shall mean any labor union, works council, trade union, or other employee representative body.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">VA</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>VA</u></font>&#8221; shall mean the U.S. Department of Veterans Affairs or any successor agency thereto.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">WARN Act</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>WARN Act</u></font>&#8221; shall mean the Worker Adjustment <a name="z_cp_text_2_30"></a>and Retraining Notification Act of 1988 or any similar foreign, state or local Legal Requirement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">willful and material breach</font><font style="font-size: 10pt;">. &#8220;<font style="font-family: 'Times New Roman';"><u>willful and material breach</u></font>&#8221; shall mean a breach that is a consequence of an act or omission undertaken by the breaching party with the knowledge that the taking of, or failure to take, such
          act would, or would reasonably be expected to, cause or constitute a material breach of the Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">A-17</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%I-%%-->
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ANNEX I</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CONDITIONS TO THE OFFER</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not validly withdrawn) pursuant to the Offer is subject to
        the satisfaction of the conditions set forth in <font style="font-family: 'Times New Roman';"><u>clauses </u></font><a name="ignore68"></a><font style="font-family: 'Times New Roman';"><u>(a)</u></font><a name="ignore69"></a> through <font style="font-family: 'Times New Roman';"><u>(h)</u></font> below. Accordingly, notwithstanding any other provision of the Offer or the Agreement to the contrary, Purchaser shall not be required to accept for payment or (subject to any applicable
        rules and regulations of the SEC, including Rule 14e-1(c) under the Exchange Act) pay for, and may delay the acceptance for payment of, or (subject to any such rules and regulations) the payment for, any tendered Shares, and, to the extent
        permitted by the Agreement, may terminate the Offer: (i) upon termination of the Agreement; and (ii) at any scheduled Expiration Date (subject to any extensions of the Offer pursuant to <font style="font-family: 'Times New Roman';"><u>Section
            1.1(c)</u></font> of the Agreement), if: (A) the Minimum Condition, the Termination Condition and conditions set forth in <font style="font-family: 'Times New Roman';"><u>clauses (e)</u></font> and <font style="font-family: 'Times New Roman';"><u>(g)</u></font> below shall not be satisfied by the time at which the Offer expires on the Expiration Date; or (B) any of the additional conditions set forth below shall not be satisfied or waived in writing by Parent by the time at
        which the Offer expires on the Expiration Date:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref_ContractCompanion_9kb9Ur15A"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">there





          shall have been validly tendered, and not validly withdrawn, in the Offer a number of Shares that, considered together with all other Shares (if any) beneficially owned by Parent and its Affiliates, represent one more Share than 50% of the total
          number of Shares outstanding at the time of the expiration of the Offer (the &#8220;<font style="font-family: 'Times New Roman';"><u>Minimum Condition</u></font>&#8221;); <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that for purposes of determining whether the Minimum Condition has been satisfied, the Parties shall exclude Shares tendered in the Offer pursuant to guaranteed
          delivery procedures that have not yet been &#8220;received&#8221; by the &#8220;depository&#8221; (as such terms are defined in Section 251(h)(6) of the DGCL);</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref460608448"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">(i</font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160;&#160; &#160;&#160; </font><font style="font-family: 'Times New Roman';">the representations and warranties of the Company set forth in:
          the first two sentences of <font style="font-family: 'Times New Roman';"><u>Section 3.1(a)</u></font> (Due Organization; Subsidiaries, Etc.), <font style="font-family: 'Times New Roman';"><u>Section 3.2</u></font> (Certificate of Incorporation
          and Bylaws), <font style="font-family: 'Times New Roman';"><u>Section 3.21</u></font> (Authority; Binding Nature of Agreement), <font style="font-family: 'Times New Roman';"><u>Section 3.22</u></font> (Takeover Laws), <font style="font-family: 'Times New Roman';"><u>Section 3.24</u></font> (Opinion of Financial Advisor) and <font style="font-family: 'Times New Roman';"><u>Section 3.25</u></font> (Brokers and Other Advisors) of the Agreement shall be accurate (without taking into
          account any &#8220;Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained in such representations and warranties) in all material respects as of the date of the Agreement and at and as of the Expiration Date as if made on and as of such
          date (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date or period);</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(ii)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the representations and warranties of the Company set forth in <font style="font-family: 'Times New Roman';"><u>Sections 3.3(a) </u></font>and <font style="font-family: 'Times New Roman';"><u>3.3(d)</u></font> (Capitalization, Etc.) of
            the Agreement shall be accurate (without taking into account any &#8220;Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained in such representations and warranties) except for <font style="font-family: 'Times New Roman'; font-style: italic;">de minimis</font> inaccuracies as of the date of the Agreement and at and as of the Expiration Date as if made on and as of such date (except to the extent any such representation or warranty expressly relates to an earlier date or
            period, in which case as of such date or period);</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">I-1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref_ContractCompanion_9kb9Ur167"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the representations and warranties of the Company set forth in <font style="font-family: 'Times New Roman';"><u>Section 3.5(b)</u></font> (No Material Adverse Effect) of the Agreement shall be accurate in all respects as of
          the date of the Agreement and at and as of the Expiration Date as if made on and as of such date with respect to the earlier period set forth in <font style="font-family: 'Times New Roman';"><u>Section 3.5(b)</u></font> of the Agreement;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 72pt; font-size: 10pt;"><a name="z_Ref227444415"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the





          representations and warranties of the Company set forth in the Agreement (other than those referred to in <font style="font-family: 'Times New Roman';"><u>clauses (b)(i)</u></font> through <font style="font-family: 'Times New Roman';"><u>(b)(iii)</u></font>
          above) shall be accurate (without taking into account any &#8220;Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained in such representations and warranties) as of the date of the Agreement and at and as of the Expiration Date as if made
          on and as of such date (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date or period), except where the failure of such representations and warranties to be so
          accurate has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref228235991"></a><a name="z_Ref_ContractCompanion_9kb9Ur14D"></a><a name="z_Ref_ContractCompanion_9kb9Ur156"></a><a name="z_Ref_ContractCompanion_9kb9Ur158"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">the Company shall have complied with or performed in all material respects the covenants and agreements it is required
          to comply with or perform at or prior to the time at which the Offer expires on the Expiration Date (or any failure to comply or perform shall have been cured by such time);</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref_ContractCompanion_9kb9Ur169"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">since





          the execution and delivery of the Agreement, there shall not have occurred any Material Adverse Effect;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref228236122"></a><a name="z_Ref_ContractCompanion_9kb9Ur127"></a><a name="z_Ref_ContractCompanion_9kb9Ur129"></a><a name="z_Ref_ContractCompanion_9kb9Ur12B"></a><a name="z_Hlk223093573"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">any waiting period (or any extension thereof) applicable to the Offer under the HSR Act
          shall have expired or been terminated and the Antitrust and Foreign Investment Approvals shall have been obtained;</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Parent and
            Purchaser shall have received a certificate executed on behalf of the Company by the Company&#8217;s Chief Executive Officer or Chief Financial Officer confirming that the conditions set forth in <font style="font-family: 'Times New Roman';"><u>clauses





                (b)</u></font>, <font style="font-family: 'Times New Roman';"><u>(c)</u></font> and <font style="font-family: 'Times New Roman';"><u>(d)</u></font> of this <font style="font-family: 'Times New Roman';"><u>Annex I</u></font> have been
            satisfied;</font></font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref460608475"></a><a name="z_Ref_ContractCompanion_9kb9Ur134"></a><a name="z_Ref_ContractCompanion_9kb9Ur136"></a><a name="z_Ref_ContractCompanion_9kb9Ur138"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">there shall not have been issued by any Specified Governmental Body of competent jurisdiction and remain in effect any
          temporary restraining order, preliminary or permanent injunction or other Order preventing the acquisition of or payment for Shares pursuant to the Offer or the consummation of the Merger, nor shall any Legal Requirement have been promulgated,
          enacted, issued or deemed applicable to the Offer or the Merger by any Specified Governmental Body which prohibits or makes illegal the acquisition of or payment for Shares pursuant to the Offer or the consummation of the Merger; and</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; text-indent: 36pt; font-size: 10pt;"><a name="z_Ref460608473"></a><a name="z_Ref_ContractCompanion_9kb9Ur15C"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">the Agreement shall not have been terminated in accordance with its terms (the &#8220;<font style="font-family: 'Times New Roman';"><u>Termination Condition</u></font>&#8221;).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing conditions are for the sole benefit of Parent and Purchaser and (except for the Minimum Condition, the Termination Condition and the conditions set forth in
        <font style="font-family: 'Times New Roman';"><u>clauses (e)</u></font> and <font style="font-family: 'Times New Roman';"><u>(g)</u></font> above) may be waived by Parent and Purchaser, in whole or in part at any time and from time to time, in the
        sole discretion of Parent and Purchaser, to the extent permitted under applicable Legal Requirements. All capitalized terms used but not defined in this <font style="font-family: 'Times New Roman';"><u>Annex I</u></font> shall have the meanings
        ascribed to them in the Agreement to which this <font style="font-family: 'Times New Roman';"><u>Annex I</u></font> is attached.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">I-2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%II-%%-->
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ANNEX II</div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FORM OF CERTIFICATE OF INCORPORATION OF THE SURVIVING CORPORATION</div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;"> <font style="font-size: 10pt;"><br>
        </font> </div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt;"> </font>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">AMENDED AND RESTATED</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
          </font> </div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CERTIFICATE OF INCORPORATION</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
          </font> </div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">OF</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
          </font> </div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">KALVISTA PHARMACEUTICALS, INC.</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
          </font> </div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 6.6pt; font-family: 'Times New Roman'; font-size: 10pt;">FIRST: The name of the corporation is KalVista Pharmaceuticals, Inc. (hereinafter, the &#8220;<font style="font-family: 'Times New Roman';"><u>Corporation</u></font>&#8221;).</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; font-size: 10pt;">&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 7.5pt; font-family: 'Times New Roman'; font-size: 10pt;">SECOND: The address of the Corporation&#8217;s registered office in the State of Delaware is 251 Little Falls Drive,
          Wilmington, New Castle County, Delaware 19808, and the name of its registered agent at such address is Corporation Service Company.</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; font-size: 10pt;">&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 7.5pt; font-family: 'Times New Roman'; font-size: 10pt;">THIRD: The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be
          organized under the General Corporation Law of the State of Delaware (the &#8220;<font style="font-family: 'Times New Roman';"><u>DGCL</u></font>&#8221;).</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; font-size: 10pt;">&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 7.15pt; font-family: 'Times New Roman'; font-size: 10pt;">FOURTH: The total number of shares of stock which the Corporation shall have authority to issue is 100 shares of
          common stock, par value $0.001 per share.</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; font-size: 10pt;">&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 6.75pt; font-family: 'Times New Roman'; font-size: 10pt;">FIFTH: The business and affairs of the Corporation shall be managed by or under the direction of the board of
          directors, and the directors need not be elected by ballot unless required by the bylaws of the Corporation.</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; font-size: 10pt;">&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 6.5pt; font-family: 'Times New Roman'; font-size: 10pt;">SIXTH: In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the board
          of directors is expressly authorized to make, amend or repeal the bylaws or adopt new bylaws without any action on the part of the stockholders of the Corporation; provided that any bylaw adopted or amended by the board of directors, and any
          powers thereby conferred, may be amended, altered or repealed by the stockholders of the Corporation.</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; font-size: 10pt;">&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 6.5pt; font-family: 'Times New Roman'; font-size: 10pt;">SEVENTH: To the fullest extent permitted by law, neither a director of the Corporation nor an officer of the
          Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable. Without limiting the effect of the preceding sentence, if the DGCL is
          hereafter amended to authorize the further elimination or limitation of the liability of a director or officer, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the
          DGCL, as so amended.&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; font-size: 10pt;">&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 6.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Corporation shall indemnify, to the fullest extent permitted by applicable law, any director or officer of the
          Corporation who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;<font style="font-family: 'Times New Roman';"><u>Proceeding</u></font>&#8221;) by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent
          of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and
          reasonably incurred by such person in connection with any such Proceeding. The Corporation shall be required to indemnify a person in connection with a Proceeding initiated by such person only if the Proceeding was authorized by the board of
          directors.&#160;</div>
        <div style="text-align: justify;">&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">II-1</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 6.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The Corporation shall have the power to indemnify, to the extent permitted by the DGCL, as it presently exists or
          may hereafter be amended from time to time, any employee or agent of the Corporation who was or is a party or is threatened to be made a party to any Proceeding by reason of the fact that he or she is or was a director, officer, employee or agent
          of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another Corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit
          plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding.&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; font-size: 10pt;">&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 6.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The rights conferred upon the applicable persons in this Article Eighth shall be contract rights that vest at the
          time of such person&#8217;s service to or at the request of the Corporation and such rights shall continue as to such person&#160;who has ceased to be a director, officer, trustee, employee or agent of the Corporation and shall inure to the benefit of the
          heirs, executors and administrators of such person.</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; font-size: 10pt;">&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 6.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Neither any amendment nor repeal of this Article Eighth, nor the adoption of any provision of this Corporation&#8217;s
          Certificate of Incorporation inconsistent with this Article Eighth, shall eliminate, reduce or otherwise adversely affect this Article Eighth in respect of any matter occurring, or any cause of action, suit or proceeding accruing or arising or
          that, but for this Article Eighth, would accrue or arise, prior to such amendment, repeal or adoption of such an inconsistent provision.</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; font-size: 10pt;">&#160;</div>
        <font style="font-size: 10pt;"> </font>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 6.5pt; font-family: 'Times New Roman'; font-size: 10pt;">EIGHTH: The Corporation reserves the right to amend and repeal any provision contained in this Certificate of
          Incorporation in the manner from time to time as prescribed by the laws of the State of Delaware. All rights herein conferred are granted subject to this reservation.</div>
        <font style="font-size: 10pt;"> </font></div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;"><font style="font-size: 10pt;"> </font><br>
      </div>
      <div style="font-size: 10pt;"> <br>
      </div>
    </div>
  </div>
  <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">II-2</font>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ef20071670_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1<br>
        <br>
      </font></div>
    <div style="text-align: right;"><font style="font-weight: bold;"> </font>
      <table cellspacing="0" cellpadding="0" border="0" id="z8151ad6b5c124edbbfdecd04b3e699df" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50.00%;"><img src="image00002.jpg"></td>
            <td style="width: 50%; text-align: right;"><img src="image00003.jpg"></td>
          </tr>

      </table>
    </div>
    <div style="text-align: right;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio </div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Highlights:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zca85c41359c946749b2bb1ca7a56c5ff">

          <tr>
            <td style="width: 28.9pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z40884044b2d348639aaa6e9525fedbb2">

          <tr>
            <td style="width: 28.9pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Acquisition adds to Chiesi&#8217;s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi&#8217;s
                long-term commitment to people living with rare conditions </div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3f60efe702a94336a3ed2228562573ec">

          <tr>
            <td style="width: 28.9pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Transaction expected to close in Q3 2026</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Parma, Italy and Framingham, Mass., USA &#8211; 29 April 2026</font> Chiesi Group
        (&#8220;Chiesi&#8221;), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>(&#8220;KalVista&#8221;) (Nasdaq: KALV),
        today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the &#8220;Transaction&#8221;). The Transaction was unanimously approved by both Chiesi&#8217;s and KalVista&#8217;s Boards of Directors and is expected
        to close in Q3 2026, subject to the satisfaction of customary closing conditions.</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Transaction, Chiesi will commence a tender offer to acquire all outstanding shares of KalVista for $27.00 per share in cash. The total value
        implied by the Transaction at closing is approximately $1.9bn. At Chiesi, initiatives in this area are spearheaded by <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Chiesi Global Rare Diseases</font>, the Group&#8217;s
        business unit focused on research, development and commercialization of therapies for rare and ultra<font style="font-size: 12pt; font-family: 'Times New Roman';">&#8209;</font>rare conditions.</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Transaction is Chiesi&#8217;s most substantial acquisition to date in value terms and reflects the company&#8217;s long<font style="font-size: 12pt; font-family: 'Times New Roman';">&#8209;</font>term ambitions, and represents an important milestone in its strategy in Rare Diseases, reinforcing its commitment across generations to improving the lives of people living with rare conditions.</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Upon completion of the Transaction, Chiesi will assume responsibility for EKTERLY<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (sebetralstat), a differentiated oral, on<font style="font-size: 12pt; font-family: 'Times New Roman';">&#8209;</font>demand treatment for hereditary angioedema (HAE), developed by KalVista, which addresses a significant unmet need for patients requiring effective and accessible therapies. By combining KalVista&#8217;s
        innovation with Chiesi&#8217;s Global Rare Diseases capabilities in Rare Immunology, the Transaction aims to accelerate patient access and strengthen medical and scientific engagement, in line with Chiesi&#8217;s mission and strategic objectives. Sebetralstat
        is also expected to meaningfully contribute to Chiesi&#8217;s 2030 strategic revenue target of &#8364;6bn, while significantly expanding its commercial infrastructure and market presence in the United States.</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Sebetralstat is a novel plasma kallikrein inhibitor and the first oral, on-demand treatment for HAE attacks in adults and adolescents aged 12 years and
          older. The therapy is already approved in the United States, United Kingdom, European Union, Japan and other regions, with ongoing studies exploring its use for treating HAE attacks in children aged 2 to 11 and multiple regulatory applications
          under review in key global markets. Following its launch in the United States in July 2025, sebetralstat demonstrated strong market uptake, reaching $49M in 2025 sales.</div>
      </div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 50.00%;"><img src="image00002.jpg"></td>
                  <td style="width: 50%; text-align: right;"><img src="image00003.jpg"></td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Jean-Marc Bellemin</font>, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Chiesi Group&#8217;s CFO, and Interim Group CEO </font>(from 15 May 2026), said: &#8220;This acquisition supports our strategy to accelerate impact in rare diseases by bringing together science, innovation and expertise to
        address areas of highest unmet need. KalVista&#8217;s proven drug discovery and development capabilities, combined with our global footprint and operational excellence, will enable us to deliver innovation to patients at greater scale.&#8221; </div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Giacomo Chiesi</font>, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Executive Vice President, Chiesi Global Rare Diseases</font> said: &#8220;This acquisition is a strong strategic fit for our rare disease portfolio and reflects our commitment to people living with rare conditions. In HAE, patients
        continue to face significant unmet needs, and KalVista&#8217;s innovation meaningfully expands our presence in rare immunology by adding a differentiated, on-demand treatment option that can bring meaningful advancement in how the disease can be managed.
        We look forward to working with KalVista towards a successful closing of the Transaction. From day one, our focus will be on working closely with the HAE community and the scientific community to improve disease management and ensure more patients
        can benefit from timely, effective treatment.&#8221;</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Ben Palleiko, CEO of KalVista </font>said: &#8220;I am extremely proud of what KalVista
        has accomplished over the past decade in advancing solutions for the unmet needs of people living with rare disease. Following a thorough review of strategic opportunities, our Board determined that this Transaction maximizes shareholder value,
        delivering a meaningful all-cash premium to our shareholders. This Transaction also reflects a shared long-term commitment to patients and a strong alignment in how we translate scientific innovation into meaningful impact. With Chiesi&#8217;s global
        infrastructure, commercial capabilities and long-term commitment to rare diseases, we are confident in their ability to help expand access to sebetralstat for people living with HAE around the world.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8221;</sup></div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Transaction Terms and Closing</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd3518c93c909415dac90fe01e0ee1029">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Tender offer by Chiesi to acquire all KalVista shares for $27.00 per share in cash. The Transaction is not subject to any financing condition.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ee2e253cd964435a3c5a244481f0f3b">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Subject to the satisfaction of the closing conditions, including the tender of at least a majority of the then outstanding KalVista shares, receipt of regulatory approvals and
                other customary offer conditions, the Transaction is expected to close in Q3 of 2026.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z41a0b2feedcc4efb924035437443f370">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of a merger agreement entered into in connection with the Transaction, a wholly owned subsidiary of Chiesi will commence a tender offer to acquire all of the
                outstanding shares of KalVista&#8217;s common stock for an offer price of $27.00 per share in cash, which represents a 36% premium to KalVista&#8217;s 30-day volume-weighted average share price as of 28 April, 2026. If the tender offer is successfully
                completed, Chiesi will acquire all remaining shares of KalVista not tendered in the offer through a second step merger for the same consideration as paid in the tender offer.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Lazard is serving as exclusive financial advisor and Ropes &amp; Gray LLP is serving as legal advisor to Chiesi. Centerview Partners LLC is serving as financial
        advisor to KalVista and Kirkland &amp; Ellis LLP and Fenwick &amp; West LLP are serving as legal advisors. Jefferies LLC also provided financial advice to KalVista. </div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">******</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 50.00%;"><img src="image00002.jpg"></td>
                  <td style="width: 50%; text-align: right;"><img src="image00003.jpg"></td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About EKTERLY<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (<a name="z_Int_0VGT8DYi"></a>sebetralstat)</div>
      <font style="font-size: 10pt;">  </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 8pt;"><font style="font-size: 10pt;">Sebetralstat is a novel plasma kallikrein inhibitor approved in the United States, European Union, United Kingdom, Switzerland,
          Australia, Singapore and Japan for the treatment of acute attacks of hereditary angioedema (HAE) in people 12 years of age and older. Sebetralstat is the first oral on-demand treatment for HAE, offering efficacious and safe treatment of attacks
          without the burden of injections. With a US regulatory filing planned for 2026 to expand use to children aged 2&#8211;11, and additional filings anticipated in key global markets, sebetralstat has the potential to become the foundational therapy for
          HAE management worldwide.<br>
        </font> </div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Hereditary Angioedema</div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent
        uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. Treatment
        guidelines recommend treating attacks as early as possible to prevent progression of swelling and shorten the time to attack resolution, and to consider treatment for all attacks, regardless of anatomic location or severity.</div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Chiesi Group</div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare
        diseases, and specialty care. The company&#8217;s mission is to improve people&#8217;s quality of life and act responsibly towards both the community and the environment.</div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">By changing its legal status in Benefit Corporation in Italy, the US, France and Colombia, Chiesi&#8217;s commitment to creating shared value for society as a
        whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet verified standards of social and environmental impact. The company aims to reach
        Net-Zero greenhouse gases (GHG) emissions by 2035.</div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,900 employees. The Group&#8217;s
        research and development centre in Parma works alongside 6 other important R&amp;D hubs in France, the US, Canada, China, the UK, and Sweden.</div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For more information, visit <u>www.chiesi.com</u> or the website of your local Chiesi affiliate.</div>
      <font style="font-size: 10pt;"> </font>
      <div><font style="font-size: 10pt;"><br>
        </font> </div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Chiesi Global Rare Diseases</div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. As a
        family business, Chiesi Group strives to create a world where it is common to have therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many
        people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system.</div>
      <font style="font-size: 10pt;"> </font>
      <div><font style="font-size: 10pt;"><br>
        </font> </div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For more information, visit <u>www.chiesiraredieases.com. </u></div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">About KalVista Pharmaceuticals, Inc.</font><font style="font-size: 10pt;">&#160;</font></div>
      <font style="font-size: 10pt;"> </font>
      <div style="font-size: 10pt;">&#160;</div>
      <font style="font-size: 10pt;"> </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant
        unmet needs. The KalVista team discovered and developed sebetralstat&#8212;the first oral on-demand treatment for hereditary angioedema (HAE)&#8212;and continues to work closely with the global HAE community to improve treatment and care for this disease
        around the world. For more information about KalVista, please visit <u>www.kalvista.com</u> and follow us on <u>LinkedIn, X</u>, <u>Facebook </u>and <u>Instagram</u><font style="font-family: 'Times New Roman';">.</font></div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 50.00%;"><img src="image00002.jpg"></td>
                  <td style="width: 50%; text-align: right;"><img src="image00003.jpg"></td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additional Information and Where to Find It</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The tender offer (the &#8220;Offer&#8221;) for the outstanding shares of common stock (the &#8220;Shares&#8221;) of KalVista Pharmaceuticals, Inc., a Delaware corporation (the
        &#8220;Company&#8221;), described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities of the Company, nor is it a
        substitute for the Offer materials that the Company, Chiesi Farmaceutici S.p.A., an Italian societ&#224; per azioni (&#8220;Parent&#8221;) and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#8220;Purchaser&#8221;), will file with the
        U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). A solicitation and offer to buy outstanding Shares of the Company will only be made pursuant to the Offer materials that Parent and Purchaser intend to file with the SEC. At the time the Offer is
        commenced, Parent and Purchaser will file Offer materials on Schedule TO with the SEC, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the Offer. THE OFFER MATERIALS (INCLUDING AN
        OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS AND THE PARTIES THERETO.
        INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND
        STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES IN THE OFFER. Free copies of these materials and certain other offering documents will be made available by the Company under the &#8220;Investors
        &amp; News&#8221; section of the Company&#8217;s website at <u>https://www.kalvista.com</u>/ or by directing requests for such materials to the information agent for the Offer, which will be named in the tender offer materials. The information contained in,
        or that can be accessed through, the Company&#8217;s website is not a part of, or incorporated by reference into, this communication. The Offer materials (including the Offer to Purchase, the related Letter of Transmittal and certain other Offer
        documents), as well as the Solicitation/Recommendation Statement on Schedule 14D-9, will also be made available for free on the SEC&#8217;s website at <u>www.sec.gov</u><font style="font-size: 10pt; font-family: 'Times New Roman';">.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In addition to the Offer to Purchase, the related Letter of Transmittal and certain other Offer documents, as well as the Solicitation/Recommendation
        Statement on Schedule 14D-9, the Company files annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements, or other information filed by Parent and the Company with the SEC for
        free on the SEC&#8217;s website at <u>www.sec.gov</u><font style="font-size: 10pt; font-family: 'Times New Roman';">.</font></div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">F</font>orward Looking Statements</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">This communication contains forward-looking statements related to the Company, Parent, the Offer, the merger of Purchaser with and into the Company, with the
        Company surviving as a wholly owned subsidiary of Parent (the &#8220;Merger&#8221;), the Agreement and Plan of Merger, dated April 29, 2026, by and among Parent, Purchaser, the Company and KalVista Pharmaceuticals Limited, a private limited company organized
        under the laws of England and Wales (the &#8220;Merger Agreement&#8221;), and the other transactions contemplated by the Merger Agreement (collectively, the &#8220;Transactions&#8221;) that involve substantial risks and uncertainties.&#160; Forward-looking statements can be
        identified by words such as: &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;position,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will&#8221; or the negative of these terms or similar
        references to future periods, although not all forward-looking statements contain these words. In this communication, forward-looking statements include statements about the parties&#8217; ability to satisfy the conditions to the consummation of the
        Offer and the other conditions to the consummation of the Transactions; filings and approvals relating to the Transactions, statements regarding the expected timetable for completing the Transactions; statements regarding plans, objectives,
        expectations and intentions; the financial condition, results of operations and business of the Company and Parent; and post-closing operations and the outlook for the parties&#8217; businesses, including, without limitation, the ability to commercialize
        current and future product candidates (including further commercialization of EKTERLY<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>). Forward-looking statements are subject to certain risks, uncertainties or other factors that are difficult to predict, and could cause actual events
        or results to differ materially from those currently indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by
        forward-looking statements include, among other things: uncertainties as to the timing of the Offer and the Merger; uncertainties as to how many of the Company&#8217;s stockholders will tender their Shares in the Offer and the possibility that the
        acquisition does not close; the possibility that competing offers will be made; the possibility that various closing conditions for the Transactions may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse
        to grant approval for the consummation of the Transactions; the effects of the Transactions on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of U.S. Food and Drug
        Administration approvals or actions, if any; the impact of competitive products and pricing; the risk that, if the Transactions are consummated, the businesses will not be integrated successfully and that Parent may not realize the potential
        benefits of the Transactions; other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217; control; transaction costs; actual or contingent liabilities; the success of the Company&#8217;s efforts
        to commercialize EKTERLY, including revenues from sales of EKTERLY; the Company&#8217;s ability to successfully obtain additional foreign regulatory approvals for sebetralstat; the Company&#8217;s expectations about the safety and efficacy of sebetralstat and
        the Company&#8217;s other product candidates; the timing of clinical trials and their results, the Company&#8217;s ability to commence clinical studies or complete ongoing clinical studies, including the Company&#8217;s KONFIDENT-S and KONFIDENT-KID trials, and the
        ability of EKTERLY to treat HAE; the timing of regulatory filings and product launches; the Company&#8217;s plans for international expansion; expectations regarding market adoption and utilization trends; and the Company&#8217;s ability to establish and
        maintain strategic partnerships.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 50.00%;"><img src="image00002.jpg"></td>
                  <td style="width: 50%; text-align: right;"><img src="image00003.jpg"></td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Further information on potential risk factors that could affect the Company&#8217;s business and financial results are detailed in the Company&#8217;s filings with the
        SEC, including in the Company&#8217;s transition report on Form 10-KT for the transition period from May 1, 2025 to December 31, 2025, the Company&#8217;s quarterly reports on Form 10-Q, current reports on Form 8-K, as well as the Schedule 14D-9 to be filed by
        the Company and the Schedule TO and related tender offer documents to be filed by Parent and Purchaser. You should not place undue reliance on these statements. All forward-looking statements are based on information currently available to the
        Company and Parent, and the Company and Parent disclaim any obligation to update the information contained in this communication as new information becomes available.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font></div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Press Info:</font>&#160;</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Chiesi Group Contacts:</font>&#160;</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Anna Bonisoli Alquati, Head of Global External Communications: <u>mediarelations@chiesi.com</u></div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Chiara Travagin, Head of Global Communications, Rare: mobile +39 348.8818985, e-mail: <u>c.travagin@chiesi.com</u> </div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail: <u>m.lijoi@chiesi.com</u> </div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">KalVista Contacts:</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ryan Baker</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Head, Investor Relations</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(617) 771-5001</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">ryan.baker@kalvista.com</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Molly Cameron</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Senior Director, Corporate Affairs</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(978) 339-3378</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">molly.cameron@kalvista.com </div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">***</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>kalv-20260429.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<xs:schema targetNamespace="http://kalvista.com/20260429" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:kalv="http://kalvista.com/20260429" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="kalv-20260429_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="kalv-20260429_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://kalvista.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>kalv-20260429_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>kalv-20260429_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://kalvista.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="kalv-20260429.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://kalvista.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  A (X# 2(  A$! Q$!_\0
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I^ _UHHI+<I['3T4459 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  _ $ # 2(  A$! Q$!_\0
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1S$L-PP/\^E-8EWMRL3@?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 29, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 29,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KalVista Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001348911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0915291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Crossing Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Framingham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">999-0075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KALV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20071670_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://kalvista.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20071670_8k.htm">ef20071670_8k.htm</File>
    <File>kalv-20260429.xsd</File>
    <File>kalv-20260429_lab.xml</File>
    <File>kalv-20260429_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20071670_8k.htm": {
   "nsprefix": "kalv",
   "nsuri": "http://kalvista.com/20260429",
   "dts": {
    "inline": {
     "local": [
      "ef20071670_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "kalv-20260429.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "kalv-20260429_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kalv-20260429_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://kalvista.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20260429to20260429",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20071670_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260429to20260429",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20071670_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://kalvista.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001140361-26-017656-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-26-017656-xbrl.zip
M4$L#!!0    ( -=#G5P?HF:E%RX  !,# 0 1    968R,# W,38W,%\X:RYH
M=&WM?6M[XLBQ\/?\BGZ=G*Q]'L 2=^S9.0^#\0X9C^T#3#;[?LG3DAJCC)"(
M)&R37W^J^B*UA(1AQO;8NYXG60-J]:6Z[E5=_>Y_[A<>N65AY ;^SS^9->,G
MPGP[<%S_YN>?^I/!:/33_[S_T[MY#,V@J1^=W%NAY_Y\,(_CY<GQ\=W=70U_
MJ07AS7'=,!K'KA_%U+?9@6SON?[7+<WQL46CI/G]1ON[!F]M]GJ]8_XT:1JY
M10VA6_/X'Y\O)O:<+6@U/Q\<WDE?U&?3/A8/55,W"IIUL[-ML:*%>B$*XZ3Q
MC$86;P@_0N-Z*^GUOJQ#$Z$'*V3_^#"^2)O'Q>W3IL=Q2/UH%H0+&L,^XFA&
MU:A7S;K6235B=J8C^%Z["6ZW]F.VJD:WVC!5/ZNH>D/I<G.1\D%FH0[+@5F-
M" \R#>U@Y<?ANKBQ?)A]816&@*9E;\BGV<G$835>+UE4#$QX?(R/\9UFU3#U
M-<=A*0;TCN&I:NA3UXZ*I\0?9>83N79Q4WB0;1@OPY*6\"33E-W;\^*F^"0+
M038K 1Z;91NNG9*&:R?3\"OU;I.6^,4%NJO9P0);M8UFO2=;EA,W<IF#]W\B
MY-V<40<_P,?8C3WV_MVQ^"M^^W_5*KEP;>9'S"%Q<$(^A %U0M>Y8;P!_W<6
MV*L%\V-BAXS&T' 5 5?3FI+K\=7,]1BIMVN-6KW6:C3KZ>N#8+D.W9MY3&!R
M+5(EN S][6I5SF;!8DIP357V[Y4+0!@$?@P#5Z> 4 ?$%M]^/HC9?7S,UW@,
M+/58K/%/[ZS 69,H7GOLYX,9M*W.Z,+UUB?DIZF[8!&Y9'=D'"RH_],IX<\C
M]S_LA)C&,CXEV&>5>NZ-?T(\-H-?[, +PA/R9X/_.R46M;_>A$!$3E4]FO%_
MIP#J=XY[2US8X;/)];F+/."CZSC,/U 3<MQHZ5&8C!_X#-YXY]Z?X,19*#[R
MUOPC-+@$>(>N37RZP%>9>]*'#7!P$\X]>G/ 1SJG=OQ/HU?O&/6>T6K17K/9
MZW7MUJS!*.O:IMUR&@T)M?MXC'AJ*PR*@Q27!)OZ^0!8V\G,O6<.P,T#.?*>
M_WEWG)E2^0R'/B#6>@!3#*DW\AUV_XFMM9DV.[W&S#"H6>^:S6:CU[.L;MNB
M]9;5-&=&J_OP3-_#-IB-9K=GFANS.L[",&0SAJR+1>_?H:0[B;@,@ZX)EWPG
M\Q!'0>JJJOYK]Y%S(!\C!_OY('(72X\!DO'N]3[YURA8A?P;E^0G<OI\Q873
ME^T8!Y3ZYCKX?>:RD/ YLD+1,AA]RBX___)[]5.V]R5 )W#4-^ C87P&)/P>
M)U4UFM5Z3[V7/DNFZ90T54_4=S7(<08."F@)E(XUC#\&<I%$(^D#16=USI!/
MG!#7=V.7>J>"AV%;\=]WT9+Z&1+72/@ &AUC ]6]8"K\H^!$[^:A>MD*0IB(
MI$8BOE6M((Z#!72WO"=1X+D.L3P@^N1Y'"Q/2#/_4$T:)G&?<@W)&K9PC0S+
M 18<L_"4+&AXX_I5Y$ GA*[B(/DI%*/PWY#OR24E@"P'3K,4.*H']5;1C/;A
MI#B2^.%. L4*/ <&_W(YF@[/R&3:GPXG/V0&D^'@RW@T'0TGI']Y1H;_&'SL
M7_XR)(.KSY]'D\GHZO(IIU4OF]:O_<G'T>4OTZO+"CFK#6H@'%O-WK:I;**]
MV/Z__MEL&Z>IV"6*R#2DW\3%1+AE*6#!''>UR%*'P,FB)Q(UBQYQDLD\$.A\
M0H!:)((K JHC_=RY3CS'I1G_M2F"OXMBGG)_C;+])>^L,"'69$^>9 [=LCF<
M7XT_DU*YK;0[H6,EXMJAK?JLT3;:S7:O:3:ZO9G3:]IVJP'ZAE-GO1W$=;?Z
M:5-.;Z[_(:Z>AV Q%WM=6/ZHB/V[Q>C2.0 K'P\OIV0\O+X:3W_(%*Y78;2B
M8!3% 9DP&\U\8C9($!*S=>@<_9 Y!3,2SQE.9Q6" @5=#,%<I3[86'T[)O#8
M[#6:^PD7(59^R')0R<1)C]DR"&-RJ+XS"FHFBV+";M$J#?ECYAR=/,SDKKFJ
M.A0*K,;MK%Z;=CJSGF%9!EA18)-8#=IJ=IR9W72Z36M/,\J!WJL+>&..4Z@Z
M=%U=PZRK8 ^^[R]#UR/U7H7;P;LPR)=*TMQ,/GA(^TQ'+9]FN7;ZQ^;LKPD;
MOF$.]5)M_0$OPYC=N!'Z6.-+>*+1<<<PF=&RF[3>,)OU3H]V&XY5[YJVPZQZ
MA\UVT%H^4>_OZ'$CUW,*%&VS5>S:U(LJ9.3;M0UZ_?'"\ 'UZ7!X#Y#A($3F
M&0K027)# 48C$BV9C6X$!RQOXL81 :D!+#7\,6+LM;"CK72_A5<5 2[KC_@N
M!O$@_&)J>0Q&]CQ8HXT!J@/C@']?4L=1W\6,^,=O]:EF;#G)4 $8'EU&T$9]
MVLGW*EZ6\P7F*UQ#ZI_VD7]Y%X?O,[_))N]B1RU&SJU1KW5;,+M;%G(R5],
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MD7$V"LPALQF\XD@( $(BH=ASSA60:K1XA/*%UEOFX?SHL'UT.$M<HF>_#"X
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M&YN,_X);J>"4@AUZY,Z[_ 9C23-WZ;G"!;S%A:OIW@4=[:KQ2D6F(G%%&3D
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M,D\J#)UTD: %H7<,Y\$65N"X*D\EB#:22#.&3F:=N,0LIUP@3\4P-$Z;E[S
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M57^2FQ]-.!=0O[R"?)-G"67DM/#=>7!'%MI%15OK;G%?4]%E/OHE8;K_24X
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M][Z D,*_,/7[C'&@%].6VR#9FPB*[R3]U'[A#K9"MEXN+;/'>1GJ47F;QMC
M$F7U5S_QA08]SS+D>]YS2JK!)DK MR'K61W#- J".'0LO+MP;,GL]-)HA&VH
M*'U%([P,&N'=Q>7U^<=/WKO/_[CX=/[I^K5)UC9= 4?[C#LX'X^1.0ROMH_)
M79@_7QQOKRZT%_<#CG83?_!Y%HHV6.G$ S? .Q\3SR?VR54MLE0_Y^<#?FY
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MJ5? V,CGP?\+7YMAF6)12'G71]N6KX[WE ,KG*NZRD?E/B98(-A!L;2_T[)
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M>,=G'T[B9"+-?_SF)S\/_'^;X;=ZA91COD?#OLA08.3"W!W::@1XWX4<KN.
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M=_W9CH/3$T0DVL;!T#5(5# BSLV(#$FW0B&8+(1O$G+>,F2_*- [#%["@L@
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M[+T3^K<>%-5KE-<=Y1V^1GE?3K$;NKM>1FSH[@;%SKK[>+.Z>U7XY89T-ZM
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M4%1;IJS6(B@UL6US4H*I^EFAN ;2,5&J34<.NTXZ=)*>*OZF!,.^#+70<AI
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M%0A'$T 52)A(BS O$^D77"*BK=OWWW2/C/2@I;@[.H.$G45N$KNQGM%"$I'
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MTZ^7_=^OL]YP.!@>^_]?M[R=\C5SG:7_@DL9=C@/J[^_AZVH_BV R]@+0C_
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M?!8KXYF>TR:%<SP<(K0X]3@+])?0J^H"**],H:-3Q V6L'H!^G[J)QO*=&!
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MJ@=.*^M--$@&*P>F<UH,9O0SENN=8ABK'E49@(U>UY8&DAC(M9EU&:0#;"?
M>,(L$RS'!,,7:6)-/W-R+'!E0I77?&LM&2POB34ZMYNFO 79':OUHD]2@W<)
MOW.9&21$.2HC8\]G-7'&U#KO/1WIGG4X\<6PNYKOCT"%E3K,UCJ!3.#-36"H
MP/$DW3DY6V;&'WIM.C+L\-W#<^^]48>3=R<]1.H?P-UJT,K3X=ELZ:.:J><5
MO/D0F2&P1/=M6QXK_V8FAN^$:J.L(@*"\L^$[OY"-F<;T^Z11<+6?4R)D^BP
M[21J.*;H)-I_Y).H]_0GT8DG+EK7?#8'5'AVC]IFEZ?^6]"/]95/:4,&>VU8
M0=3("4M#TJA"#*P^&&ZQ=H^FC>B; FLFKSG3%!23\WH=EU=I@D]#@2OJ7:I_
M,9ZRG0!B',U;G_BY;3O.R<*O%Z@QWD<T8I7-L_WTF^?"@E!54*'6Y),I*CY2
M2C1^&2E1S)TTZ.:U6Y7*&A5A2YJTD:V1^9S&H^GU %P)L0A^CF]]^%(<U,QO
M84P9\1B/*-@L- OCF_H=BR'+HAVI>ZG<R\Y%&B,I$C02@4T\2D>16;3SJ&3N
M@(UA7N3O:K9;W:!E6CV05]G<2=?MF&M<9O$::H)C*D2:5=-B#-DB#-$!:%?^
MAR'#0;YD$L_A_PP@5&KM6U%C:J8+(4$Q98U_LXR:1BV>;.D)X)=N]9R'L4;9
M#;)2153@] VTR[LHEX&]"1&&%4-26XL5L82T?&I.5#8NF[2"[%9673,P"YH_
ML98(=!G02U3-QC4.M8-C%;.B%<%-BXH\!8R?6K=>]E?*@5N=<"G[)"6_ ?ZE
M'&<_4IOZ'14''*C-6$I<\@Q$5 >S2A'S%:ZE"JU"RI*:1@L++U646E0]J\<T
M*-FLFR7BSZYF6:)G8CP;76E ?BT1=IK"XM-L!EHY>(7/,S6^SJ66GOH503#P
MG?,<QZG>[B=*1Y+-<2_T3[43,.774FDYRS[<'0^O;JK\ZK?;D]V_Y[/]O?_)
M/O?F!R=TZO^V>;G9^9@FF/.\A* R!\6OSB<UN'2$;>A@D:6FCV=]!;#EAJ?X
M>GWQR[%O !,?Y*I#LZ6$0^CB%,W'25(B]+3F3S9OQ[=Z^0^LE^^]U<N?H7/X
M0NKES7E5P/>YCI[8Y%^Y,:]!2;'$4%:&N^Y:0'(D5*MK%X0SP);5FHMHC4XK
MM1!I:!#BVDASP%A]QE)V!V'[N,KHEU1E:D%JYT6P>C0,EXW"DTCEGF+ J42V
MY!Y6H%X5"Q3"M*Q8BV^('(C2E), .0HMHP?SFJQEVP.WIM:@AF\FQ:K'JE60
MJ(<!+4O1ZQ<\[YM"_QF>(2GC6W66>RQ(4O;CKV$I6_9:5M?(TMM(/:]Z?%3
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M#_FLWOW\3@"BPDR&P4SAIIK$[7?[>@Z_0=I_5LYUO8<H19[(D@.>P:@@XI
M$QKY.XP;1O$M#15#"RPZ@PI+2H)4" (NT-/KSXU+Z S*H<%9N@8LLTF9J7A6
MK7_CO1G+[C6.ZA 4"D\W%$[!81;0'SK&I@L .H9QZ$)3URT4.P^AYJ!%8.HU
MV;07H@S\39:US"XZRP>S<;^DJI9_RM$JH6Y+MG8/-HW\-_#L4H::-?N!44<L
M5-BK=%E8F_-T"ED\F;I[G6ODZF6LD39WS$/)"&0,.7:9( R1P*+\CJ;M^"9U
M?ZO7>[>[T>]N;'=;#:N&*]%2$C>WPO 6 R/;E"YCB,.LI,.CV>U=>K;_SU%6
M7/VV]?GX<*^WO?L3A8K&=O\?L7(O12"M906C'\4":F:IVK8X&/.:7PCJFODN
M'KW%".I&@6\BA]_MLH-M<'%ISDSK@A$ ^Z:W10=6/#F7SBD:5YC#(4FBR2C.
M64B,K:PYQ&O(M!HK]IO\BJWV(+B0K+96=W">6J<YD<HO/P"&?XXL5[J2T138
MVY-^)5H"XR"O5@JK[9VW6LMCUUIVMMYJ+<_0WJY?=&[M@@LMMM;HMJ60G5$O
M/ )CEJHEET-4:.38B5TOORO=##!R"09!$O]&BEL@=C^7GB7%GOS/#&HNKU0@
M_+<%6&7>@U%=1V2\1)B+#R"S50'&\%)W7@K^1N F699BQC_XXT@AUJZS*2 I
M8SR:ZRC-R1D:.1KY&/8VN1F[+&F9^_ 4TP";)T#G:\4C^=J@23%#G&-\I].U
M*%2)LI^OTTM:O_+=#]NUZ+\;I#GL.3"DG?Z<FL3 GBG4GF7!1,/@\2H#:OU:
MI.-U7+)H59*.<RP7!,3EK*@JBVTXR9JYIT'!T$MH*V9Z;:FU#(!R\D!4! #K
M[Q2;%OCMD;P,A;UJ>Z;D=2[6[R_;I<_<&BR9GM1=DB3$.]1V/:-C@+7?PU]-
M4MW?%5@-D<D#\R4<LT<9_CZT^Z%"&7A!]6484],15':G1,D_,+EK.W^.T^EU
MD=3;<E)Y0(L--]Z7-4W]NTN$>G_.,&6O5J(/#.W,[Q[V'&=>)S1M_R,N'#;*
MR#,'TG2\$P_TGG*Y.ISB.3*[T&I[N-.0I-4 Q*71*] />M#;7O%)E\O%!L:3
MWH$P9YHTCPE;SLZI&?" <]LR24&+#AP8]:/*E'V<@<G4ASO^BP:^HY=,V=O:
M#DZ('C\JSLFYN?>$0(<YND!X/FZZV#%0'0:D48%8:O4 $W0Y[+0T+Q3/V2):
MYJ1,"8V!^ E+3*)2,DFLEM"*>!:^:J>83<')6937?IWF?OT2;D^3P8E=@#V8
MM9%.1<^1\>.E<CKMI;'#HX.-@<P_XN81&1M1[6/+"QGR;)BY!HFOT^MN''?1
MS(G+O<X5]5@"5VM>4<>HWTH>'3NX;F;LIAC=4,S2M/2L JCNB(GAS-ATVAFI
MN!5R<$A":J,JV7/6,=91<^:[F3V?-&:X7?,I3;LE=UH++Q;X*+[=[+2CXVPG
MHZ@1+D8L.DMZ2XK!;$PL8&JCXT/BT,EO?4EX:);)PIFL5S57G-G7N5=?B#+7
M<M%I+>Q4'MIX0E$G_/4:\0MSN]3A'TOCV#NA)XJE4[:]!>S_FI9"\6*6@G+B
M;I B2&U9RQF+4$_3P35W,$^PP<HX':N5DB=Q@WQ]87XLC+E!E44N\,$*$S<B
M]4)XL-8^#VU(MQ8,1BSH_J*\Z2Q@8?])$IG!G8:K5(/<38I;7O+3:5'FJ4UX
M0,3 HL=:T92J];K$:WG% )9$>J_US#1BCZ<MV"W[K;+SXRH[O;?*SC,TOY.7
M87Z_H3^50Z^M#$S!99I#1/VE@)BKI6[!=)H*$JV#M$Z=@2GNJS]C.<=GSN@L
MVU0293K?O!:FF <H69X3:9#T,)@5AB)]!AD U'?'+YKOD5LZ16> F8V^LTC4
MADIG#LXO+FF<2+80#54;)@:\"VXJ##A*P,%H^#"ZN#@1KQ<E\M?+6-O4_>=4
MA2<(J=TAN8F]9B@NK#KH!.4"X3@VL9T9L@=T9MC;W 88U-U-)KLSO&@!'"$8
MT*)QL[NUTR: L_W(4@/[3Z]Q<\;<KQ<C+K#S^L0%4!5GV89(Z]*M<9LCB;D>
M3/X77L__]O[WB.>ZGH:W?%7E[!-]D%2\0'C'_G5B=%SKE]_^WR-N5$_*-UI"
M1XX?4EX98S"'XL*BN!1^<&Z;U;E5OF3%A^B,!>H0,@$.J.U(IA4%TKPR12DK
M*$?Z0B%BI/(/&IJY+9"2@9*O^N&,^D$36<T9N*/XD]Z!?@U57"R0+GSY14V>
M\:Y>\=S2&71Q!4754"PMSD80]8%#$\]Y/@74 ONAHJH#?-*E@8\A6G0FV)U/
M\D]F(S4\C(]=/8W@1$=:<6>YZU-.Q@[#EV5"J1SP_3[&6=GY.581 :3T51!?
M)I6:60(&N$P;IVNZ7<4]K:%&ZGPHC5K?+Z^,2_5"V/A+9?0B@39QT+ 6FQ5Q
M<7<T8HI^7\67W(O$R8=0QN^$URT;6J@907:0.:GHBYNO9!430_/TJI@2JZHE
MAV&N(O0N:Y33EH,#8@P2Q;3WP<>KI94(Q26,N9&G:LXR43]4VR 2J[ZTTVF;
M&A!/G? AB>B+.!VE?>X(7V:-14;'!@1A@S0A!>2(1#6SJZN4VL)%W$I'=[[$
MB517.Y9OE !V:@SC<6R_E3H Y]<93[T0.87F UBM=IMP55MFA&8>0.7?H5'&
MJ!A\AZ)\I,[,\GNG&A6W27&;F[]/BPFDHM3?9_D0C@GZO?9I $%3XL>3=)I9
MYB4H$ESE&:U4^@E#(=%7&@XQQ ?80 FJM)%ZQCP1[7\GV>![BGZ59<IKHKF[
MS)MU<87P:@QVJJ+S#%.F&B#9;%T"4T<X.--EQ- > TK!KW,S)"]C,WPK9Y[T
MH6P<%)O4$K@QD4ZH=_XL^AVUA$=IW1'>Z(.>816/8'/IJF^_R&<5-Y$TS;:P
M%<PLM^MC$(]2<*AP6<"NW.^:[G;ZSOXIUN@S:S5BJ#,GZ,FZ>^$K4GZ-( /W
M1YN@!*J%*[7Q[.D$,P]&I\(-8H>^I_9H,AS?MN>%T?.%B)SL^*?+7 '5B!?(
M7[LS@+(%ZH%SW94<OLTH5<=%=GP5='1T<ZH$.3^T2 R^U?< %CZZ0+Q,;],1
MV(;>=A=Z24^OK1["2)E;#7*133LUYSHSDM[FY2%H(%,K#FL][NC19-]D56R]
M,/RG6 J6FDJ2;HFD'C.9<7$(WO[#WKHG"#Z]MBZD%E1-[U@:FW'&\PE>&EY
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M38_9DA*=# N^ UV3D0X%I^<T9%_MR5O4RYERY3!D4M=$@]SU:)#39I^4:Q7
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MG4!Y,L[&%N$2G)G7V=O^A0"?SL.K$EA9B?+4KKB4(K.+K:N\B:G&P;Q+)Y0
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MLZJI7P+II73)I*.C9^<X,I(YZM$ %('(,>6L%G,Z9#R&C5#M<0LD &V6DB/
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M:1W(3=FR#6X$0AZLG <"XE <#'4LRCH&[]7%\)>?TM#OTA%YU(M(F+ AH0<
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M(T8?HT1U-R);]^&DHW0SOD=[+::(^>EK7P885(W)K9*3!'$KMT\AKO"G&FN
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M^$%DZ\M4\N(\>>NP_K'Z\0O)+JU3QN+N;DF\_EJ6B.95-.>8- 02%H_FKA$
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M*UY:*R3HDV*:QYX3J&"@EO8$:R84:$:,N0[^'HBJVB)C;P^PQRO/L.>5D[I
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M J$%I)/&5)H]U<F*S<YI.]AX'>(6@?'F:<88FV .-"]T4[LQXJ53D\TPV31
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MLO"6PPS$@24H2/T=75(Y#<N6]0O;?HNR$#]BZ:I7"#QN &4!D&O7S_(8+U@
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M&KRL%\("'/":D+Y@;O^).>&#F@L/G)TX=03W02+T&=O#P"B#-]=(I]1'1C5
MY<M4*]!!<&9FPXFB>%2SFIG32KE%UK2._*_AJ!A9<!.:'IX:FH/ZGK.7V#J-
MXE]X$OF6TQL(7;%P!#@Z$<;"0/)9UTLUML-SUCOJE<^N[]1RH$< ($?!Z]X
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MS_K: F7 T](0(,%W1H LN-A+/(?A0JN][L5F=7YIZVPY0[Y/#'&QI6Y5N;D
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M87#P3MZAN5ZJ/:N?P&;IF1&&AA-[_<T<UBP+P2RFS6.D<)-A?T5V)?L]@'^
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M[2%#[E+"X/6-56MX>GF@YJ.["-S;JS>CO/,M*6B_GPLQ MZNAK@+^UDH=E;
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M=,)DBZ: 3!IT!JR@@_@H&4;%7(5<S6U0O^.KP^56W$GNI0(-E0YF7I9XHV2
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M;/;7VH:Y436^CZJQN<\VNL9F;985$I'_$K\&O(7ZRVH@8&78O[=XQ97E=L
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M#_O^&$VJ;US;(B=:=]K4M :T=^@WE)5--.'%:(3]?TB*")+BLB+*904R/@5
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MSZPQ+"?>M,X@BO8:&]UZ8$6B%L+M%P>>'9@_I-IISY/GN;8:<9_EG>;:9B/
M_Z[#TPGV41[XV.N"9=N<V.!G(^7F2W0U&L0O3\EI=3,?(,/XMR3GQJU&EQ3*
M2>-1(3C @LP6CD$UN+K>&)!B+K+4VTW O,UB$W+_O7_1B9$:9>BTV)*VD&#1
M EO/#T@^^7D?1.<(YS&>8;? T[QCUGP!Y7'UMW@B7* 7M]Y#Q+R:Z?3Q2!4F
M^W^:RG4!3?;_U$TT.2'Z>S09!/-+$^)GYID 24![YBQ73#ZQR6XQH/0N3=8
M#\ X(=$:I'4OY5P'0GT*?-8A8S/W<T+R/#Q ,!E"Y_'2?XY6U;W3IOXV[E6]
MX)B@1Y8_[WYKRRSI7N5\39YTBN,L?;*EE7ND\/H@YQ=O-,CYR9LO[W>/]HKO
MW[_O;POVQ@5"BF,ZDCZQK@@LYY"IA^<%;*WR OXA"@!W7W+=D2GT-.J@WN:R
M=H#M%WNP[=?/":MMP),".#_@;GRBHQ9+%X'1!A][_D?#78^+Q<@;SE@GP[.6
M)<[V6[8 Z5:FY1%=P_J6W,/72=8D_A[$]( 3+L;HGO<L9>D&U;A=)N'25WNM
ML9$YP]DJJ"2HUT^R.Z7H0E,"7/1AI\@$*P_1.21TW\]C, )BKK3E5".5@L8@
MWQN[(DIAF$">$R4/1^@'77S;,+4_#7%6*\Y H @N'4BS7/R^QFW@<]#8$$A6
ME;BAZ:WE<TK1#R2W5<^[M.CC^?')LF6,V[A76><UNK^J_"XX5>A ZKENY8\D
M#L0J)'@[QURL+@1&SWL>,1UPZ1/)C<Q]5OSCXN<X*_Z2DXJ,")I7'&][DDD>
M;729B&[=E?D_701.I-Z+ II/ >PWL=E96IQQ,K1'WP:[=<5:89.7&39;IY#"
M X3+]JI*5+"U&VUL.UD39U*0@B#]*X&PA[.E0V^,MK=,3;#R!\^8^-.LQ9#<
M3S/O3G/+G':UFO;ITXZ$QT^D]*6IN8V\MW^LC+S%)QCS362S?)II]AI<J?0?
M,_48"+GG=#^NAW1AV>$>SRH1S+BR&I,^&\'7*NIPOFN<?JU2 8K09=I%&?='
M*K3A1RHR;@0#E>NR;K="#S/0B."@%T;*2RP2XDG,9Z%<>4%!, F'H_71SUL$
MJ_(7)WN:\ 8KMJ=?7S@Y W/9^Z%NY9$E9GS:YQ0I6L&D39<#/P2Q] /0A$:7
MEPVULV(VF"D"#\-*<.V$!XK%XN@)@A[ [JR&$+./P>?EC.#9I>&CN H:WJ#3
M0;I[!-?1P /P>]SKAW'NF4R@='0GG LCE81W]TKMUQGVHR %7DTPTC@0X6V"
MT(%IRB %MOS(%N1RJ=ASE_<R5D^AY+B9:6([4KK4,.744DRYRNA;>D;?]BJC
M[Q^PJ,NG<-U.)&09X\.CCXPF@)D:TTA\GKD^IK+%X\Z3'$C<MI:7?+F_JKF8
M.N$4]CP'/?4$$^ZTM9KP'S/AZ%XLT:8^2UNPY>>8_+#TF1_?Z#1K#)'"\"#A
MW$"J^SJ\A0;6J/052TF%!B.J&)E1\X%B@:RNCQW O$12&\L!^QAY-PEK EI7
M1<DBAVQ76.L/ICE"'/292LF'L/6!V!!@K-Y)@_FC06$L-UNK*L!6HU2_HD)4
M-B4TI475=)/]'LI&ZB04&,@#[*9EP(4SC"U&S%6B!B'#'< HQ0AEU@^%\I<?
M)9 S_G&*6(\3ANJ@Q(=<0]!TC//9)#$2*JZ#*MQ3>#2,6QJ$Q)[>X#9]YH+S
M8YCGL26#;B!%W8UWQ1!$H)M5!<(<VV]A%N#\YUV8P$B#'1998FF'!1KF LYN
M'6*.YN,H#0_6?]^'RK@^'SY%K4\4B]QD'L%QIIF<<9I >Q2%&7>A*G=QIGP6
M\W7C_Z>RW"G0'+-?0@CZ1N19^+48ZH*)S.1A1)-=$RYO@3@/*NR"Q;?.8SDO
MAYT0*;A96O$@W1;0B *IZWH&98.TN#Q B'2->6>DG(J!34^(<BS-T@V";"FP
M<#>!.4@%7F::%>@/ZUP"X!5!CZQ-&>6U]L@@YLIA=&Q,&#J<=.$J9[VRD;4W
MX)B#(+RM/ M;7?VK,\8-!PQJ#$F@UQ(,+4/@(-UWA3%4.\R/\?[4_@2DS%&/
M3I21=J=[R#^$GT;</(QJASAE!'T ,X>8Z2BT\"6LN*H4;(3<H$_5D3&]P?<A
M0L8W)TH^J+7HP9#KL7&P)#6"#:),:]SGX'N64CR0(%<20<UI5G$2:6)%#26=
MTBLY<,\%]BDK./Y7C_EAV;G@%W^M0)-%L4#_#'#VL1LCKVT$S;Z_=5AE[-IB
MTGDLG7_NEE2Q_#HEW<HLAZM=2PW-:X*0,*LH\,B,P4B<AF7X-!-G&KN/K1NG
MA#;)>H%78D((K:0:P<1JZL0 1B(BI>#=Q+!-[9@)<C5L8L- _TB1"5*^%5DK
M)ATI*0/V7M+]^A-J1U>I:5"[/KV>41EQX;KNP49A*[PM=G95"&X+/Q6LE-J#
M/-)A^<YXWC']"L'EA?6VW\5!2<E?B32 M^9OM=$+X\1>2>^8(.%J15#P?)V#
MI&B6QX8D5)A!R'F;%@,?F5H]O$9OW,VY-2RTN/3U[..=,N6-D1^=9TRZ)KGS
MIF+:+6#I]*LF[&C!/ T@B49"\* 3+_7V::\W$^\E\T'L"[;.A,C5Q\)R=N 1
M2*OGK:JZ5^^/P9*-EG\V=UJ:E?;NI4)>[?QUG6_O[^^>OO[7NRC;2EK=S==[
M_;BX^=?^P;?=@SM.B;SLAB :+05&6(LFN%!ACD<K!"8:_[PW?[WZNGNK6L/S
ML^^;YZ=;'__<.CBYRS\UCS;YF>_#M$(TNBI77!MW#(=/>+Q?%Q=1BOZ$-BZN
MWVY7Y;?6<.?[WK%)WE2Y#N.15IQP[Q_7QV&\_?UK5-[]W7ZUF>^]?75XMK7Y
M!S_F#:V)%AI1<*AH@R)B\O)I;_RV]650I%]OM_+O,FK.Z7KB.[S[\_PV'0P&
MAX.W[^ZVMHMDT/]V,M3].&&F'!R>DR1.:?2OT9!]YB[NK"@W3I*,<-T^G9V
M1*(I.W>XHO*>]!__ _\3./]XCZX>/X\"P2]6/L[Q4YPK,\.71'*P="4ZIL5E
M.;CW7FP]I8-[%:<>%Z?>6<6I_P%J(AZ$K3O:E_&0%GS2YP3'"EU^&/N>O9AB
MF_UN3I C1G1A?$42C8 Y3ABQ'N'(6VB=X)\5_U\4%RU68W"8PNOR+!4X9?+-
M8A2'?N0C%?SE(?AWB<A/B 3ER6!ZW @?&3MW-==?46:YU$)Z9V7W*(@]9GLJ
MN$B+BCW2E["GZF0L'+5CQJ+47QVSS;-U=+0?K.UN4\7]"<[/UO[!RV!K9WLS
M"A1,D?KV @D)P2[K(>""08DV[=GSW;5J=5-8'!T&>C@C;'XX9]5X:8R9)8\X
M1A\TT<IAM(1F.0F'1;!&OK>0BT1/8*G 0],X)#RBJL?%272UO,KVYM;AN)Z.
M7"^^:W/;]J;-8?H2H\YP6R%I Q.UE(T%;ENO4Q2E=Y:^#2?$\3PVZN@SKT\O
MKQH.4OT88?2>A;W">]C';@#T,5"$G?XC[-N(#K\3GT*<+KNRXTS82SJX9W 6
M[HB75$Z?23(N"(9=G@0I[H3"X)/UBG(N/OH^W"%@GXM.:]9KC?TD=E&,B/Q+
M#@HA']04KB$=M](@XRZD/Q_\$?4\HW!F/X./Z/_%D?1I2 HW#!>W]1U9.G$<
M;,NJ6<0E>I'Z7.9&J9(%<Y(7Z_Y(=,(\JFL==/142),IB@8.<%8Q-$@EA!W*
MY,27$SK$7&%80<II$B5_Q05TG&@8LX@PWS6Y:7I#C^ 1+^\Y_N3LB=9=AP2,
MV89P:5!D&:U]^:QY$749#J]']_7/3X]K0X OU,D)C5G[HQI&+? L);&#XFS5
M;U#<P0SU>"[1G\3N-+ AH94-69'H?4(H];@DYQ_\2$#4%%SR 7.=5Y0?;*!B
MBO0]\Q,%R4XCD#_81WII).H!F=E>=>F;U[JZ]/"D^?=.OW-[PH?Y!<P*ZMNH
MW=!X@*4B[S[&&('1>.!CQ_(OUZP+L7<:(SSM-0,B3&W,C354Z7.Z67K?+*>8
M(@;.*SB@T$(B-*A&H'=I5WE-TE M%?=+^H."I!W4/YTP-0RK1=B&=1K*;U8!
M%&6.%#EL-IF'AU'8%RY6CR8F[8:&ITJE><S17HJ6)Z72-,XQD@/RG\A$$.NR
M0R> 0$HUC]4 %2AELR>:^Y7)81"ONZ:H2<NQ$5APU:*Q]ZP&A\L+Y=8ONG%4
M8M@0M'IDK:65K]^@UCL3O?9&(%(;VO^L%3Z\-O4.'A$I'D[X_GEKJQJ0__+.
M+K:A>R3AKJJ^QDW6E>I@W@1NMQ>7RYZP6F-3@\KPAZ18-[#"!7GD\QLV0DZR
M_IVDM3E)/>;19"N3832!CWEL@7*#FA3KA W5MB&/\>D>,#$$%; ?F.SIY!H)
M^_54!,>=+J9]/7/XNRNV$;/\+N!4S">0LWJ#LV0M3@>X:W7T,3"%1T9YU?$D
M C8K?<8NF6+6)3*'GR?<1>F62H1MPC5LV],6Y3YT3+A2;@B;S5P-.(@^X9GP
M1K#5Q07OT[Q$C D2>AIR>RLX>7'^XLIX*K8W#UB<Y:P%1YN"R$'O=V?/B9'1
MO@P#U@03)V<B#J2JA>.3FQ%'?)<P5SH1$";%CAO^[@T%NB+X!Y,9J.]"JR/,
MZ80QF77^N:](RM]<_CJ49F:E#[&# &U99<T[,!T3-%95GZQ2>-0-BG0K[/.G
M5M<X#<$2Q$OB]*NVE/L5F)[D#,S$O%6]?GG'=^C?G%-\W-'V*Q$Q4[]1\;\)
MOX/9G%4>7Z:N2RV8F8G(:Z&9EF)?$N;/]L5;I-)!#,=H#<WA>A:Q0A3NBZ'Y
MN(=,13JU$@Q*6#K(ODBTC>P>EP]X8Z&&Y*Y SC]]/&?SO0=:((SI]<4ADPUQ
MF99@^Q#.)R4P"QD.LD+:7QS['VU9&1E]^%_%=)8>T]E=Q73^ 7K5NCH'RR\L
M'FENFIZU0,\.^K.#"1W":LI3=5<T-+U62-J(+2-2'LTPO:$GZ#,[71!V6&U9
M&N P&L0%HTLS[:E\=I*)<[_KR]Z-OU8%)O[]Q(+#'@?0U50&LWS)J;<W:XMF
M'Q>%^DS] _I8.$&TEUGNW_JS@W=@_14<%*'$<Q49_Q3_J5/[8^)\+<C'PD@&
M)(<Y',Z0 3E&BUXVZ(ZA9(V]K9GVQZJ)=@!59(2I+O2(D"2N,&A5B)?-#VCF
M61@YC*V.0QJ=.B&B94E&EE"#3^D3QU)XUY7D_!P=>-AF0[-W8@P@#9H*1KA-
M%*?C3IGDU<2@ +4,%G./T;MY(@H\]7HYH<;3Y3#/,J&JQH? 3%@Z$0L; !VK
M@W?A<+7\QHKL4R]"W>J$I?C_3"(D'L5<Z<:(&V-,N/0 $J85&/X/H3!J3\ZD
M/+MH_=6/XFYR^TJ=;^T/MH8[AV7TY?#-Z1_[' ?XA S'%(\_55@?5:\Y^2#'
M9];TKV"UW^#+B<3BZS6FM?_'GQ=;Q4U:=CY^*S</=H[..NK@V^#XLFI+4J'&
MI/]DEO79 &0XO\>SWZIWK6)O-^^U+_-JZW#W^#RYJO;>O=G=VY%WHST123+,
MPR\\9Z]NQ*F(P?GRCJ5CE,S4$7_7?34XA+-*_/G/[V<GAZ>]OU]]X.[06C]5
M:3S/ +Z/7PTO=C>W+I(_=U\[SY&2C)GW?_CZZN1?^W>#S?ZW;[W/GP_?.L_X
M#'9 S@GZ9ASJFG?"8S_>O-I]EQ=;57G1^7.HLKV]]/^>7CK/?H]Q1RSM.@.;
M\3-"64L3Z)*KC:FA,;#L!91DRB6@ZJ5$?-,B2^*(O"-ZN<@P-L9W<V]__\/[
MK;V#_2(KWEZ^.C@\&NP/BL.[[>')YS^YKZ_!J.T7]1>GP<6U]TGV'3@"GGT.
MSHTY9 2*7"<F"<&^SH3^'+R_';ZYN]W<_OSGT68QV,K"_/#CZ>N_=_L7W!]H
M!5\;]A*],/XK[/5?VAR>2XS#WTV1P+W]PS^+O689%:>G%^KRX.3L<&?8WW\U
M5.KBLR04OS>$$7Z"LS/"[V2$Q[QS<(UG\]*4%7]^6R]]+;@\.;?:<+PRTX:C
ME MW7-^.]N_&S]S5^BG,P4A7Q<;'VT11!L^R-[%Q+4X@N,'I'[V<<X4VMY_W
MO+6Z*F)(_M.-HZ7/6:VUY2$3;Z_ ,*9,^MG268&HB9FD0"Y1D]X\=/:6X83
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MC$OYD_6*-6F_HPLEJR]A_H[/T_@"J7+.N?_]OY&-EO[HEKT$_OC_4$L#!!0
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M&-\HB>AC0JE#%E ,&A!**M+E/%%SU4Y<,RI<8!VDJ%856*$59/(_D/$T!S"
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M RJ@@IL"ZS6$?=??7SH=7.QSRO6DE +\$DJKIKX(!4ST4'B";+^.OKA>^-D
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MH;ZH1BXPIE']'<AM.AO]H*$%@H86"-Z3!?2BGFF!X,D"D'M\-OJ]AA;H-;1
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M[:5=^I4EO.4'Q,_.=Q'Q1_Q,^\/_4$L! A0#%     @ UT.=7!^B9J47+@
M$P,! !$              ( !     &5F,C P-S$V-S!?.&LN:'1M4$L! A0#
M%     @ UT.=7%MA7;RQH $ ?!D+ !0              ( !1BX  &5F,C P
M-S$V-S!?97@R+3$N:'1M4$L! A0#%     @ UT.=7&84K+3-(@  AI<  !4
M             ( !*<\! &5F,C P-S$V-S!?97@Y.2TQ+FAT;5!+ 0(4 Q0
M   ( -=#G5RU8+B>1@,  #D/   1              "  2GR 0!K86QV+3(P
M,C8P-#(Y+GAS9%!+ 0(4 Q0    ( -=#G5RW1O-,>@@  #!6   5
M      "  9[U 0!K86QV+3(P,C8P-#(Y7VQA8BYX;6Q02P$"% ,4    " #7
M0YU<T+.LI=P%  #Q/@  %0              @ %+_@$ :V%L=BTR,#(V,#0R
?.5]P<F4N>&UL4$L%!@     &  8 B0$  %H$ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ef20071670_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kalv-20260429.xsd" xlink:type="simple"/>
    <context id="c20260429to20260429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001348911</identifier>
        </entity>
        <period>
            <startDate>2026-04-29</startDate>
            <endDate>2026-04-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20260429to20260429"
      id="Fact_0927029055a944998c5f3eae8c1c5d33">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20260429to20260429"
      id="Fact_4793f00a128144399bb86ba25b41f058">0001348911</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20260429to20260429"
      id="Fact_da52f360646941389fd94cc53270d2e9">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20260429to20260429"
      id="Fact_b96a77f90bb04995b4b3a547dfc4d84b">2026-04-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20260429to20260429"
      id="Fact_701e05c4a2314279a83db281cdeb27ef">KalVista Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20260429to20260429"
      id="Fact_5c7163ba233f4019a53e024e318b5b24">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20260429to20260429"
      id="Fact_d392c14cf0044b479995ed571fa7354c">001-36830</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20260429to20260429"
      id="Fact_3a49560e5ea14d97a69a488745f06b45">20-0915291</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20260429to20260429"
      id="Fact_896176a8bf494ebd9438871a1d2df236">200 Crossing Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20260429to20260429"
      id="Fact_7bcf6a4dc21c4e5e9aa4dc1f309a90d6">Framingham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20260429to20260429"
      id="Fact_a624f77f237b4eb882178c12e5908c14">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20260429to20260429"
      id="Fact_1805e2793a7f4b55b64c897451791dc7">01702</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20260429to20260429"
      id="Fact_206263bd59314fb29d6d244ee8f0520b">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20260429to20260429"
      id="Fact_ce37eea9e5e0408098692cc0625b3934">999-0075</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20260429to20260429"
      id="Fact_92c066d0d4a9471ca33c608006e664ed">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20260429to20260429"
      id="Fact_e4386cbce3d4444fa5dfdaafe740cb43">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20260429to20260429"
      id="Fact_052994716c1c49188783957ec2953e75">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20260429to20260429"
      id="Fact_87edba76fa904f7e8a0392ab9af38cc3">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20260429to20260429"
      id="Fact_05d780b24fb6405ea9e3937087185904">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20260429to20260429"
      id="Fact_6578be1ba7514a7290f288bfe8d84895">KALV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20260429to20260429"
      id="Fact_e7ad41f626404d39b6d9e350fd1b7e4d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20260429to20260429"
      id="Fact_e21229dc42b74cc4b472d99a1b8de28c">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
